IMIDAZOPYRIDAZINE AS MODULATORS OF IL-17

DE602021031124T2Active Publication Date: 2025-05-21JANSSEN PHARMA NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602021031124
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-30
Filing Date
2021-04-28
Publication Date
2025-05-21
Estimated Expiration
2041-04-28

AI Technical Summary

Technical Problem

Current treatments for autoimmune and inflammatory diseases, such as psoriasis, psoriatic arthritis, and rheumatoid arthritis, often rely on biologic antibodies that are costly and have limitations in accessibility and convenience, highlighting the need for small molecule IL-17A inhibitors that can offer effective long-term disease management.

Method used

Development of imidazopyridazine compounds that modulate IL-17A, providing a therapeutic option for treating IL-17A-mediated inflammatory syndromes, disorders, or diseases by administering a therapeutically effective amount of these compounds or their pharmaceutically acceptable salts.

Benefits of technology

The imidazopyridazine compounds effectively target IL-17A, potentially offering similar or better efficacy than biologic antibodies with the advantages of small molecule inhibitors, including improved tissue penetration, cost-effectiveness, and convenient dosing regimens, thereby providing effective long-term disease management for various inflammatory conditions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and / or disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] IMID AZOPYRID AZINE S AS MODULATORS OF IL-17

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63 / 017,682, filed April 30, 2020, the disclosure of which is incorporated herein by reference in its entirety.

[0004] REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0005] This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “716604_NTT-6306PC-SEQ-TEXT-FILE.txt”, creation date of April 27, 2021 and having a size of 5KB. The sequence listing submitted via EFS- Web is part of the specification and is herein incorporated by reference in its entirety.

[0006] FIELD

[0007] Disclosed herein are imidazopyridazine compounds, and pharmaceutical compositions thereof, which modulate Interleukin- 17 A. Also disclosed herein is the therapeutic use of such compounds, for example, in treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease.

[0008] BACKGROUND

[0009] Interleukin- 17 (“IL-17”), also known as IL-17A and CTLA-8, is produced mainly by CD4+ Thl7 cells, and also by other immune cells such as CD8+ T cells, gd T cells, NK cells, NKT cells, and innate lymphoid cells (ILCs). IL-17A exists as a homodimer (A / A) or as a heterodimer (A / F) with IL-17F and signals through binding to dimeric receptor complex IL-17RA and IL-17RC. IL-17RA is ubiquitously expressed at particularly high levels by haematopoietic cell types, whereas IL- 17RC is preferentially expressed by non-haematopoietic cells (Gaffen, S. Structure and signaling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9, 556-567). IL-17A / IL-17R signaling induces de novo gene transcription by triggering NF-kB, C / EBP and MAPK pathways through ACT1-TRAF6-TRAF4. It can also stabilize target mRNA transcripts through the ACT1-TRAF2- TRAF5 complex (AmatyaN. e / a / ., Trends in Immunology, 2017, 38, 310-322). IL-17A stimulates the release of inflammatory mediators including IL-6, IL-8, G-CSF, TNF-a, and IL-Ib that recruit and activate lymphocytes to the site of injury or inflammation and maintain a proinflammatory state.

[0010] As discussed below, preclinical and clinical data have demonstrated the significant pathological role of IL-17A in multiple autoimmune and inflammatory diseases.

[0011] For psoriasis: IL-17A mRNA and / or protein levels are elevated in the lesional skin and blood of patients with psoriasis and correlate with disease severity. IL-17A acts directly in synergy with other cytokines (such as TNFa, IFNy or IL-22) on keratinocytes triggering a self-amplifying inflammatory response in the skin and leading to the formation of psoriatic plaques. The blockade of IL-17A by means of antibodies to IL-17A or IL-23 results in complete reversal of the molecular and clinical disease features in majority of psoriasis patients, manifesting the significant role of IL-17A and IL-17-producing T-cells in the immunopathogenesis of psoriasis. (Hawkes el al ., Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies. J Allergy Clin Immunol. 2017, 140(3): 645-653). The development and approval of IL-17 monoclonal antibodies such as secukinumab, ixekizumab, and brodalumab and their transformational efficacy for psoriasis have demonstrated IL-17A as a valid target for psoriasis treatments. (Blauvelt A. and Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018, 55(3):379-390).

[0012] For psoriatic arthritis (PsA): IL-17A is mechanistically relevant to PsA through NFKB activation that triggers transcription of several PsA related genes including the receptor activator of nuclear factor KB ligand (RANKL). RANKL triggers the differentiation of osteoclast precursor cells into activated osteoclasts, resulting in bone resorption and subsequently joint deformity in PsA (Adamopoulos I. and Mellins E. Nature reviews Rheumatology 2015; 11 :189-94). PsA joint is enriched for IL-17+CD8+ T cells, and the levels of this T cell subset are correlated with disease activity (Menon B. et al., Arthritis & Rheumatology 2014; 66: 1272-81). Synovial fibroblasts isolated from PsA patients also contain elevated IL-17R expression and secrete increased IL-6, CXCL8 and MMP3 ex vivo compared to osteoarthritis patients. Both secukinumab and ixekizumab are FDA approval drugs for PsA. In matching-adjusted indirect comparison analysis, secukinumab was associated with higher ACR 20 / 50 / 70 response rates in patients with active PsA than anti- TNFa antibodies (Mease P. etal ., Eur. J. Rheumatol. 2019 Jul 1;6(3): 113-121; Strand V. etal ., J. Comp. Eff. Res. 2019, 8(7):497-510; Nash P. et al. , Rheumatol. Ther. 2018, 5(1):99-122). In a recent head-to-head study, ixekizumab was superior to adalimumab in achieving simultaneous improvement of joint and skin disease (ACR50 and PASI100) in patients with PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drug (Mease, P. et al. Ann Rheum Diss 2020; 79:123-131). By hitting the same target, IL-17A small molecule inhibitor compounds may exert similar or better efficacy than biologies considering that small molecules generally have better tissue penetration.

[0013] For rheumatoid arthritis (RA): IL-17A has been recognized as critical to the progression of rheumatoid arthritis. “The recognition of IL-17 as a pro-inflammatory T cell derived cytokine, and its abundance within rheumatoid joints, provides the strongest candidate mechanism to date through which T cells can capture and localize macrophage effector functions in rheumatoid arthritis” Stamp, L. et al., Immunol. Cell Biol. 2004, 82(1): 1-9. Moreover, in rheumatoid arthritis IL-17A acts locally on synoviocytes and osteoblasts contributing to synovitis and joint destruction. Robert and Miossec have proposed the use of synovial biopsies and / or biomarkers to precisely identify patients that would respond to IL-17A inhibition. Their work concludes that IL-17 inhibitors should now be considered in the development of precision medicine in RA. (Robert M. and Miossec P., Front. Med., 2019, 5:364)

[0014] For Ankylosing Spondylitis (AS): Various studies have reported elevated IL-17A and Thl7 and other cells producing IL-17 in AS blood samples (Wendling D. et al., Joint Bone Spine. 2007;74:304-305; Shen H. et al. , Arthritis Rheum. 2009;60(6): 1647-56; Zhang L. et al. , PLoS One. 2012;7(4):e31000; Jansen D. et al., Rheumatology (Oxford). 2015 Apr; 54(4) : 728-735). In situ analysis of AS spine has revealed increased IL-17A-producing cells in bone of facet (zygapophyseal) joints (Appel H. et al., Arthritis Res. Ther. 2011;13(3):R95). Two advanced IL- 17A neutralizing antibodies, secukinumab, approved by FDA for AS, and ixekizumab, have demonstrated efficacy over placebo even in anti-TNF inadequate responders. In contrast, anti-IL- 23 p40 and pl9 biologies failed to demonstrate beneficial effect (Deodhar A. et al., Arthritis Rheumatol. 2019, 71(2):258-270; Baeten D. et al., Ann. Rheum. Dis. 2018,77(9): 1295-1302), indicating the differential underling mechanism along IL-23 / IL-17 pathway in AS and providing a strong evidence to support continuing developing IL-17A inhibitors.

[0015] For hidradenitis suppurativa (FIS): Increased IL-17 and IL-17-producing T helper cells in the skin lesions of HS patients were reported and molecular proteomics and gene expression data indicate that the IL-23 / Thl7 pathway is upregulated in HS lesions (Schlapbach C. et al., J. Am. Acad. Dermatol. 2011;65(4):790; Kelly G. et al., British J. Dermatol. 2015 Dec; 173(6): 1431-9; Moran B. et al., J. Invest. Dermatol. 2017; 137(11):2389; Thomi R. et al., JAMA Dermatol. 2018;154(5):592). Seven of nine (78%) patients with moderate-to-severe HS achieved HiSCR in an open-label pilot-trial with Secukinumab (Prussick L. et al., British J. Dermatol. 2019 Sep;181(3):609-611), and more clinical trials with anti-IL-17 mAbs in HS are on-going.

[0016] For bullous pemphigoid (BP): IL-17 is elevated in the blister fluid and perilesional skin of BP patients. (Le Jan S. et al., J. Invest. Dermatol. 2014; 134 (12):2908-2917.; Chakievska L. J Autoimmun. 2019, 96:104-112). Exome sequencing of BP patients revealed mutations in twelve IL-17-related genes in one third of patients, providing the genetic link between IL-17 pathway and BP (Chakievska L. J Autoimmun. 2019, 96: 104-112). In experimental murine BP, IL-17 A- / - mice are protected, and anti-IL-17A treatment significantly reduced skin lesions in wild type (Chakievska L. J Autoimmun. 2019, 96:104-112). Ixekizumab Phase 2 of treatment naive and refractory BP patients is on-going (NCT03099538).

[0017] For atopic dermatitis (AD): IL-17 was found to be elevated in peripheral blood and lesions in AD patients and Thl7 cells infiltrated more markedly in acute than chronic lesions, suggesting its role in acute phase of AD (Koga C. et al., J. Invest. Dermatol. 2008, 128, 2625-2630). Molecular profile analysis from ustekinumab Phase II suggest likely contribution of IL-23 / Thl7 / IL-17 pathway in AD (Khattri S. et al., Exp. Dermatol. 2017 Jan;26(l):28-35).

[0018] For vitiligo: Many studies in vitiligo patients have demonstrated an increased frequency of Thl7 cells and higher levels of IL-17 in both circulation and lesions that positively correlates with disease duration, extent, and activity (Singh R. etal., Autoimmun. Rev 2016, Apr; 15 (4): 397-404). Mouse studies demonstrated that depigmentation correlates with greater IL-17 expression / secretion, which modulates vitiligo development (Eby J. et al ., Pigment Cell & Melanoma Res. 2014, Nov;27(6): 1075-85).

[0019] For multiple sclerosis (MS): IL-17 expression is increased in PBMCs, cerebrospinal fluid (CSF) as well as in brain lesions and cells from MS patients (Lock, C. et al, Nat. Med. 2002, 8: 500- 508; Matusevicius, D. et al., Mult. Scler. 1999, 5: 101-104; Tzartos, J. et al, Am. J. Pathol. 2008, 172: 146-155). IL-17-producing T cells are enriched in active MS lesions (Tzartos, J. et al, Am. J. Pathol. 2008, 172: 146-155; Willing A. etal, J. Immunol. 2018, 200(3):974-982). IL-17Alevels were elevated in the CSF of relapsing-remitting MS (RRMS) patients and correlated with the CSF / serum albumin quotient, a measure of blood-brain barrier (BBB) dysfunction, together with in vitro data that IL-17A in combination with IL-6 reduced the expression of tight junction - associated genes and disrupted monolayer integrity in a BBB cell line, highlighting the potential importance of targeting IL-17A in preserving BBB integrity in RRMS (Setiadi AF et al, J Neuroimmunol. 2019, 332:147-154). Secukinumab yielded promising first results in a proof-of- concept study in MS patients (Havrdova, E. etal, J. Neurol. 2016, 263: 1287-1295).

[0020] For Asthma: IL-17 expression is increased in the lung, sputum, bronchoalveolar lavage fluid, and sera in patients with asthma, and the severity of airway hyperresponsiveness is positively correlated with IL-17 expression levels. (Chakir J. et al, J. Allergy Clin. Immunol. 2003, 111(6): 1293-8). IL-17 was reported to be increased in asthmatic airways and induce human bronchial fibroblasts to produce cytokines (Molet S. et al, J. Allergy Clin. Immunol. 2001, 108(3):430-8). Anti-IL-17 antibody modulates airway responsiveness, inflammation, tissue remodeling, and oxidative stress in chronic mouse asthma models (Camargo LdN. et al, Front Immunol. 2018; 8:1835; dos Santos T. etal, Front. Physiol. 2018, 9:1183).

[0021] For Chronic Obstructive Pulmonary Disease (COPD): An increase in Thl7 cells was observed in patients with COPD compared with current smokers without COPD and healthy subjects, and inverse correlations were found between Thl7 cells with lung function (Vargas-Rojas M. et al, Respir. Med. 2011 Nov; 105(11): 1648-54). In three recent human COPD studies, gene expression profile in bronchial epithelia showed that higher IL-17 signature expression is associated with a lack of response to inhaled corticosteroid, suggesting that there is a COPD subgroup that may benefit from IL-17 inhibitor therapy (Christenson S. et al., J. Clin. Invest. 2019; 129(1): 169—181).

[0022] For Uveitis: IL-17 promotes the release of inflammatory mediators from retinal pigment epithelium cell line, disrupting the retinal pigment epithelium barrier function (Chen Y. et al., PLoS One. 2011;6:el8139). IL-17 levels were elevated in the serum or aqueous humor of uveitis patients (El-Asrar A. et al., Clin. Immunol. 2011; 139(2): 177-84; Jawad S. etal., Ocul. Immunol. Inflamm. 2013; 21(6):434-9; Kuiper J. etal. , Am. J. Ophthalmol. 2011 ; 152(2): 177- 182 ). Anti-IL- 17 antibody delayed the onset of ocular inflammation and markedly inhibited the development of experimental autoimmune uveitis in rats (Zhang R. et al., Curr. Eye Res. 2009 Apr; 34(4): 297- 303). The analysis of secondary efficacy data from subcutaneous (sc) secukinumab phase 3 trials in uveitis suggested a beneficial effect of secukinumab in reducing the use of concomitant immunosuppressive medication (Dick A. etal., Ophthalmology 2013; 120(4):777-87). Later study of intravenous secukinumab in uveitis demonstrated greater efficacy than sc dosing, suggesting requiring optimal exposure for efficacy and confirming the therapeutic potential of IL-17A inhibition (Letko E. et al., Ophthalmology 2015, 122(5), 939-948). Ustekinumab that blocks IL- 23 / IL-17 pathway was also reported to successfully treat a noninfectious uveitis patient who had severe concomitant psoriasis and PsA and failed to respond to conventional immune suppressants (Mugheddu C. etal., Dermatol. Ther. 2017 Sep;30(5);el2527.).

[0023] For multiple myeloma (MM): IL-17A serum levels were significantly higher in MM patients and also in patients with advanced stage compared with healthy subjects (Lemancewicz D. etal., Med. Sci. Monit. 2012; 18(1): BR54-BR59). Administration of secukinumab in the SCIDhu model of human myeloma weekly for 4 weeks after the first detection of tumor in mice led to a significant inhibition of tumor growth and reduced bone damage compared to isotype control mice (Prabhala R. et al., Leukemia. 2016 February; 30(2): 379-389).

[0024] For systemic lupus erythematosus (SLE): Increased serum or plasma levels of IL-17, expansion of IL-17-producing T cells in the peripheral blood, and infiltration of Thl7 cells in target organs like the kidneys was observed in SLE patients (Wong C. et al., Lupus. 2000;9(8):589-593; Wong C. et al., Clinical Immunology. 2008;127(3):385-393; Zhao X-F. et al., Mol. Biol. Rep. 2010 Jan;37(l):81-5; Chen X. etal ., J. Clin. Immunol. 2010Mar;30(2):221-5; Xing Q. et al., Rheumatol. Int. 2012 Apr; 32(4):949-58). Imbalance between Thl7 cells and regulatory T (Treg) cells has been observed in SLE patients including quiescent stage (Ma J. et al., Clin. Rheumatol. 2010;29(11): 1251-1258; Dolff S. et al. , Clin. Immunol. 2011, 141(2): 197-204). Overexpression of IL-17A using adenovirus enhanced the severity of lupus nephritis, while blockade of IL-17A using neutralizing antibody resulted in decreased severity of lupus nephritis (Wen, Z. etal., PLoS One. 2013, 8: e58161). In a phase 2 study, ustekinumab, an anti-IL- 12 / 23 p40 monoclonal antibody blocking IL-23 / IL-17 pathway, has demonstrated efficacy in SLE patients (van Vollenhoven R. et al., Lancet 2018; 392: 1330-39). Human expression studies, animal models, and clinical trials indicate that IL-17 blockade may become a promising therapeutic strategy for SLE ( Koga T. et al., Expert Rev. Clin. Immunol. 2019, 15 (6) 629-637).

[0025] In summary, animal and human studies have shown that IL-17A plays crucial role in pathogenesis of the multiple diseases and / or conditions discussed above. The significance of targeting IL-17A has been demonstrated by the transformational efficacy of IL-17A neutralizing antibodies in patients. While no oral small molecule IL-17A inhibitors have progressed into late stage clinical trials yet, they are in an attractive area for discovery as their development may broaden treatment options for many patients without access to biologies. In addition, a safe and efficacious small molecule IL-17A inhibitor may offer significant benefits to patients such as convenient dosing regimens and cost savings, which in turn may provide effective long-term disease management. Accordingly, there is a need for new small molecule IL-17A modulators (e.g., inhibitors).

[0026] SUMMARY

[0027] The present application discloses a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;

[0028] R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups;

[0029] Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -OC(i-3)alkyl or - OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;

[0030] R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o- i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH3- CHF2, -CF3, OH and =0;

[0031] R4is -C(3-6)Cycloalkyl, phenyl, or a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl wherein the - OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, -C(i-4)alkyl and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl) or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, - OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0032] R4CI, R4c2, R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and

[0033] R5is hydrogen or halogen; wherein when R4is 1,2,4-triazolyl, then R4is when R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

[0034] The present application also discloses compounds of Formula G. All compounds of Formula I are compounds of Formula G. Some compounds of Formula I’ are compounds of Formula I. Accordingly disclosed herein is a compound of Formula G: or a pharmaceutically acceptable salt thereof, wherein:

[0035] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;

[0036] R2is H, -C(3-5)Cycloalkyl, -C(i-4)alkyl, or a 6-membered heterocycle having 1 to 2 oxygen atoms; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups; and wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;

[0037] Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -OC(i-3)alkyl or - OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;

[0038] R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o- i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH3- CHF2, -CF3, OH and =0;

[0039] R4is -C(3-6)Cycloalkyl, phenyl, or a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl wherein the - OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, -C(i-4)alkyl and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl) or a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, - OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0040] R4CI, R4c2, R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3- to 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and

[0041] R5is hydrogen or halogen; wherein: when R4is 1,2,4-triazolyl, then R4is when R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

[0042] In some embodiments, disclosed herein is a pharmaceutical composition comprising a compound of Formula I, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0043] Also described herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments, disclosed herein is the use of a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof, for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.).

[0045] In some embodiments, disclosed herein is the use of a compound of Formula I, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and / or ameliorating an IL- 17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.).

[0046] In some embodiments, provided herein are processes and intermediates disclosed herein that are useful for preparing a compound of Formula I or pharmaceutically acceptable salts thereof.

[0047] In some embodiments, disclosed herein is a pharmaceutical composition comprising a compound of Formula I’, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also described herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, disclosed herein is the use of a therapeutically effective amount of compound of Formula G, or a pharmaceutically acceptable salt thereof, for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.).

[0049] In some embodiments, disclosed herein is the use of a compound of Formula G, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease (e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, etc.).

[0050] In some embodiments, provided herein are processes and intermediates disclosed herein that are useful for preparing a compound of Formula I’ or pharmaceutically acceptable salts thereof.

[0051] The disclosure also provides a compound or method as described herein.

[0052] DETAILED DESCRIPTION

[0053] Definitions

[0054] Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.

[0055] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set forth in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set forth fully herein.

[0056] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.

[0057] In an attempt to help the reader of the application, the description has been separated in various paragraphs or sections, or is directed to various embodiments of the application. These separations should not be considered as disconnecting the substance of a paragraph or section or embodiments from the substance of another paragraph or section or embodiments. To the contrary, one skilled in the art will understand that the description has broad application and encompasses all the combinations of the various sections, paragraphs and sentences that can be contemplated. The discussion of any embodiment is meant only to be exemplary and is not intended to suggest that the scope of the disclosure, including the claims, is limited to these examples.

[0058] The term “administering” with respect to the methods of the invention, means a method for therapeutically or prophylactically preventing, treating or ameliorating a syndrome, disorder or disease as described herein by using a compound of the disclosure, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof. Such methods include administering a therapeutically effective amount of a compound of the disclosure, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof, at different times during the course of a therapy or concurrently or sequentially as a combination therapy.

[0059] The term “subject” refers to a patient, which may be an animal, preferably a mammal, most preferably a human, whom will be or has been treated by a method according to an embodiment of the application. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs) such as monkeys or apes, humans, etc., more preferably a human. The term “therapeutically effective amount” or “effective amount” means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes preventing, treating or ameliorating the symptoms of a syndrome, disorder or disease being treated.

[0060] As used herein, “IL-17” or “IL-17A” refers to interleukin 17A. It is also named IL17, CTLA8, CTLA-8. Interleukin 17A is a pro-inflammatory cytokine. This cytokine is produced by a group of immune cells in response to their stimulation. An exemplary amino acid sequence of human IL-17 is represented in GenBank Accession No. NP 002181.1, which can be encoded by a nucleic acid sequence such as that of GenBank Accession No. NM_002190.3.

[0061] The term “modulator” as used herein refers to any agents or molecules that can bind to IL-17, including small molecule compounds.

[0062] As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

[0063] As used herein, the term “treat”, “treating”, or “treatment” of any disease, condition, syndrome or disorder refers, in one embodiment, to ameliorating the disease, condition, syndrome or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, “treat”, “treating”, or “treatment” refers to alleviating or ameliorating at least one physiological or biochemical parameter associated with or causative of the disease, condition, syndrome or disorder, including those which may not be discernible by the patient. In a further embodiment, “treat”, “treating”, or “treatment” refers to modulating the disease, condition, syndrome or disorder either physically ( e.g . stabilization of a discernible symptom), physiologically, (e.g. stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating”, or “treatment” refers to preventing or delaying the onset or development or progression of the disease, condition, syndrome or disorder.

[0064] As used herein, the term “QD” means once daily. As used herein, the term “BID” means twice daily.

[0065] The term “alkyl” is a straight or branched saturated hydrocarbon. For example, an alkyl group can have 1 to 12 carbon atoms (i.e., (Ci-Ci2)alkyl) or 1 to 6 carbon atoms (i.e., (Ci-C6)alkyl). Examples of alkyl groups include, but are not limited to, methyl (Me, -CEE), ethyl (Et, - CH2CH3), 1-propyl («- Pr, «-propyl, -CH2CH2CH3), isopropyl (z-Pr, z-propyl, -CH(CH3)2), 1- butyl ( / / -bu, «-butyl, -CH2CH2CH2CH3), 2-butyl (.v-bu, 5-butyl, -CH(CEE)CH2CEE), te / 7-butyl ( / - bu, / -butyl, -CH(CH )3), 1 -pentyl («-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3) CH2CH2CH3), 1 -hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), heptyl (-(CH2)6CH3), octyl (-(CH2)7CH3), 2,2,4-trimethylpentyl (-CH2C(CH3)2CH2CH(CH3)2), nonyl (-(CH2)8CH3), decyl (-(CH2)9CH3), undecyl (-(CH2)IOCH3), and dodecyl (-(CEE) 11 CEE). Any alkyl group may be unsubstituted or substituted.

[0066] The term “C(fl-* / ’ (where a and b are integers referring to a designated number of carbon atoms) refers to an alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl radical or to the alkyl portion of a radical in which alkyl appears as the prefix root containing from a to b carbon atoms inclusive. For example, C(i-4)denotes a radical containing 1, 2, 3 or 4 carbon atoms.

[0067] The term “perfluoroalkyl” refers to an alkyl group, as defined herein, wherein all carbon-hydrogen bonds have been replaced with carbon-fluorine bonds. For example, a perfluoroalkyl group can have 1 to 6 carbon atoms (i.e., (Ci-6)perfluoroalkyl) or 1 to 3 carbon atoms (i.e., (Ci-3)perfluoroalkyl). Examples of perfluoroalkyl groups include, but are not limited to, trifluoromethyl (-CF3), pentafluoroethyl (-CF2CF3), heptafluoropropyl (-CF2CF2CF3), and heptafluoroisopropyl (-CF(CF3)2).

[0068] The term “heterocycle” or “heterocyclyl” refers to a single saturated or partially unsaturated ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur. Exemplary heterocycles include, but are not limited to oxetanyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, and thiomorpholinyl.

[0069] The term “cycloalkyl” refers to a saturated or partially unsaturated all carbon ring system having 3 to 8 carbon atoms (i.e., C(3-8)Cycloalkyl), and preferably 3 to 6 carbon atoms (i.e., 3-6)Cycloalkyl), wherein the cycloalkyl ring system has a single ring or multiple rings in a spirocyclic or bicyclic form. Exemplary cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Unless otherwise stated specifically in the specification, a cycloalkyl group may be unsubstituted or substituted. Some cycloalkyl groups may exist as spirocycloalkyls, wherein two cycloalkyl rings are fused through a single carbon atom; for example and without limitation, an example of a spiropentyl group is ; for example and without limitation, examples of spirohexyl groups include , ; for example and without limitation examples of cycloheptyl groups include , for example and without limitation examples of cyclooctyl groups include . Unless otherwise stated specifically in the specification, a siprocycloalkyl group may be unsubstituted or

[0070] A substituted. Bicyclic cycloalkyl ring systems also include or i>

[0071] The term “heteroaryl” refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur. The term “heteroaryl” includes single aromatic rings of from 1 to 6 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. Exemplary heteroaryl ring systems include but are not limited to pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, imidazolyl, tetrazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, or furyl.

[0072] The terms “ortho,” “meta,” and “para” have the meanings as understood in the art and are used herein to indicate the position of a substituent on a phenyl or 6-membered heteroaryl ring relative to the point of attachment of the ring. For example, the structure below is described as 3-pyridinyl with the Xi substituent in the ortho position, the X2 substituent in the meta position, and the X3 substituent in the para position:

[0073] The term “halogen” refers to bromo (-Br), chloro (-C1), fluoro (-F) or iodo (-1).

[0074] Where the compounds disclosed herein have at least one stereocenter, they may accordingly exist as enantiomers or diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

[0075] “Diastereoi somers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.

[0076] “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A “racemic” mixture is a 1:1 mixture of a pair of enantiomers. A “scalemic” mixture of enantiomers is mixture of enantiomers at a ratio other than 1:1.

[0077] Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, a scalemic mixture, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di- / oluoyl-D-tartaric acid and / or (+)-di - / Mol uoyl -L-tartari c acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral column vial HPLC or SFC. In some instances rotamers of compounds may exist which are observable by ¾ NMR leading to complex multiplets and peak integration in the 'H NMR spectrum. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. Chiral centers, of which the absolute configurations are known, are labelled by prefixes R and S, assigned by the standard sequence-rule procedure, and preceded when necessary by the appropriate locants {Pure & Appl. Chem. 45, 1976, 11-30). Certain examples contain chemical structures that are depicted or labelled as an (R*) or S*). When (R*) or S*) is used in the name of a compound or in the chemical representation of the compound, it is intended to convey that the compound is a pure single isomer at that stereocenter; however, absolute configuration of that stereocenter has not been established. Thus, a compound designated as (R*) refers to a compound that is a pure single isomer at that stereocenter with an absolute configuration of either (R) or S), and a compound designated as S*) refers to a compound that is a pure single isomer at that stereocenter with an absolute configuration of either R) or (S). For example, N-{{S)-{7-{{S*)~ Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-0]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-l -(3,3,3-trifluoropropyl)- l / / -pyrazole-4-carboxamide: , refers to a compound that is either:

[0078] Pseudoasymmetric stereogenic centers are treated in the same way as chiral centers, but are given lower-case symbols, r or 5 (Angew. Chem. Int. Ed. Engl. 1982, 27, 567-583).

[0079] During any of the processes for preparation of the compounds disclosed herein, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts. Protective Groups in Organic Synthesis John Wiley & Sons. 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

[0080] Furthermore, it is intended that within the scope of the present invention, any element, in particular when mentioned in relation to a compound of the disclosure, or pharmaceutically acceptable salt thereof, shall comprise all isotopes and isotopic mixtures of said element, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. For example, a reference to hydrogen includes within its scope 'H,2H (i.e., deuterium or D), and ¾ (i.e., tritium or T). In some embodiments, the compounds described herein include a2H (i.e., deuterium) isotope. By way of example, the group denoted -C(i-6)alkyl includes not only -CFb, but also CD3; not only CH2CH3, but also CD2CD3, etc. Similarly, references to carbon and oxygen include within their scope respectively12C,13C and14C and150 and160 and170 and180. The isotopes may be radioactive or non-radioactive. Radiolabelled compounds of the disclsoure may include a radioactive isotope selected from the group comprising ¾,UC,18F,35S,122I,123I,125I,131I,75Br,76Br,77Br and82Br. Preferably, the radioactive isotope is selected from the group of3H,UC and18F.

[0081] Compounds of the Disclosure

[0082] The present application discloses a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein:

[0083] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;

[0084] R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups;

[0085] Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -OC(i-3)alkyl or - OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;

[0086] R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o- i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH3- CHF2, -CF3, OH and =0;

[0087] R4is -C(3-6)Cycloalkyl, phenyl, or a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl wherein the - OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, -C(i-4)alkyl and a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 - to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl) or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, - OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0088] R4CI, R4c2, R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and R5is hydrogen or halogen; wherein when R4is 1,2,4-triazolyl, then R4is when R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

[0089] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0090] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the piperidinyl is unsubstituted or substituted with one to three Rlcgroups;

[0091] Rlaand Rlbare each independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine; each Rlcis independently -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms;

[0092] R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl;

[0093] R3is -C(5-6)Cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms;

[0094] R4is -C(3-4)Cycloalkyl, phenyl, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen and Cn-ualkyl that is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one or two R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i.4>alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5-membered heteroaryl is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0095] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, - o- 2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl), wherein the -C(i-3)alkyl, - OC(i.3>alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; R4dland R4d2are each independently H or -C(i.3>alkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0096] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0097] R1is -C(i-6)alkyl, -CH2C(3-6)Cycloalkyl, or piperidinyl wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -CH2C(3-6)Cycloalkyl is unsubstituted or substituted with one to four fluorine atoms; and wherein the piperidinyl is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine;

[0098] R2is H, -C(3-5)Cycloalkyl, or -C(i-3)alkyl;

[0099] R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms;

[0100] R4is -C(3-4)Cycloalkyl, spiropentanyl, spirohexanyl, spiroheptanyl, spirooctanyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, imidazolyl, or thiadiazolyl; wherein the -C(3-4)Cycloalkyl is unsubstituted or substituted with one to three groups selected from halogen, and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl, pyridinyl, pyrimidinyl, and pyrazinyl are unsubstituted or substituted with one or two groups selected from halogen and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, imidazolyl, and thiadiazolyl are substituted with one or two R4cgroups; each R4Cis independently -C(o-2)alkylC(3-6)Cycloalkyl, or -C(i-4)alkyl, wherein the -C(o-2)alkylC(3- 6)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine.

[0101] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: wherein the -C(3-5>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the is unsubstituted or substituted with one to four fluorine atoms; and wherein the is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH or fluorine;

[0102] R2is H, cyclopropyl, methyl, or isopropyl;

[0103] R3is cyclohexyl,

[0104] R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyridinyl, pyrazolyl, oxazolyl, isoxazolyl, triazolyl, imidazolyl, or 1,2,3-thiadiazolyl; wherein the cyclopropyl is unsubstituted or substituted with one to three groups selected from fluorine and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl and pyridinyl are unsubstituted or substituted with one to two groups selected from chlorine and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is unsubstituted or substituted with C(i-3)alkyl, wherein the C(i-3)alkyl is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, isoxazolyl, triazolyl, and imidazolyl are unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-4)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and

[0105] R5is hydrogen or fluorine.

[0106] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0107] R1is -C(i-6)alkyl, -CH2C(3-6)Cycloalkyl, or piperidinyl wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -CH2C(3-6)Cycloalkyl is unsubstituted or substituted with one to four fluorine atoms; and wherein the piperidinyl is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine;

[0108] R2is H, -C(3-5)Cycloalkyl, or -C(i-3)alkyl;

[0109] R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms;

[0110] R4is -C(3-4)Cycloalkyl, spiropentanyl, spirohexanyl, spiroheptanyl, spirooctanyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl; wherein the -C(3-4)Cycloalkyl is unsubstituted or substituted with one to three groups selected from halogen, and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one or two groups selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i-4)alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl are substituted with one or two R4cgroups; each R4cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0111] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0112] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: wherein the -C(3-5>alkyl is substituted with one to six Rlagroups; wherein the is substituted with two fluorine atoms; and each Rlais independently -OH or fluorine; R2is H, cyclopropyl, methyl, or isopropyl; R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyridinyl, pyrazolyl, oxazolyl, isoxazolyl, triazolyl, imidazolyl, or 1,2,3-thiadiazolyl; wherein the cyclopropyl is substituted with one to two groups selected from fluorine and C(i>alkyl that is unsubstituted or substituted with three fluorine atoms; wherein the phenyl is unsubstituted or substituted with -chlorine, or -C(i-2)alkyl; wherein the pyridyl is substituted with C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is substituted with C(2-3>alkyl; wherein the pyrazolyl, oxazolyl, isoxazolyl, triazolyl, and imidazolyl are substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen.

[0113] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: wherein the -C(3-5)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the is unsubstituted or substituted with one to four fluorine atoms; wherein the is unsubstituted or substituted with one to four fluorine atoms; and wherein the is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH or fluorine;

[0114] R2is H, methyl, isopropyl or cyclopropyl; R3is cyclohexyl

[0115] R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5- oxadiazolyl,triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl; wherein the cyclopropyl is unsubstituted or substituted with one to three groups selected from fluorine and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one to two groups selected from chlorine and C aralkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is unsubstituted or substituted with C(i-3)alkyl, wherein the C(i-3)alkyl is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl, or 1,2,5-thiadiazolyl are unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-4)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and

[0116] R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0117] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: wherein the -C(3-5>alkyl is substituted with one to six Rlagroups; wherein the is unsubstituted or substituted with one to two fluorine atoms; wherein the substituted with two fluorine atoms; and wherein the is substituted with -CF3; each Rlais independently -OH or fluorine;

[0118] R2is H, methyl, isopropyl or cyclopropyl;

[0119] R3is cyclohexyl

[0120] R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl; wherein the cyclopropyl is substituted with one to two groups selected from fluorine and C(i>alkyl that is unsubstituted or substituted with three fluorine atoms; wherein the phenyl is unsubstituted or substituted with -chlorine, or -C(i-2)alkyl; wherein the 1,2,3-thiadiazolyl and 1,2,5-thiadiazolyl are substituted with Ca-^alkyl; wherein the pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl and imidazolyl are substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and

[0121] R5is hydrogen; wherein when R4is 1,2,4-triazolyl, then R4is

[0122] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R1is -C(3-6>alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or a 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i.6>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to three Rlbgroups; and wherein the 6-membered heterocyclyl is substituted with one Rlcgroup; each Rlais independently fluorine or -OH; each Rlbis independently fluorine;

[0123] Rlcis -C(i-4)alkyl that is substituted with one to three fluorine atoms.

[0124] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0125] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is: In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0126] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is

[0127] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is

[0128] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1is

[0129] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, isopropyl or cyclopropyl.

[0130] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2is H or cyclopropyl. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2is H. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2is cyclopropyl.

[0131] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2is unsubstituted cyclopropyl.

[0132] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is a compound of formula la:

[0133] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R3is -C(o-i)alkylC(3-6)cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms.

[0134] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically

[0135] In some embodiments, disclosed herein is a compound of Formula I or la, or a pharmaceutically acceptable salt thereof, which is a compound of formula lb: wherein R3ais fluorine and n is 0, 1, or 2.

[0136] In some embodiments, disclosed herein is a compound of Formula I, la or lb, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-1 : (Ib-1) , wherein R3ais fluorine and n is 2. In some embodiments, disclosed herein is a compound of Formula I, la, lb or Ib-1, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-2a: wherein R3ais fluorine and n is 2.

[0137] In some embodiments, disclosed herein is a compound of Formula I, la, lb or Ib-1, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-2b: (Ib-2b) , wherein R3ais fluorine and n is 2.

[0138] In some embodiments, disclosed herein is a compound of Formula I, la, lb, Ib-1, or Ib-2a, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-3a:

[0139] In some embodiments, disclosed herein is a compound of Formula I, la, lb, Ib-1, or Ib-2b, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-3b:

[0140] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R3is In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0141] R4is -C(3-6)Cycloalkyl that is unsubstituted or substituted with one to three R4agroups; and each R4ais independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl, wherein the - OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl.

[0142] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each R4agroup is fluorine, methyl, or -CF3, or two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a cyclopropyl, cyclobutyl or cyclopentyl.

[0143] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is cyclopropyl that is unsubstituted or substituted with one to three groups selected from fluorine, CFF, and CF3.

[0144] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is cyclopropyl that is unsubstituted or substituted with one to two groups selected from fluorine, CFF, and CF3.

[0145] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is

[0146] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is a spirocycle. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is spiropentanyl or spirohexanyl. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0147] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0148] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0149] R4is phenyl that is unsubstituted or substituted with one to two R4bgroups; and each R4bis independently selected from chlorine, fluorine, -CN, cyclopropyl, -OCH2- cyclopropyl, -OC(i-2)alkyl, -C(i-2)alkyl and pyrrolidin-2-one, wherein the cyclopropyl, -O i- 2>al kyl , and C(i.2>alkyl are unsubstituted or substituted with one to three fluorine atoms.

[0150] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each R4bgroup is independently H, fluorine, chlorine, -CN, methyl, ethyl, -CHF2, -CH2CF3, -OCHF2, -OCH2CHF2, -OCH2CF3, cyclopropyl,

[0151] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is phenyl that is unsubstituted or substituted with halogen (e.g., chlorine), -CH3, or -CH2CH3. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is phenyl that is unsubstituted or substituted with chlorine, - CH , or -CH2CH3. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0152] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0153] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0154] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R4is a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S, that is substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl,

[0155] -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, - o- 2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl), wherein the -C(i-3)alkyl, - OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; and

[0156] R4dland R4d2are each independently H or -C(i.3>alkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; wherein when R4is 1,2,4-triazolyl, then R4is 1 / / - 1 ,2,4-triazolyl, and when R4is a 6-membered heteroaryl, the heteroaryl is unsubstituted at the para-position.

[0157] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: each R4Cis independently fluorine, -CN, methyl, ethyl, isopropyl, -CD2CD3, -OCH3, -OCH2CH3, -OCH(CH )2, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CF2CH3, -CH2CH2CH2F, -

[0158] CH2CH2CHF2, -CH2CH2CF3, -CH(CH )CF3, -CH(CH2F)2, -CH2OCH3, -CH2CH2OCH3, - CH2CH2OCHF2, -CH2CH2OCF3, -0CHF2, -OCH2CHF2, -OCH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, -CFh-cyclopropyl, -O-cyclopropyl, -O-cyclobutyl, alternatively two R4cgroups attached to adjacent ring atoms can be combined to form the group:

[0159] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R4is a 5 membered heteroaryl ring having from 1 to 4 heteroatoms selected from N, O and S, that is substituted with one or two R4cgroups, wherein when R4is 1,2,4-triazolyl, then R4is

[0160] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0161] R4is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl, that is substituted with one or two R4Cgroups, wherein when R4is 1,2,4-triazolyl, then R4is

[0162] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrrolyl, pyrazolyl, imidazolyl, 1 / / - 1 ,2,3 -tri azolyl , 2 H-

[0163] 1.2.3-triazolyl, \H- 1,2,4-triazolyl, tetrazolyl, furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl,

[0164] 1.2.4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl or 1,3,4-thiadiazolyl, that is substituted with one or two R4cgroups.

[0165] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl, imidazolyl, 1 / / -l, 2, 3-tri azolyl, 2 / / -1 ,2,3- triazolyl, \H- 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, or 1,2,5-thiadiazolyl, that is substituted with one or two R4cgroups.

[0166] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R4is oxazolyl, isoxazolyl or oxadiazolyl that is substituted with one or two R4cgroups, wherein each R4cis independently C(3-5)Cycloalkyl, -C(i-3)alkyl or wherein the C(3-5)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with -OCH3, or one to three fluorine atoms.

[0167] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein

[0168] R4is oxazolyl, isoxazolyl, or thiadiazolyl (e.g., 1,2,3-thiadiazolyl) that is or substituted with one or two R4Cgroups, wherein each R4cis independently cyclopropyl or -C(i-3)alkyl, wherein the cyclopropyl and - i- 3>alkyl groups are unsubstituted or substituted with one to three fluorine atoms.

[0169] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is isoxazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, -

[0170] CF3, -CH2CH2F, -CH2CH2CF3, -CH2-OCH3, cyclopropyl, cyclopentyl, or oxazolyl substituted with one isopropyl, or oxadiazolyl substituted with one methyl or ethyl.

[0171] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is oxadiazolyl substituted with one -C(i-3)alkyl.

[0172] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0173]

[0174] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is a compound of Formula Ic:

[0175] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is a compound of Formula Ic-1 : wherein R3ais fluorine and n is 2.

[0176] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0177]

[0178] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0179] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0180] R4is pyrazolyl or imidazolyl that is unsubstituted or substituted with one or two R4cgroups, wherein each R4cis independently fluorine or -C(i-3)alkyl that is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine.

[0181] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl or imidazolyl that is unsubstituted or substituted with one or two R4cgroups, wherein each R4cis independently -C(i-3)alkyl that is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine.

[0182] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl or imidazolyl that is substituted with one or two R4Cgroups, wherein each R4cis independently -C(i-3)alkyl that is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, - CD2CD3, fluorine, -CHF2, -CF3, -CH2CHF2, -CH2CF3, -CH(CH )CF3, -CH(CH2F)2, - CH2CH2OCHF2, or -CH2CH2OCF3, or imidazolyl substituted with one isopropyl.

[0183] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one -C(i-3)alkyl.

[0184] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0185] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0186]

[0187] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0188] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is

[0189] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is

[0190] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0191] R4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, -C(i-3)alkyl, wherein the -C(o-i)alkylC(3-4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; and each R4dis independently -OCH3, -OCF3, -OCHF2, fluorine, wherein when R4is 1,2,4-triazolyl, then R4is

[0192] Alternatively, when R4is 1,2,4-triazolyl, then R4is 1H- 1,2,4-triazolyl.

[0193] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein

[0194] R4is triazolyl that is unsubstituted or substituted with one or two R4cgroups, wherein: each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; and each R4dis independently -OCH3, -OCF3, or -OCHF2, or fluorine.

[0195] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0196] R4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; and each R4Cis independently methyl, ethyl, isopropyl, -CH2CH20CH3,-CHF2, -CF3, -CH2CH2F, - CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -CH2CH2OCHF2, - CH2CH2OCF3, cyclopropyl, -CH2-cyclopropyl, wherein when R4is 1,2,4-triazolyl, then R4is

[0197] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0198]

[0199] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0200]

[0201] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is tetrazolyl substituted with -C(i-4)alkyl. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is tetrazolyl substituted with methyl or isopropyl. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0202] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl, thiazolyl, isothiazolyl or thiadiazolyl, each substituted with -C(i-3)alkyl, or -C(3-6)Cycloalkyl.

[0203] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl, thiazolyl, isothiazolyl or thiadiazolyl, each substituted with methyl, isopropyl or cyclopropyl.

[0204] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl substituted with isopropyl, isothiazolyl substituted with methyl, thiazolyl substituted with isopropyl, or thiadiazolyl substituted with methyl, isopropyl or cyclopropyl.

[0205] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0206] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R4is a 6-membered heteroaryl having 1 to 2 heteroatoms selected from N, that is substituted with one or two R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3- 4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and C(i.3>alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms, alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the heteroaryl is unsubstituted at the para-position. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein when R4is a substituted 6-membered heteroaryl, then R4is

[0207] each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3-4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and C(i.3>alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms, alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl.

[0208] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0209] R4is a pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl, that is substituted with one or two R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3- 4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and C(i-3)alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the heteroaryl is unsubstituted at the para-position.

[0210] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0211] R4is pyridyl that is unsubstituted or substituted with 1 to 2 R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -

[0212] OC(3-4)Cycloalkyl, -OC(i-3)alkyl, or C(i-3)alkyl wherein the -OC(i-3)alkyl, and C(i-3)alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the pyridyl is unsubstituted at the para-position.

[0213] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyridyl unsubstituted or substituted with C(i.2>alkyl unsubstituted or substituted with one to three fluorine atoms, wherein the pyridyl is unsubstituted at the para-position. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is pyridinyl that is unsubstituted or substituted with C aralkyl that is unsubstituted or substituted with one to three fluorine atoms. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0214] R4is pyridyl that is unsubstituted or substituted with 1 to 2 R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, cyclopropyl, cyclobutyl, -O- cyclopropyl, -O-cyclobutyl, -OMe, -OEt, -O-isopropyl, -OCHF2, -OCH2CHF2, -OCH2CF3, methyl, ethyl, isopropyl, -CH2-OCH3, -CHF2, -CF3, -C(CH )F2, -CH2CHF2, -CH2CF3, or - CH2CH2CHF2; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a cyclopentyl, wherein the pyridyl is unsubstituted at the para-position.

[0215] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein when R4is a substituted 6-membered heteroaryl, then R4is:

[0216] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0217] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

[0218] R4is pyridazinyl, pyrimidinyl, or pyrazinyl, wherein each is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently selected from -C(3-4)Cycloalkyl, -OC(i-3)alkyl and -C(i-4)alkyl, wherein the -C(i-4)alkyl groups are unsubstituted or substituted with one to three fluorine atoms, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position.

[0219] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R4is pyridazinyl, pyrimidinyl, or pyrazinyl, wherein each is unsubstituted or substituted with one or two R4Cgroups; and each R4Cis independently selected from methyl, isopropyl, -OMe, cyclopropyl, -CHF2, and -CF3, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein when R4is a substituted 6-membered heteroaryl, then R4is:

[0220]

[0221] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is: pyridazinyl unsubstituted or substituted with -OCH3or -CH3, pyrimidinyl unsubstituted or substituted with methyl, isopropyl, -OCH3, or cyclopropyl, wherein the methyl is unsubstituted or substituted with one to three fluorine atoms, or pyrazinyl unsubstituted or substituted with -OCH3, -CH3, or -CF3, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position.

[0222] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0223]

[0224] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0225] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R5is hydrogen or halogen.

[0226] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R5is hydrogen or fluorine. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R5is hydrogen.

[0227] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R5is halogen. In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R5is fluorine.

[0228] Table 1A

[0229]

[0230]

[0231]

[0232] Table 1G O 2021 / 222404

[0233] WO 2021 / 222404

[0234]

[0235]

[0236] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 1 A, Table IB, Table 1C, Table ID, Table IE, Table IF, Table 1G, Table 1H, Table II and Table 1J.

[0237] In some embodiments, disclosed herein is a compound of Formula I, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

[0238]

[0239] 5

[0240] In some embodiments, disclosed herein is a compound of Formula I, which is In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0241] In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0242] In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a compound of Formula I, which is In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0243] In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0244] In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0245] In some embodiments, disclosed herein is a compound of Formula I, which is pharmaceutically acceptable salt thereof.

[0246] In some embodiments, disclosed herein is a pharmaceutical composition, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for oral administration (e.g., a tablet or capsule).

[0247] In some embodiments, disclosed herein is a pharmaceutical composition made by mixing a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0248] In some embodiments, disclosed herein is a process for making a pharmaceutical composition comprising mixing a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0249] The present application also discloses compounds of Formula I’. All compounds of Formula I are compounds of Formula I’. Some compounds of Formula I’ are compounds of Formula I. Accordingly, disclosed herein is a compound of Formula G: or a pharmaceutically acceptable salt thereof, wherein:

[0250] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;

[0251] R2is H, -C(3-5)Cycloalkyl, -C(i-4)alkyl, or a 6-membered heterocycle having 1 to 2 oxygen atoms; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups; and wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;

[0252] Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -OC(i-3)alkyl or - OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;

[0253] R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o- i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH3- CHF2, -CF3, OH and =0;

[0254] R4is -C(3-6)Cycloalkyl, phenyl, or a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl wherein the - OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, -C(i-4)alkyl and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl) or a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, - OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0255] R4CI, R4c2, R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3- to 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and

[0256] R5is hydrogen or halogen; wherein: when R4is 1,2,4-triazolyl, then R4is when R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

[0257] In some embodiments, disclosed herein is a compound of Formula I’, or a pharmaceutically acceptable salt thereof, wherein:

[0258] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the piperidinyl and pyrrolidinyl are unsubstituted or substituted with one to three Rlcgroups;

[0259] Rlaand Rlbare each independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine; each Rlcis independently -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms;

[0260] R2is H, -C(3-5)Cycloalkyl, -C(i-4)alkyl or a 6-membered heterocycle having 1 to 2 oxygen atoms; wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;

[0261] R3is -C(5-6)Cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms;

[0262] R4is -C(3-4)Cycloalkyl, phenyl, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen and C(i.4>alkyl that is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one or two R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i.4>alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5-membered heteroaryl is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0263] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i.4>alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, - o- 2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl), wherein the -C(i-3)alkyl, - OC(i.3>alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0264] R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and

[0265] R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0266] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0267] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl, or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with one to three Rlcgroups;

[0268] Rlaand Rlbare each independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine; each Rlcis independently -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms;

[0269] R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl; wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;

[0270] R3is -C(5-6)Cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms;

[0271] R4is -C(3-4)Cycloalkyl, phenyl, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen and Cn-ualkyl that is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one or two R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i.4>alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5-membered heteroaryl is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0272] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, - o- 2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl), wherein the -C(i-3)alkyl, - OC(i.3>alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms;

[0273] R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0274] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0275] R1is -C(i-6)alkyl, -C(i-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-CF3, pyrrolidinyl, or piped dinyl: wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(i-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to four fluorine atoms; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine;

[0276] R2is H, -C(3-5)Cycloalkyl, or -C(i-3)alkyl; wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;

[0277] R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms; R4is -C(3-4)Cycloalkyl, spiropentanyl, spirohexanyl, spiroheptanyl, spirooctanyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl; wherein the -C(3-4)Cycloalkyl is unsubstituted or substituted with one to three groups selected from halogen, and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one or two groups selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i-4)alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl are substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0278] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and

[0279] R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0280] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0281] R1is -C(3-5)alkyl, wherein the -C(3-5>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the is unsubstituted or substituted with one to four fluorine atoms; wherein the is unsubstituted or substituted with one to four fluorine atoms; wherein the is unsubstituted or substituted with one to four fluorine atoms; and wherein the is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH or fluorine;

[0282] R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN;

[0283] R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5- oxadiazolyl,triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl; wherein the cyclopropyl is unsubstituted or substituted with one to three groups selected from fluorine and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one to two groups selected from chlorine and C aralkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is unsubstituted or substituted with C(i-3)alkyl, wherein the C(i-3)alkyl is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl, or 1,2,5-thiadiazolyl are unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-4)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is

[0284] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0285] R1is -C(3-5)alkyl, wherein the -C(3-5)alkyl is substituted with one to six Rlagroups; wherein the i ifs unsubstituted or substituted with one to two fluorine atoms; wherein the is unsubstituted or substituted with one to four fluorine atoms; wherein the substituted with two fluorine atoms; and wherein the is substituted with -CF3; each Rlais independently -OH or fluorine; R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN;

[0286] R3is cyclohexyl

[0287] R4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5- oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl; wherein the cyclopropyl is substituted with one to two groups selected from fluorine and

[0288] C(i>alkyl that is unsubstituted or substituted with three fluorine atoms; wherein the phenyl is unsubstituted or substituted with -chlorine, or -C(i-2)alkyl; wherein the 1,2,3-thiadiazolyl and 1,2,5-thiadiazolyl are substituted with C(2-3>alkyl; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl and imidazolyl are substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the -C(o-i)alkylC(3- 4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and

[0289] R5is hydrogen; wherein when R4is 1,2,4-triazolyl, then R4is

[0290] All embodiments described hereinabove with respect to the compounds of Formula I are incorporated herein by reference with respect to the compounds of Formula G. Accordingly, any definitions for variables R1, R2, R3, R4, and / or R5that apply to Formula I also apply to Formula G. Certain embodiments of the compound of Formula I’ are also provided below.

[0291] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0292] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl, or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with one to three Rlcgroups.

[0293] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0294] R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -CH2-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with one to three Rlcgroups.

[0295] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0296] R1is -C(3-6>alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl, or piperidinyl; wherein the -C(i.6>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to four Rlbgroups; and wherein the pyrrolidinyl and piperidinyl are substituted with one Rlcgroup; each Rlais independently fluorine, -CN,-OH, -OC(i-3)alkyl, or -OC(3-4)Cycloalkyl, wherein the - OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlbis independently fluorine;

[0297] Rlcis -C(i-4)alkyl that is substituted with one to three fluorine atoms.

[0298] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0299] R1is -C(3-6>alkyl, -C(i-2)alkylC(3-6)Cycloalkyl, or -C(i-2)alkyl-cyclopropyl-CF3; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(i-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one or two Rlbgroups; each Rlais independently fluorine; each Rlbis independently fluorine.

[0300] In some embodiments disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is -C(o-2)alkylC(3-6)cycloalkyl that is unsubstituted or substituted with one to three Rlbgroups, wherein each Rlbis independently fluorine. In some embodiments disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is -CH2C(3-6)Cycloalkyl that is unsubstituted or substituted with one to three Rlbgroups, wherein each Rlbis independently fluorine.

[0301] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0302]

[0303] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0304] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0305] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0306] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0307] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0308] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R1is:

[0309] FSCXA.

[0310] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is H, cyclopropyl, cyclobutyl, -C(i-3)alkyl, or tetrahydropyran, wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN; wherein the -C(i-3)alkyl is substituted with one to three R2agroups; and wherein each R2ais independently fluorine, -C(3-4)Cycloalkyl, -CN, -OH, or -OC(i-3)alkyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, tetrahydropyranyl,

[0311] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, isopropyl, cyclopropyl, cyclobutyl, or tetrahydropyran; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -

[0312] CN.

[0313] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN.

[0314] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is cyclopropyl or cyclobutyl, wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN.

[0315] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is unsubstituted cyclopropyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is cyclopropyl substituted with -CN. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is:

[0316] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is unsubstituted cyclobutyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is cyclobutyl substituted with -CN. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R2is:

[0317] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fa:

[0318] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb: wherein R3ais fluorine and n is 0, 1, or 2. In some embodiments, R3ais fluorine and n is 2.

[0319] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb-1 : wherein R3ais fluorine and n is 2. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb-2a: wherein R3ais fluorine and n is 2.

[0320] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb-2b: wherein R3ais fluorine and n is 2.

[0321] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb-3a: In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fb-3b: In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fc:

[0322] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula I’d: wherein Riais fluorine and n is 0, 1, or 2. In some embodiments, Riais fluorine and n is 2.

[0323] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fd-1 :

[0324] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fd-2a: wherein R3ais fluorine and n is 2.

[0325] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fd-2b:

[0326] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fd-3a:

[0327] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fd-3b:

[0328] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R3is C(3-6)Cycloalkyl, -C(3-6>alkyl or -CH2-0-C(i-3)alkyl, wherein the C(3-6)Cycloalkyl, -C(3-6>alkyl and -CH2-0-C(i-3)alkyl are unsubstituted or substituted with one to three R3agroups each independently selected from fluorine, -CFF, and -CF3. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R3is: In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R3is

[0329] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R3is

[0330] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R .3 is

[0331] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of formula Fe:

[0332] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein: R4is -C(3-6)Cycloalkyl that is unsubstituted or substituted with one to three R4agroups; and each R4ais independently selected from fluorine and -C(i-4)alkyl, wherein the -C(i-4)alkyl is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl.

[0333] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0334] R4is -C(3-6)Cycloalkyl that is unsubstituted or substituted with one to three R4agroups; and each R4ais independently selected from fluorine, CFb, CFhF, CF2H, and CF3; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a cyclopropyl, cyclobutyl, or cyclopentyl.

[0335] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0336] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0337] R4is a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S, that is substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -NFh, -N(CH3)2, -C(o-2)alkylC(3-6)Cycloalkyl, -

[0338] OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(o-2)alkylC(3-6)Cycloalkyl, - C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl), or a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, - OC(i-3)alkyl, -OC(3-4)Cycloalkyl, and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms; and

[0339] R4dland R4d2are each independently H or -C(i.3>alkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; wherein when R4is 1,2,4-triazolyl, then R4is \H- 1,2,4-triazolyl, and when R4is a 6-membered heteroaryl, the heteroaryl is unsubstituted at the para-position.

[0340] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein: each R4Cis independently fluorine, -CN, -OH, -MH, N(0¾)2, methyl, ethyl, isopropyl, -CD3, - CD2CD3, -0CH3, -OCH2CH3, -OCH(CH )2, -OC(CH )3, CH(CH )OH, -CHF2, -CF3, - CH2CH2F, -CH2CHF2, -CH2CF3, -CF2CH3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, - CH(CH )CHF2, -CH(CH )CF3, -CH(CH2F)2, -CH2CF2CH3, -CH2CH2CF2CH3, -CH2OCH3, - CH2CH20CH3, -CH2CH20CHF2, -CH2CH20CF3, -CH20CHF2, -OCHF2, -OCH2CHF2, - OCH2CH2F, -OCH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, -CH2-cyclopropyl, -O- cyclopropyl, -O-cyclobutyl, alternatively two R4cgroups attached to adjacent ring atoms can be combined to form the group:

[0341] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0342] R4is oxazolyl, isoxazolyl or oxadiazolyl that is substituted with one or two R4cgroups, wherein each R4cis independently -OH, -NH2, -N(CH3)2, -C(o-i)alkylC(3-5)Cycloalkyl, - OC(3-4)Cycloalkyl, -C(i-3)alkyl, -OC(i-3)alkyl, wherein the -C(o-i)alkylC(3-5)Cycloalkyl, -C(i-3)alkyl, and -OC(i-3)alkyl groups are unsubstituted or substituted with one to three groups selected from -OH, -OCH3, -OCHF2, -CH3, and fluorine. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein

[0343] R4is oxazolyl, isoxazolyl, or oxadiazolyl (e.g., 1,2,5-oxadiazolyl) that is unsubstituted or substituted with one or two R4cgroups, wherein each R4cis independently cyclopropyl, -C(i-3)alkyl, or -OC(i-3)alkyl, wherein the cyclopropyl, -C(i-3)alkyl, and -OC(i-3)alkyl groups are unsubstituted or substituted with one to three fluorine atoms.

[0344] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is isoxazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, - CF3, -CH2CH2F, -CH2CH2CF3, -CH2OCH3, cyclopropyl, cyclopentyl, or oxazolyl substituted with one isopropyl, or oxadiazolyl substituted with one methyl, ethyl, -OCH2CHF2, or cyclopropyl.

[0345] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is 1,2,5-oxadiazolyl substituted with cyclopropyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0346]

[0347] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0348] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0349] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0350] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0351] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0352] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0353] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of Formula I’f:

[0354]

[0355] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of Formula Fg:

[0356] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of Formula Fh:

[0357] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, which is a compound of Formula Fi: wherein R3ais fluorine, n is 2, and m is 1 or 2. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0358] R4is pyrazolyl or imidazolyl that is unsubstituted or substituted with one or two R4cgroups, wherein each R4cis independently fluorine, cyclopropyl, or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine.

[0359] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl or imidazolyl that is substituted with one or two R4Cgroups, wherein each R4cis independently -C(i-3)alkyl that is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine.

[0360] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one or two R4cgroups each independently cyclopropyl, methyl, ethyl, isopropyl, -CD3, -CD2CD3, fluorine, -CHF2, -CF3, -CH2CHF2, -CH2CF3, -CH(CH )CF3, - CH(CH2F)2, -CH2CH2OCHF2, or -CH2CH2OCF3, or imidazolyl substituted with one methyl or isopropyl.

[0361] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one -C(i-3)alkyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with isopropyl, -CD3, or -CD2CD3.

[0362] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0363]

[0364] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is: In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is

[0365] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is

[0366] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is

[0367] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0368] R4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; each R4cis independently -C(o-i)alkylC(3-4)Cycloalkyl, -C(i-4)alkyl, wherein the -C(o-i)alkylC(3-4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; and each R4dis independently -OCH3, -OCF3, -OCHF2, fluorine, wherein when R4is 1,2,4-triazolyl, then R4is

[0369] Alternatively, when R4is 1,2,4-triazolyl, then R4is 1H- 1,2,4-triazolyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein:

[0370] R4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; and each R4Cis independently methyl, ethyl, isopropyl, -CFhCFhOCFb CFQ^, -CF3, -CH2CH2F, - CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -CH(CH )CHF2, - CH(CH )CF3 -CH2CF2CH3, -CH2CH2CF2CH3, -CH2CH2OCHF2, -CH2CH2OCF3, cyclopropyl, -CH2-cyclopropyl, wherein when R4is 1,2,4-triazolyl, then R4is

[0371] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is:

[0372] 5 In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl, thiazolyl, or thiadiazolyl, each substituted with methyl, isopropyl or cyclopropyl. In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl substituted with isopropyl, thiazolyl substituted with isopropyl, or thiadiazolyl substituted with methyl, isopropyl or cyclopropyl.

[0373] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein R4is: In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein

[0374] Table 2A WO 2021 / 222404

[0375]

[0376] Table 2G

[0377]

[0378]

[0379]

[0380]

[0381] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 2A, Table 2B, Table 2C, Table 2D, Table 2E, Table 2F, Table 2G, Table 2H, Table 21, Table 2J, Table 2K, and Table 2M.

[0382] In some embodiments, disclosed herein is a compound of Formula G, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

[0383]

[0384] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0385] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0386] In some embodiments, disclosed herein is a compound of Formula I’ that is

[0387] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0388] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0389] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0390] In some embodiments, disclosed herein is a compound of Formula I’ that is In some embodiments, disclosed herein is a compound of Formula I’ that is In some embodiments, disclosed herein is a compound of Formula I’ that is

[0391] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof.

[0392] In some embodiments, disclosed herein is a compound of Formula I’ that is pharmaceutically acceptable salt thereof. In some embodiments, disclosed herein is a pharmaceutical composition, comprising a compound of Formula G, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for oral administration (e.g., a tablet or capsule). In some embodiments, disclosed herein is a pharmaceutical composition made by mixing a compound of Formula G, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, disclosed herein is a process for making a pharmaceutical composition comprising mixing a compound of Formula G, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0393] III. Therapeutic Use

[0394] The present application is also directed to a method for treating and / or ameliorating a IL-17 mediated inflammatory syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof.

[0395] The present application is also directed to a method for treating and / or ameliorating a IL-17 mediated inflammatory syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound of Formula G, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof.

[0396] In some embodiments, disclosed herein is a method for treating or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

[0397] In some embodiments, disclosed herein is a method for treating or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof.

[0398] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0399] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0400] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriasis.

[0401] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriasis.

[0402] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis.

[0403] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is rheumatoid arthritis.

[0404] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is rheumatoid arthritis.

[0405] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is ankylosing spondylitis.

[0406] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is ankylosing spondylitis. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is hidradenitis suppurativa.

[0407] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is hidradenitis suppurativa.

[0408] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is bullous pemphigoid.

[0409] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is bullous pemphigoid.

[0410] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is atopic dermatitis. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is atopic dermatitis.

[0411] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is vitiligo.

[0412] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is vitiligo.

[0413] In some embodiments, disclosed herein is a method for treating or ameliorating and / an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple sclerosis.

[0414] In some embodiments, disclosed herein is a method for treating or ameliorating and / an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple sclerosis. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

[0415] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

[0416] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is asthma.

[0417] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is asthma.

[0418] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is uveitits. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is uveitits.

[0419] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is chronic obstructive pulmonary disorder.

[0420] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is chronic obstructive pulmonary disorder.

[0421] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple myeloma.

[0422] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple myeloma. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is administered orally (e.g., as a tablet or capsule).

[0423] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the compound of Formula I’ or the pharmaceutically acceptable salt thereof is administered orally (e.g., as a tablet or capsule).

[0424] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the therapeutically effective amount is a dose of about 10 mg to 300 mg QD. In some embodiments, the therapeutically effective amount is a dose of about 20 mg to 200 mg QD. In some embodiments, the therapeutically effective amount is a dose of about 50 mg to 100 mg QD. In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the therapeutically effective amount is a dose of about 10 mg to 300 mg QD. In some embodiments, the therapeutically effective amount is a dose of about 20 mg to 200 mg QD. In some embodiments, the therapeutically effective amount is a dose of about 50 mg to 100 mg QD.

[0425] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the therapeutically effective amount is a dose of about 10 mg to 300 mg BID. In some embodiments, the therapeutically effective amount is a dose of about 20 mg to 200 mg BID. In some embodiments, the therapeutically effective amount is a dose of about 50 mg tolOO mg BID.

[0426] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or a pharmaceutically acceptable salt thereof, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus, wherein the therapeutically effective amount is a dose of about 10 mg to 300 mg BID. In some embodiments, the therapeutically effective amount is a dose of about 20 mg to 200 mg BID. In some embodiments, the therapeutically effective amount is a dose of about 50 mg tolOO mg BID.

[0427] In some embodiments, disclosed herein is the use of a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof, for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0428] In some embodiments, disclosed herein is the use of a therapeutically effective amount of compound of Formula G, or a pharmaceutically acceptable salt thereof, for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0429] In some embodiments, disclosed herein is the use of a compound of Formula I, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and / or ameliorating an IL- 17A mediated inflammatory syndrome, disorder, or disease selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0430] In some embodiments, disclosed herein is the use of a compound of Formula G, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and / or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

[0431] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0432] In some embodiments, disclosed herein is a method for treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0433] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, wherein the syndrome, disorder or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, atopic dermatitis, vitiligo, multiple sclerosis, asthma, allergic asthma, steroid resistant asthma, neutrophilic asthma, chronic obstructive pulmonary disease, uveitis, multiple myeloma, and systemic lupus erythematosus, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0434] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, wherein the syndrome, disorder or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, atopic dermatitis, vitiligo, multiple sclerosis, asthma, allergic asthma, steroid resistant asthma, neutrophilic asthma, chronic obstructive pulmonary disease, uveitis, multiple myeloma, and systemic lupus erythematosus, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0435] In some embodiments, disclosed herein is a method of treating or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, wherein the syndrome, disorder or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, and ankylosing spondylitis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0436] In some embodiments, disclosed herein is a method of treating or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, wherein the syndrome, disorder or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, and ankylosing spondylitis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof.

[0437] In some embodiments, disclosed herein are methods of modulating IL-17 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I, or pharmaceutically acceptable salt thereof.

[0438] In some embodiments, disclosed herein are methods of modulating IL-17 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula G, or pharmaceutically acceptable salt thereof.

[0439] Also disclosed herein is a method of inhibiting production of interleukin- 17, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salt thereof. Also disclosed herein is a method of inhibiting production of interleukin- 17, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula G, or pharmaceutically acceptable salt thereof.

[0440] IV. Combination Therapy

[0441] A compound of Formula I, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof may also be used in combination with one or more additional therapeutic agents. Likewise, a compound of Formula G, or pharmaceutically acceptable salt thereof, a composition thereof, or a medicament thereof may be used in combination with one or more additional therapeutic agents.

[0442] In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of anti-inflammatory agents, immunomodulatory agents, and immunosuppressive agents.

[0443] In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of: anti-TNF alpha agents such as infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), golimumab (Simponi®), etanercept (Enbrel®), thalidomide (Immunoprin®), lenalidomide (Revlimid®), and pomalidomide (Pomalyst® / Imnovid®); anti-p40 antibody agents such as ustekinumab (Stelara®); and anti-pl9 antibody agents such as guselkumab (Tremfya®), tildrakizumab (Ilumya™ / Ilumetri), risankizumab (Skyrizi™), and mirikizumab.

[0444] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof in a combination therapy with one or more additional therapeutic agents, such as anti-inflammatory agents, immunomodulatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, atopic dermatitis, vitiligo, multiple sclerosis, asthma, allergic asthma, steroid resistant asthma, neutrophilic asthma, chronic obstructive pulmonary disease, uveitis, multiple myeloma, and systemic lupus erythematosus.

[0445] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Formula G, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof in a combination therapy with one or more additional therapeutic agents, such as anti-inflammatory agents, immunomodulatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, atopic dermatitis, vitiligo, multiple sclerosis, asthma, allergic asthma, steroid resistant asthma, neutrophilic asthma, chronic obstructive pulmonary disease, uveitis, multiple myeloma, and systemic lupus erythematosus.

[0446] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof in a combination therapy with one or more additional therapeutic agents, such as anti-inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is psoriasis, psoriatic arthritis, ankylosing spondylitis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is psoriasis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is psoriatic arthritis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is ankylosing spondylitis.

[0447] In some embodiments, disclosed herein is a method of treating and / or ameliorating an IL-17 mediated inflammatory syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Formula G, or pharmaceutically acceptable salt thereof, composition thereof, or medicament thereof in a combination therapy with one or more additional therapeutic agents, such as anti-inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is psoriasis, psoriatic arthritis, ankylosing spondylitis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is psoriasis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is psoriatic arthritis. In some embodiments, the IL-17 mediated inflammatory syndrome, disorder or disease is ankylosing spondylitis.

[0448] Dosage Regimen

[0449] When employed as IL-17A modulators, the compounds disclosed herein may be administered in an effective amount within the dosage range of about 0.5 mg to about 1 g, preferably between about 0.5 mg to about 500 mg, in single or divided daily doses. In some embodiments, the dosage amount is about 5 mg to 400 mg. In some embodiments, the dosage amount is about 10 mg to 300 mg. In some embodiments, the dosage amount is about 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg of a compound of Formula I, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg of a compound of Formula I, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, or 300 mg of a compound of Formula I, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 300, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, or 400 mg of a compound of Formula I, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500 mg of a compound of Formula I, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 10 mg to 300 mg. In some embodiments, the dosage amount is about 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg of a compound of Formula I’, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg of a compound of Formula I’, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, or 300 mg of a compound of Formula G, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, or 400 mg of a compound of Formula G, or pharmaceutically acceptable salt thereof. In some embodiments, the dosage amount is about 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500 mg of a compound of Formula G, or pharmaceutically acceptable salt thereof.

[0450] In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 10 mg to 300 mg QD. In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 20 mg to 200 mg QD. In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 50 mg to 100 mg QD.

[0451] In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 10 mg to 300 mg QD. In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 20 mg to 200 mg QD. In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 50 mg to 100 mg QD.

[0452] In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 10 mg to 300 mg BID. In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 20 mg to 200 mg BID. In some embodiments, a compound of Formula I, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 50 mg to 100 mg BID. In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 10 mg to 300 mg BID. In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 20 mg to 200 mg BID. In some embodiments, a compound of Formula G, or pharmaceutically acceptable salt thereof, may be administered in an effective amount within the dosage range of about 50 mg to 100 mg BID.

[0453] The dosage administered will be affected by factors such as the route of administration, the health, weight and age of the recipient, the frequency of the treatment and the presence of concurrent and unrelated treatments.

[0454] It is also apparent to one skilled in the art that the therapeutically effective dose for compounds of the present invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined by one skilled in the art and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

[0455] Pharmaceutically Acceptable Salts

[0456] Pharmaceutically acceptable acidic / anionic salts include, and are not limited to acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methyl sulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate and triethiodide. Organic or inorganic acids also include, and are not limited to, hydriodic, perchloric, sulfuric, phosphoric, propionic, glycolic, methanesulfonic, hydroxyethanesulfonic, oxalic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, saccharinic or trifluoroacetic acid.

[0457] Pharmaceutically acceptable basic / cationic salts include, and are not limited to aluminum, 2- amino-2-hydroxymethyl-propane-l,3-diol (also known as tris(hydroxymethyl)aminomethane, tromethane or “TRIS”), ammonia, benzathine, / -butylamine, calcium, calcium gluconate, calcium hydroxide, chloroprocaine, choline, choline bicarbonate, choline chloride, cyclohexyl amine, diethanolamine, ethylenediamine, lithium, LiOMe, L-lysine, magnesium, meglumine, NH3, NH4OH, / V-methyl-D-glucamine, piperidine, potassium, potassium - / -butoxide, potassium hydroxide (aqueous), procaine, quinine, sodium, sodium carbonate, sodium-2-ethylhexanoate, sodium hydroxide, triethanolamine, or zinc.

[0458] Pharmaceutical Compositions

[0459] The compounds of Formula I, or pharmaceutically acceptable salt thereof, may be formulated into pharmaceutical compositions comprising any known pharmaceutically acceptable carriers. The compounds of Formula I’, or pharmaceutically acceptable salts thereof, may likewise be formulated into pharmaceutical compositions comprising any known pharmaceutically acceptable carriers. Exemplary carriers include, but are not limited to, any suitable solvents, dispersion media, coatings, antibacterial and antifungal agents and isotonic agents. Exemplary excipients that may also be components of the formulation include fillers, binders, disintegrating agents and lubricants.

[0460] The pharmaceutically-acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts which are formed from inorganic or organic acids or bases. Similarly, the pharmaceutically-acceptable salts of the compounds of Formula I’ also include the conventional non-toxic salts or the quaternary ammonium salts which are formed from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, benzoate, benzenesulfonate, citrate, camphorate, dodecyl sulfate, hydrochloride, hydrobromide, lactate, maleate, methanesulfonate, nitrate, oxalate, pivalate, propionate, succinate, sulfate and tartrate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamino salts and salts with amino acids such as arginine. Also, the basic nitrogen-containing groups may be quatemized with, for example, alkyl halides.

[0461] The pharmaceutical compositions of the invention may be administered by any means that accomplish their intended purpose. Examples include administration by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, topical, buccal or ocular routes. Alternatively or concurrently, administration may be by the oral route. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts, acidic solutions, alkaline solutions, dextrose-water solutions, isotonic carbohydrate solutions and cyclodextrin inclusion complexes.

[0462] Also disclosed herein is a method of making a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier with any of the compounds of Formula I, or pharmaceutically acceptable salt thereof. Further disclosed herein is a method of making a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier with any of the compounds of Formula G, or pharmaceutically acceptable salt thereof. Additionally, the present application includes pharmaceutical compositions made by mixing a pharmaceutically acceptable carrier with any of the compounds of the present invention.

[0463] EXAMPLES

[0464] ABBREVIATIONS

[0465] Herein and throughout the application, the following abbreviations may be used.

[0466] A Angstrom

[0467] Ac acetyl acac acetyl acetone

[0468] ACN acetonitrile

[0469] BAST Bis(2-methoxyethyl)aminosulfur trifluoride

[0470] Boc tert- butyl oxy carb onyl br broad

[0471] Bs / ¾ / ra-bromophenylsulfonyl (brosyl)

[0472] Bu butyl Bz benzoate

[0473] CAM ceric ammomium molybdate

[0474] COD or cod cyclooctadiene d NMR chemical shift in parts per million downfield from a standard d doublet d day(s)

[0475] DAST (diethylamino)sulfur trifluoride dba dib enzyli deneacetone

[0476] DBU l,8-diazabicyclo[5.4.0]undec-7-ene

[0477] DCM dichloromethane

[0478] DEA diethylamine

[0479] DIAD diisopropyl azodicarboxylate

[0480] DffiAL-H diisobutylaluminum hydride

[0481] DIPEA / V, / V-diisopropyl ethyl amine (Hiinig’s base)

[0482] DMA Af,A di m ethyl acetam i de

[0483] DMAP 4-(dimethylamino)pyridine

[0484] DME 1 ,2-dimethoxyethane

[0485] DMF Af, A -di m ethy 1 form am i de

[0486] DMP Dess-Martin Periodinane

[0487] DMSO dimethyl sulfoxide

[0488] DPPE ethylenebis(diphenylphosphine) dppf 1 , 1 '-bis(diphenylphosphino)ferrocene

[0489] ELSD evaporative light scattering detector

[0490] EDCI 1 -ethyl-3 -(3 -dimethylaminopropyl) carbodiimide hydrochloride

[0491] ESI electrospray ionization

[0492] Et ethyl

[0493] EtOAc ethyl acetate

[0494] Fmoc fluorenylmethyloxycarbonyl g gram(s) h hour(s) HATU 6>-(7-azabenzotri azol -1 -y 1 )-N, N, N A"-tetram ethyl uroni um hexafluorophosphate

[0495] HOAt 1 -hydroxy-7-azabenzotri azole

[0496] HOBt 1 -hydroxybenzotri azole

[0497] HPLC high pressure liquid chromatography

[0498] Hz Hertz i iso

[0499] J coupling constant (NMR spectroscopy)

[0500] L liter(s)

[0501] LC liquid chromatography

[0502] LDA lithium diisopropylamide m milli or multiplet m / z mass-to-charge ratio

[0503] M+parent molecular ion

[0504] M molar (moles / liter) or mega

[0505] Me methyl

[0506] MeCN acetonitrile min minute(s) m micro

[0507] Ms methanesulfonyl

[0508] MS mass spectrometry

[0509] MTBE tert- butyl methyl ether

[0510] NCS A -chi orosucci ni m i de n normal n nano

[0511] N normal (equivalent concentration)

[0512] NMM A - ethyl morpholine

[0513] NMR nuclear magnetic resonance

[0514] NPA «-propylamine

[0515] Pd / C palladium on carbon

[0516] Ph phenyl PPTS pyridinium p-toluenesulfonate

[0517] Pr propyl

[0518] Psi pounds per square inch

[0519] Pd(dtbpf)Cb [1,1 '-bis(di- / er / -butylphosphino)ferrocene]dichloropalladium(II) q quartet

[0520] Rochelle salt sodium potassium tartrate rt room temperature

[0521] RuPhos PD G3 (2-Dicyclohexylphosphino-2',6'-diisopropoxy-l,l'-biphenyl)[2-(2'- amino- 1 , 1 '-biphenyl)]palladium(II) methanesulfonate s singlet

[0522] SFC supercritical fluid chromatography t tert t triplet

[0523] TBAT tetrabutylammonium difluorotriphenylsilicate

[0524] TBD triazabicyclodecene

[0525] TEA triethylamine

[0526] TFA trifluoroacetic acid

[0527] THF tetrahydrofuran

[0528] TLC thin layer chromatography

[0529] TMP tetramethylpiperidinyl

[0530] Ts / ¾ / ra-toluenesulfonyl (tosyl)

[0531] XPhos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

[0532] XPhos Pd G1 (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2- (2-aminoethyl)phenyl)]palladium(II) chloride, (XPhos) palladium(II) phenethylamine chloride, Chloro(2- dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2-(2- aminoethyl)phenyl)]palladium(II)

[0533] XtalFluor-E®(diethylamino)difluorosulfonium tetrafluorob orate

[0534] In some embodiments, provided herein are processes and intermediates disclosed herein that are useful for preparing a compound of the disclosure or pharmaceutically acceptable salts thereof. GENERAL SCHEMES: Scheme 1 cat Pd (dba) R3a1. HCI

[0535] R2= H R3a= H or F Certain compounds of formula I-aa in the present invention can be prepared, for example, according to Scheme 1. Cyanation of A-I using reagents such as zinc cyanide in the presence of a catalyst, such as Pd2(dba)3, affords nitriles A-II. Removal of the Boc group under acidic conditions, such as aqueous hydrochloric acid, afforded an amine that was subsequently coupled to a carboxylic acid through the use of a coupling agent, such as HATU or EDCI, in the presence of a base, such as DIPEA, in a solvent, such as DMF, MeCN, or DCM, with or without an additive, such as HOBt, to yield amides A-III. Reduction of the nitrile of A-III with hydrogen in the presence of a catalyst, such as Raney nickel affords the corresponding primary amines A-IV, which can be coupled to carboxylic acids in a manner analogous to the conversion of A-II to A- III to give compounds of the general structure I-aa shown in Scheme 1. Scheme 2a

[0536] HCI or TFA R4C02H

[0537] R1C02H

[0538] Scheme 2b

[0539] A-Vlb A-Vllb

[0540] R3a -

[0541] Certain compounds of general structure I-aa-1 and I-aa in the present invention can also be prepared according to Scheme 2a and 2b, respectively. Removal of the Boc group of compounds of type A-Ia or A-Ib under acidic conditions, such as aqueous hydrochloric acid or TFA, affords amines of type A-V (e.g., A-Va and A-Vb). Amides of formula A- Via and A-VIb can be formed from A-Va and A-Vb, respectively, in a manner analogous to the conversion of A-II to A-III (see Scheme 1). Conversion of compounds of type A- VI to A- VII was conducted using a reagent mixture capable of transferring a vinyl group, such as potassium trifluoro(vinyl)borate, in the presence of a catalyst, such as Pd(dtbpf)Cl2. Compounds of general structure A- VII could be converted to compounds of structure A- VIII through the oxidative cleavage of the vinyl substituent using reagents, such as sodium periodate, in the presence of a catalyst, such as potassium osmate, in a solvent, such as aqueous 1,4-dioxane. Subsequent condensation of compounds of general structure A- VIII with fV)-(-)-2- ethyl-2-propanesulf a ide gives the corresponding sulfmimide, that upon addition of nucleophilic carbon-containing reagents, such as alkyl magnesium halides, yields sulfmamides of general structure A-IX. Conversion of compounds of structure A-IX to A-X could be conducted under acidic conditions, such as aqueous hydrochloric acid, and subsequently converted to compounds of general structure I-aa-1 and I-aa in a manner analogous to the conversion of A-II to A-III. Compounds of general structure I-aa obtained as mixtures of isomers were subjected to additional purification techniques, such as HPLC or SFC using columns with a chiral stationary phase, to give single-isomer products I-aa-1 and I-aa.

[0542] Compounds I-aa-2 can be prepared by the reaction shown in Scheme 2c. Treatment of L -oxides I- A with trimethyl phosphite in toluene generates compounds I-aa-2.

[0543] Scheme 2d

[0544] Compounds I-aa-3 can be prepared as shown Scheme 2d. Hydration of the olefin within I-A-I using reagents such as Co(acac)2, (cobalt(II) acetylacetonate), and PhSiH3 (phenyl si lane) in an oxygenated atmosphere in THF provides compounds I-aa-3. Scheme 3 amide formation

[0545] The compounds of formula I-aa in the present invention can also be prepared according to Scheme 3 in which the relative order of transformations is reversed compared to Scheme 2b. Aldehydes of formula A-XI can be formed from A-I (e.g., A-Ib) in a manner analogous to the conversion of A- VI to A- VIII. Similarly, compounds of general structure A-XII can be formed from A-XI in a manner analogous to the conversion of A- VIII to A-IX. Selective removal of the sulfmamide functionality from compounds of general structure A-XII under acidic conditions such, as aqueous hydrochloric acid in EtOAc, yields amines of general structure A-XIII. Acylation of A-XIII, followed by removal of the Boc group, and amide formation to give compounds of general structure I-aa could be conducted as described in the preceding schemes, though in some cases they were prepared (i) using an acid chloride in a solvent such as DCM, (ii) by direct conversion of an ester to an amide by heating with A1(CH3)3 in a solvent such as toluene or (iii) by conversion of the A-hydroxy succinate ester in the presence of DIPEA in a solvent such as acetonitrile.

[0546] Scheme 3a

[0547] 1. CH2=CHBF3K

[0548] (where R2= cyclopropyl or cyclobutyl) or

[0549] R2X, Indium, THF (method f)

[0550] Compounds of the general structure A-XXXI can be made as shown in Scheme 3a. Following a sequence similar to that shown in Scheme 3 chlorides A-la can be converted in a two step sequence to the corresponding aldehydes A-XIa. Condensation of compounds A-XIa with either ( R )- or fV)-2-methyl-2-propanesulfinamide gives the corresponding sulfmimides A-XXX. Addition of grinard reagents, such as R2MgX (X= halide), in a solvent such as DCM (method a) to A-XXX yields compounds of the general formula A-XXXI. Addition of nucleophilic carbon- containing reagents such as TMSCF3 to A-XXX in the presence of reagents such as TBAF in solvents such as THF (method b) yields compounds of the general formula A-XXXI. Alternatively, addition of nucleophilic carbon-containing reagent such as TMSCHF2 in the presence of reagents such as potassium / cvv-butoxide in solvents such as THF (method c) affords compounds of the general formula A-XXXI. Trimethylsilylacteonitrile can be metallated using reagents such as tetrabutylammonium phenolate in a solvent such as THF (method d) to afford sulfmamides of general structure A-XXXI. Cycloalkyl nitriles can be deprotonated using bases such as LiHMDS in a solvent such as THF (method e) and upon addition to A-XXX provide compounds A-XXXI. Addition of indium reagents to A-XXX, such as allyl indium formed by in situ treatment of allyl bromide and indium in THF (method f), provides compounds A-XXXI. Scheme 3b

[0551] A-XXXIV

[0552] The compounds of formula A-XXXIV can be prepared according to Scheme 3b. Ketones of formula A-XXXIII can be formed from A-Ia using a vinyl transferring agent such as a 4, 4,5,5- tetramethyl-vinyl-l,3,2-dioxaborolane (J-III), in the presence of a catalyst, such as RuPhos Pd G3, followed by oxidative cleavage of the vinyl substituent using reagents such as sodium periodate in the presence of a catalyst such as potassium osmate in a solvent such as aqueous 1,4- dioxane. Reductive amination using reagents such as ammonium formate in the presence of a reducing agent such as sodium cyanoborohydride with an additive such as acetic acid in a solvent such as methanol yields amines of general structure A-XXXIV.

[0553] Scheme 3c 04

[0554] R2= allyl

[0555] Amides of the structure A-XVIIa can be prepared as shown in Scheme 3c. Amide formation from amines A-XIIIa can be performed as described in previous schemes to provide A-XVa. Oxidative cleavage of the olefin within A-XVa using reagents such as sodium periodate and potassium permanganate in solvents such as 1,4-dioxane and water affords corresponding aldehydes A-XVIa. Treatment of A-XVIa with XtalFluor-E®in the presence of reagents such as triethylamine trihydrofluoride and DAST in solvents such as DCM then yields the corresponding geminally difluorinated products A-XVIIa. These may then be converted to analogs 1-aa using the sequence shown in Scheme 3.

[0556] Scheme 3d

[0557]

[0558] A-XIXa A-Xaa

[0559] Compounds of the general formula A-Xaa can be prepared using sequence shown in Scheme 3d. Protection of the amine within A-XIIIa using FmocCI in the presence of DIPEA in a solvent such as DCM then affords carbamates A-XVIIIa. Deprotection of the Boc group using an acid such as HCI in a solvent such as EtOAc then affords the corresponding amine hydrochloride salts A-XIXa. Sequential amide bond formation using conditions mentioned above and Fmoc deprotection using a reagent such as piperdine in a solvent such as DCM then affords amines A-Xaa.

[0560] Scheme 3e

[0561]

[0562] Compounds I-aa, such as I-aa-4, can be prepared as shown in Scheme 3e. Amide bond formation using conditions as described above using cyanoacetic acid yields amides A-XX. Treatment of A- XX with NaNCh in the presence of HC1 in a solvent such as acetonitrile yields oximes A-XXI. Subsequent treatment of A-XXI with hydroxylamine in THF then affords oxadiazoles A-XXII. Oxidation of the amine within A-XXII using Na2W04*2H20 in the presence of hydrogen peroxide and sulfuric acid then generates the nitro compounds A-XXIII. Displacement of the nitro group in A-XXIII with a hydroxyl group can be achieved using sodium hydroxide in a solvent such as THF / H2O to afford oxadiazoles A-XXIV. Treatment of amines A-XXII with NaNC in the presence of LiCl in solvents such as water and CH3CN affords the chlorides A-XXIVa. Treatment of chlorides A-XXIVa with aliphatic alcohols, R4ccOH, in the presence of a base such as sodium hydride in a solvent such as THF affords compounds I-aa-4, wherein R4ccis Cn-ualkyl or C(o-2)alkyl-C(3-4)Cycloalkyl and wherein R4ccis unsubstituted or substituted with one to six R4dgroups. Scheme 3f

[0563] Additional oxadiazole containing analogs can be prepared by the route shown in Scheme 3f. Treatment of amines A-XIIIa with lactones I-XI in solvents such as DCM, or in the presence of triazabicyclodecene and in solvents such as THF affords amides A-XXV. In the case where A- XXV contains a primary alcohol, oxidation using DMP can generate the corresponding aldehydes A-XXVI. Treatment of A-XXVI with DAST in a solvent such as DCM then affords compounds I-aa-5. Scheme 3g

[0564] A-Xllla A-XXVII

[0565] Amides of the general formula A-XXVII can be prepared by the method shown in Scheme 3g. Treatment of amines A-XIIIa with diazo-l-(3-fluorobicyclo[l.l.l]pentan-l-yl)ethan-l-one J-I in the presence of DIPEA and silver benzoate (AgBz) in CEECN affords homologated amides A-

[0566] XXVII

[0567] Scheme 4

[0568] Compounds of formula A-I can be prepared according to the route in Scheme 4. Chloromethyl ketones B-I are converted to the corresponding iodomethyl ketones B-II under conditions of halide interconversion, such as sodium iodide in acetone. Cyclocondensation with 5-chloropyridazin-3- amine then affords the imidazopyridazines A-I.

[0569] Scheme 4a chlorocyclopentadienyl- bis(tri hen l hos hine)ruthenium(ll)

[0570] Compounds of formula A-Ia can be prepared according to the route in Scheme 4a. Ylides of general structure C-X undergo cyclocondensation with 5-chloropyridazin-3 -amine in the presence of a catalyst such as chlorocyclopentadienylbis(triphenylphosphine)ruthenium(II) in the presence of additives such as sodium triflate and 4Ά molecular sieves in a solvent such as toluene to afford imidazopyridazines A-Ia.

[0571] Scheme 4b

[0572] G-la A-XVIlb Compounds of the general structure A-XVII can be prepared as shown in Scheme 4b. Cyclocondensation of aminopyridazines G-I with iodoketones B-lc in a solvent such as DMA in the presence of 4 A molecular sieves affords compounds A-XVII. Alternatively, chlorinated compounds G-Ia can undergo cyclocondensation with iodoketones B-lc under similar conditions to generate chlorinated aminopyridazines A-XVIIb. Hydrogenation using palladium catalysis in the presence of hydrogen gas and ammonium formate in ethanol, or in the presence of hydrogen gas and acetic acid in a solvent such as THF then yields compounds A-XVII.

[0573] Scheme 5

[0574] Alternatively, A-I (e.g., A-Ib) can be prepared as shown in Scheme 5. Treatment of 4,4- difluorocyclohexyl ketone with methyl 2-(( / er / -butoxycarbonyl)amino)-2- (dimethoxyphosphoryl)acetate and a base, such as DBU, affords corresponding tetrasubstituted olefins B-III. Reduction of B-III with a hydrogen source, such as hydrogen gas, in the presence of a catalyst, such as Pd / C, yields racemic B-IV. Treatment of B-IV with (dimethyl(oxo)-A6- sulfanylidene)methane, formed by deprotonation of trimethyl sulfoxonium iodide with a base, such as sodium / c / 7-but oxide, affords ylides B-V. Cyclocondensation of B-V with 5-chloropyridazin-3- amine in the presence of a catalyst, such as di-p-chlorobis[(l,2,5,6-p)-l,5- cy cl ooctadi ene] di i ri di u followed by resolution of the enantiomers affords compounds A-Ib.

[0575] Scheme 6 B-VI

[0576] Chloromethyl ketones B-Ia may also be prepared by the route outlined in Scheme 6. Treatment of methyl fV)-2-amino-2-cyclohexyl acetate with di- / <z / 7-butyl dicarbonate with or without a base, such as TEA, in a solvent, such as DCM, affords B-VI which can be subsequently converted to the chloromethyl ketones B-Ia upon treatment with chloroiodomethane treated with LDA in an aprotic solvent, such as THF.

[0577] Scheme 7

[0578] C-lll B-IV

[0579] Alternatively, compounds of general structure B-Ib can be prepared according to Scheme 7. ( S )- 2-Amino-2-(4-hydroxyphenyl)acetic acid can be converted to C-I by esterifying the acid under acidic conditions, such as thionyl chloride in dry methanol, and subsequent treatment with di -tert- butyl dicarbonate in the presence of a mild base, such as potassium carbonate, in a solvent mixture, such as water and 1,4-dioxane. Reduction of the phenyl ring of C-I using a hydrogen source, such as hydrogen gas, and a catalyst, such as platinum(IV) oxide, in a solvent, such as HO Ac, gives C- II. Oxidation of the alcohol of C-II with an oxidant, such as DMP, affords ketones C-III. Conversion of C-III to geminal difluorides B-IV can be achieved by treatment with deoxygenative fluorinating reagents, such as BAST (bis(2-methoxyethyl)aminosulfur trifluoride), in a solvent, such as DCM. Saponification of the ester using a base, such as lithium hydroxide, furnishes the corresponding acids C-IV, which upon conversion to a mixed anhydride by treatment with a reagent such as isobutyl chloroformate followed by addition of diazomethane yields corresponding diazoketones C-V. C-V could be converted to B-Ib by treatment with aqueous hydrochloric acid.

[0580] Scheme 7b

[0581] Compounds of the general formula B-Ic and C-IX can be prepared as shown in Scheme 7b. Condensation of aldehydes H-II with fV)-(-)-2-m ethyl -2-propanesulfinamide gives corresponding sulfmimides C-VI. Cyanation using TMSCN in the presence of scandium triflate then affords nitriles C-VII. Subsequent treatment with HCI in methanol then affords esters C-VIII. Coincident ester saponification and Boc protection of the amine then yields C-IX. Activation of the carboxylic acid within C-IX using a reagent such as CDI or isobutylchloroformate in the presence of a base such as potassium / c / V-butoxide in a solvent such as THF then generates ylides of the structure C- X. Treatment of ylides C-X with methanesulfonic acid in the presence of lithium chloride in a solvent such as THF then provides the chloromethyl ketones B-Ib, that can be converted to the corresponding iodides by treatment with sodium iodide in acetone to yield compounds B-Ic. Alternatively, acids C-IX can be prepared from nitriles C-VII by treatment with aqueous HC1 and subsequent treatment of resulting amino acids C-XI with sodium hydroxide and Boc anhydride to afford protected amino acids C-IX. Scheme 8 cat. Pd / C

[0582] D-l

[0583] (racemic mixture)

[0584] Trans- l-( / er / -butoxycarbonyl)-3-(trifluoromethyl)piperidine-2-carboxylic acid D-I can be prepared as shown in Scheme 8. Esterification of 3-(trifluoromethyl)picolinic acid in acidic methanol yields ester D-II. Reduction of the pyridine ring D-II using a hydrogen source, such as ammonium formate, in the presence of a catalyst, such as palladium on carbon, afforded racemic piperidine D-III. D-I could then be prepared by epimerizing the 2-position of D-III under basic conditions, such as sodium methoxide in methanol, followed by treatment with di- / c / 7-butyl dicarbonate with a base such as aqueous sodium bicarbonate, and then converting the ester to the corresponding acid under alkaline conditions, such as with aqueous LiOH in a solvent such as THF. Scheme 9

[0585] R = Me or Et PPh3, THF

[0586] E-l KOH, EtOH E-ll

[0587] X = Br, OBs or OTs R = Me or Et Base = K2C03or NaH mixture of alkylation products at N 1 , L / 2 and L / 3

[0588] Substituted l,2,3-triazole-5-carboxylic acids E-II can be prepared as shown in Scheme 9. Methyl or ethyl \H-\ ,2,3-triazole-5-carboxylate can be alkylated by treating the ester with a base such as potassium carbonate or sodium hydride and an alkylating agent such as alkyl bromide, brosylate or tosylate in a solvent such as DMF to yield a mixture of l,2,3-triazoles-5-carboxylates E-I alkylated at the M, N2 or N3 positions that could be separated by silica gel chromatography. Alternatively, alkylation can be accomplished by treatment of methyl or ethyl l / / -l,2,3-triazole- 5-carboxylate with an alcohol using Mitsunobu conditions, such as DIAD and triphenylphosphine in a solvent such as THF, to provide E-I. Hydrolysis of the ester with aqueous base such as sodium hydroxide or potassium hydroxide in a solvent such as THF or EtOH leads to the carboxylic acids E-II Scheme 10 either PPh3or PCy3mixture of alkylation products at L / 1 , N2 and L / 4

[0589] Scheme 10 shows that substituted l,2,4-triazole-5-carboxylic acids E-IV can be prepared in a similar sequence as described in Scheme 9 using methyl l,2,4-triazole-5-carboxylate as the starting material wherein PCy3is tricyclohexylphosphine. Scheme 11

[0590] E-V

[0591] 5-Substituted isoxazole-4-carbonyl chlorides E-V can be prepared as described in Scheme 11. 5- Substituted isoxazole-4-carboxylic acids are treated with excess thionyl chloride and upon concentration afford corresponding acid chlorides E-V.

[0592] Scheme 12

[0593] E-VI E-VI I Scheme 12 shows that substituted l,2-pyrazole-4-carboxylic acids E-VII can be prepared in a similar sequence as described in Scheme 9.

[0594] Scheme 13

[0595] 3-Substituted isoxazole 4-carboxylic acid E-X can be prepared as shown in Scheme 13. Condensation of 4,4,4-trifluorobutanal with hydroxylamine hydrochloride in a solvent such as ethanol yields the corresponding oxime E-VIII. Subsequent treatment with NCS and cycloaddition with ethyl-3-(diethylamino)acrylate in a solvent such as chloroform affords the ester E-IX. Saponification of the ester is accomplished with reagents such as sodium hydroxide in aqueous ethanol to furnish the isoxazole 4-carboxylic acid E-X. Scheme 13a

[0596] 3-Substituted isoxazole 4-carboxylic acid esters E-IXa can be prepared as shown in Scheme 13a. Condensation of aldehydes with hydroxylamine hydrochloride in a solvent such as ethanol yields the corresponding oximes E-VIIIa. Subsequent treatment with NCS and cycloaddition with ethyl- 3-(diethylamino)acrylate in a solvent such as THF affords esters E-IXa.

[0597] Scheme 13b

[0598] Isoxazoles E-Xa can be prepared by the process outlined in Scheme 13b. Treatment of a suitable nitroalkane with phenylisocyanate in the presence of Et3N, followed by treatment with 3- pyrrolidin-l-yl-acrylic acid ethyl ester in the presence of triethyl amine in a solvent such as benzene affords corresponding esters E-IXa. Subsequent saponification using a reagent such as Li OH or NaOH in aqueous ethanol yields corresponding acids E-Xa.

[0599] Scheme 13c

[0600]

[0601] Isoxazole esters E-XIII and E-XV can be prepared by the route shown in Scheme 13c. Desilylation of ester E-XI using TBAF affords the alcohol E-XII. Difluoromethylation using 2,2- difluoro-2-(fluorosulfonyl)acetic acid in the presence of an additive such as Cul and a base such as EtiN in a solvent such as CH3CN affords the ester E-XIII. Ethyl 3-hydroxyisoxazole-4- carboxylate E-XIV can be alkylated with iodoalkanes in the presence of sodium hydride in a solvent such as DMF to afford ethers E-XV. Alternatively treatment of ethyl 3-hydroxyisoxazole- 4-carboxylate E-XIV with aliphatic alcohols and reagents such as triphenyl phosphine and DIAD in a solvent such as THF provides ethers E-XV.

[0602] Scheme 13d

[0603] Isoxazole acids E-XVI can be prepared by the route shown in Scheme 13d. Alkylation of ethyl 4-hydroxyisoxazole-3-carboxylate using alkyl iodides in the presence of a base such as cesium carbonate in a solvent such as DMF affords the corresponding esters. Subsequent saponification using reagents such as LiOH in solvent mixtures such as THF and water affords isoxazole acids

[0604] E-XVI Scheme 13e

[0605] 4-Substituted isoxazole-3-carboxylic acids of the general formula E-XVIII can be prepared as shown in Scheme 13e. Condensation of a suitable aldehyde with ethyl 2-chloro-2- (hydroxyimino)acetate in the presence of pyrrolidine in a solvent such as DCM and a base such as triethylamine yields compounds E-XVII. Oxidation of the pyrrolidine within E-XVII using reagents such as wCPBA in solvents such as DCM then affords the corresponding isoxazole-3- carboxylic esters (structure not shown) that upon saponification using regents such as aqueous Li OH in solvents such as THF affords compounds of formula E-XVIII.

[0606] Scheme 14

[0607] Compounds I-ab possessing an R5= F may be prepared as shown in Scheme 14. Compounds A- XIV (prepared from A- VIII as shown in Scheme 3) may be treated with fluorinating reagent such as l-chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane / v.s(tetrafluoroborate) in a solvent such as acetonitrile to afford compounds with the structure A-XV with R5= F. Subsequent amide bond formation as previously described then provides compounds I-ab.

[0608] Scheme 15

[0609] Functionalized tetrazines can be prepared as shown in Scheme 15. Treatment of 3,6-dichloro- 1,2,4,5-tetrazine with (4-methoxyphenyl)methanamine in the presence of reagents such as DIPEA in a solvent such as MTBE yields the aminated product (not shown). Subsequent dechlorination reduction using palladium catalysis and Boc protection of the amine affords tetrazine F-I.

[0610] Scheme 16

[0611]

[0612] Aminopyridazines of the general structure G-I can be prepared by the route shown in Scheme 16. Conversion of Boc protected amino acids to the corresponding aldehydes by a two step process involving Weinreb amide formation and subsequent reduction using hydride reagents such as DIBAL-H in solvents such as THF affords aldehydes G-II. Treatment of aldehydes G-II with dimethyl (l-diazo-2-oxopropyl)phosphonate in a solvent such as methanol in the presence of a base such as potassium carbonate then affords alkynes G-III. Deprotection of the Boc group using hydrochloric acid in methanol provides amines G-IV. Subsequent amide bond formation with carboxylic acids using reagents such as HATU in solvents such as DCM in the presence of additives such as DIPEA then yields amides G-V. Condensation of G-V with tetrazine F-I under thermal conditions (60-115 °C) generates compounds G-VI. Deprotection of the Boc with HC1 in methanol to give G-VII and subsequent deprotection of the 4-methoxybenzyl groups with TFA then affords aminopyridazines G-I.

[0613] Scheme 17

[0614] G-la

[0615] Aminopyridazines of the general structure G-Ia can be prepared by the route shown in Scheme 17. Treatment of 6-chloropyridazin-3 -amine with pivaloyl chloride in the presence of pyridine in DCM then yields amide G-VIII. Metalation of amide G-VIII using a reagent such as TMPMgCFLiCl in a solvent such as THF followed by treatment with a sulfmimine H-I then affords sulfmamines G-IX. Removal of the sulfmimine and pivaloyl groups by acidic hydrolysis using reagents such as aqueous hydrochloric acid then affords diamines G-X. Subsequent amide bond formation generates aminopyridazines G-Ia. Scheme 18

[0616] Sulfmimides H-I are prepared as shown in Scheme 18. Condensation of aldehydes with sulfimamides such as C.V)-2-m ethyl propan e-2-sulfinamide in the presence of reagents such as copper sulfate and PPTS in solvents such as DCM, THF and / or toluene yields sulfmimines H-I.

[0617] Scheme 19 Aldehydes of the general structure H-II are prepared as shown in Scheme 19. In some cases, carboxylic esters H-III can be reduced using reagents such as DIBAL-H in solvents such as DCM to afford aldehydes H-II. Carboxylic acids H-IV can be converted to the corresponding amides H-V by treatment with Af / / -di methyl hydroxyl a ine in the presence of reagents such as HATU or CDI and the presence of additives such as DIPEA in solvents such as DCM. Reduction of amides H-V using reducing agents such as DIBAL-H or lithium aluminum hydride in solvents such as DCM or ethyl ether afford the corresponding aldehydes H-II. Terminal olefins H-VI may be cleaved under oxidative conditions by treatment with reagents such as ozone in DCM followed by treatment with dimethyl sulfide to afford H-II. Alternatively, treatment of H-VI with reagents such as potassium osmate dihydrate and sodium periodate in solvents such as THF and water afford aldehydes H-II.

[0618] Scheme 20 5-Substituted oxadiazole-4-carbonyl chlorides (I-II) and Af-hydroxy succinate esters (I-IP) can be prepared as described in Scheme 20. Acids I-I are treated with a chlorinating agent such as excess thionyl chloride and upon concentration this affords the corresponding acid chlorides I-II. Subsequent reaction with A -hydroxy sued ni m i de affords the corresponding esters I-III. Scheme 21

[0619] Oxadiazole adds I-V can be prepared as shown in Scheme 21. Treatment of a,b-unsaturated aldehydes with sodium nitrite in solvents such as acetic add affords the corresponding oxadiazole formyl- 1, 2, 5-oxadiazole 2-oxides I-IV. Oxidation of I-IV with a reagent such as Jones reagent in a solvent such as acetone affords the carboxylic acids I-V.

[0620] Scheme 22

[0621] Oxadiaxole acids of the general formula I-I can be prepard as shown in Scheme 22. Treatment of acids I-V with aniline affords amides I- VI. Reduction with trimethyl phosphite in a solvent such as toluene then affords compounds I- VII. Susequent treatment of I- VII with di-fe / 7-butyl dicarbonate in the presence of DMAP in a solvent such as DCM affords compounds I- VIII. Treatament of I- VIII with Li OH in THF / water then yields acids I-I.

[0622] Scheme 23

[0623] Amides I-IX can be prepared by the route shown in Scheme 23. Lactones I-XI may be prepared using the procedures outlined in Pollet, P.; Gelin, S. Tetronic Acids and Derivatives; Part VI. A Convenient Synthesis of New 4-Oxo-2-phenyl -2 / 7-4, 6-dihydrofuro[3,4-<7]tri azole and 4-Oxo-4,6- dihydrofuro[3,4-c]furazan Systems. Synthesis. 1979, 72, 977. Treatment of lactones I-XI with aniline in a solvent mixture such as DMF and EtOH then affords the amides I-IX. Scheme 24

[0624] 2-(fluorosulfonyl)acetic acid

[0625] Cul, CH3CN

[0626] -► l-IXa l-IXa l-XIII l-XIV Oxadiazole amides may be prepared as shown in Scheme 24. Treatment of alcohol l-IXa with copper (I) iodide and 2-(fluorosulfonyl)acetic acid in a solvent such as acetonitrile provides the corresponding difluoromethyl ether I-XII. Activation of the hydroxyl in l-IXa using methansulfonyl chloride in the presence of Et3N in a solvent such as DCM affords I-XIII. Treatment of I-XIII with 3-presence of DIPEA in a solvent such as DCM affords I-XIV.

[0627] Scheme 25

[0628] R4C1NH, DIPEA 1 ,4-dioxane or neat R4c1NH or l-IXb F

[0629] NaH, THF, R4ccOH l-IXc

[0630] Oxadiazole amides I-IXb and I-IXc can be prepared as shown in Scheme 25. Treatment of chloro- / V-phenyl-l,2,5-oxadiazole-3-carboxamide with certain amines in the presence of DIPEA in 1,4- dioxane, or sodium hydride in THF, or neat affords amides I-IXb. Similarly, treatment of chloro- A-phenyl-l,2,5-oxadiazole-3-carboxamide with certain alcohols in the presence of sodium hydride in THF or, in the case of R4cc= Me, sodium methoxide in methanol, yields amides I-IXc.

[0631] Scheme 26

[0632] Diazoketone J-I can be prepared as shown in Scheme 26. Subjection of 3- fluorobicyclo[l.l.l]pentane-l -carboxylic acid to oxalyl chloride in the presence of DMF in a solvent such as DCM affords the corresponding acid chloride J-II. Subsequent treatment of J-II with (trimethylsilyl)diazomethane in THF and acetonitrile then affords the diazoketone J-I.

[0633] INTERMEDIATES Intermediate 1

[0634] Methyl 3-(trifluoromethyl)picolinate

[0635] Methanol (600 mL) was cooled to 0 °C in an ice bath, and then AcCl (95 g, 1.2 mol) was added dropwise at a rate that maintained the internal temperature below 10 °C. After the addition was complete, the resulting solution was allowed to warm to rt. Neat 3-(trifluoromethyl)pyridine-2- carboxylic acid (30 g, 160 mmol) was then added, and the resulting solution was heated at reflux temperature for 16 h. After this time, the reaction mixture was allowed to cool to rt and then concentrated. The residue was diluted with EtOAc and saturated aqueous NaHCCb solution, the layers were mixed and then separated, and the aqueous layer was extracted with EtOAc. The organic layers were combined, dried with anhydrous MgS04, and concentrated to afford the title compound as a yellow oil. Intermediate 2

[0636] Methyl (cA-2,3)-3-(trifluoromethyl)piperidine-2-carboxylate

[0637] Methyl 3-(trifluoromethyl)picolinate (20 g, 97 mmol, Intermediate 1), HCO2NH4 (37 g, 0.58 mol), and Pd / C (9.0 g, 20% w / w, 17 mmol) were added to a reactor containing DMF (260 mL) under an atmosphere of nitrogen gas, and the resulting mixture was stirred at rt for 3 h. After this time, the mixture was filtered, and the filter cake was washed with MTBE. The combined filtrate and wash were diluted with water. The layers were mixed and then separated, and the aqueous layer was extracted twice with MTBE. The organic layers were combined and then concentrated to afford the title compound as a yellow oil.

[0638] Intermediate 3

[0639] {Trans- 2,3)- 1 -(tert- butoxycarbonyl)-3 -(trifluoromethyl)piperidine-2-carboxylic acid Boc

[0640] Sodium methoxide (2.6 g, 47 mmol) was added to a solution of methyl (cis- 2,3)-3- (trifluorom ethyl )piperidine-2-carboxylate (10 g, 47 mmol, Intermediate 2) in dry MeOH (100 mL), and the resulting solution was maintained at rt for 1 h. The solution was then warmed to 45 °C and maintained at that temperature overnight. The solution was then allowed to cool to rt and maintained at that temperature for an additional 24 h. After this time, a solution of aqueous HC1 (80 mL, 1.0 M, 80 mmol) was added, and the mixture was partially concentrated to remove most of the MeOH. The resulting concentrated aqueous solution was diluted with water (220 mL), and then B0C2O (46 g, 0.21 mol) and NaHC03(18 g, 0.21 mol) were added. The resulting mixture was stirred at rt for 20 h. After this time, the pH of the reaction mixture was adjusted to pH 6-7 with 1 N aqueous HC1. The mixture was then diluted with THF (250 mL). Lithium hydroxide (3.95 g, 165 mmol) and water (75 mL) were added, and the resulting mixture was stirred at rt for 16 h. After this time, 1 N aqueous HC1 was added to make the mixture acidic. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined and then concentrated to give a colorless solid. This solid was crystallized from EtOAc / / / -heptane (250 mL, 1 :4 v / v) to afford the title compound as a colorless crystalline solid.

[0641] Intermediate 4

[0642] Methyl fV)-2-(( / t77-butoxycarbonyl)a ino)-2-cyclohexyl acetate

[0643] Di- / t7 / -butyl dicarbonate (200 mL, 870 mmol) was added to a mixture of (A)-methyl 2-amino-2- cyclohexylacetate hydrochloride (120 g, 578 mmol) and TEA (240 mL, 1.73 mol) in DCM (1.5 L), and the resulting mixture was stirred at rt for 16 h. After this time, the pH of the mixture was adjusted to pH 5 by adding a saturated aqueous citric acid solution. The mixture was then poured into water (1 L) and extracted three times with DCM. The organic extracts were combined, dried over anhydrous NaiSCri, filtered, and concentrated. The residue was triturated with petroleum ether (350 mL) and then isolated by filtration to afford the title compound as a colorless solid.

[0644] Intermediate 5

[0645] / c / V-Butyl fV)-(3-chloro- l -cyclohexyl-2-oxopropyl (carbamate

[0646] A solution of LDA was prepared by adding «-BuLi (194 mL, 2.5 M in hexane, 485 mmol) dropwise to a -70 °C solution of diisopropylamine (62.0 mL, 441 mmol) in THF (80 mL), and then allowing the resulting solution to warm to 0 °C (ice bath) over 30 min. This solution was then added dropwise to a -70 °C solution of methyl fV)-2-(( / t77-butoxycarbonyl)a ino)-2-cyclohexyl acetate (20 g, 74 mmol, Intermediate 4) and chloroiodomethane (21.6 mL, 295 mmol) in THF (120mL). The resulting mixture was stirred at -70 °C for 3 h before it was quenched with a saturated aqueous NH4CI solution (200 mL) and allowed to warm to rt. The resulting mixture was extracted three times with EtOAc. The organic extracts were combined, dried over anhydrous NaiSCL, filtered, and concentrated. The residue was purified by silica gel chromatography (20:1 to 5:1 petroleum ether / EtOAc) to afford the title compound as a black oil. Intermediate 6

[0647] / ert-Butyl fV)-( l -cyclohexyl -3 -iodo-2-oxopropyl (carbarn ate

[0648] Sodium iodide (11.0 g, 73.4 mmol) was added to a solution of / er / -butyl (,S)-(3-chloro-l- cyclohexyl-2-oxopropyl)carbamate (35.0 g, 121 mmol, Intermediate 5) in acetone (150 mL), and the resulting mixture was stirred at rt for 48 h. The mixture was then concentrated, and the residue was diluted with EtOAc (150 mL). The resulting suspension was filtered, and the filter cake was washed with EtOAc. The filtrate and wash were combined and concentrated to afford the title compound, which was used directly in next step without further purification.

[0649] Intermediate 7

[0650] Methyl fY)-2-amino-2-(4-hydroxyphenyl)acetate hydrochloride

[0651] Thionyl chloride (711 g, 5.98 mol) was added to a solution of S)-2-amino-2-(4- hydroxyphenyl)acetic acid (500 g, 2.99 mol) in MeOH (2.0 L) at 0 °C. After the addition was complete, the mixture was stirred at 80 °C for 12 h. After this time, the mixture was allowed to cool to rt and then concentrated to afford the title compound as a yellow solid.

[0652] Intermediate 8

[0653] Methyl (A)-2-(( / er / -butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate

[0654] A solution of K2CO3(508 g, 3.68 mol) in water (2.0 L) was added to a suspension of methyl (S)- 2-amino-2-(4-hydroxyphenyl)acetate hydrochloride (400 g, 1.84 mol, Intermediate 7) in 1,4- dioxane (1.0 L), and the mixture was cooled to 0 °C. Di- / er / -butyl dicarbonate (421 g, 1.93 mol) was then added, and the mixture was allowed to warm to 18 °C and stirred for 12 h. After this time, the mixture was diluted with EtOAc, and the layers were mixed and then separated. The organic layer was washed with brine, dried with anhydrous NaiSCri, filtered, and then concentrated to give the title compound as a colorless solid.

[0655] Intermediate 9

[0656] Methyl fV)-2-(( / c / 7-butoxycarbonyl)amino)-2-(4-hydroxycyclohexyl (acetate

[0657] Platinum dioxide (7.50 g, 33.1 mmol) was added to a solution of methyl ( S)-2-((tert - butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate (100 g, 355 mmol, Intermediate 8) in acetic acid (1.0 L), and the resulting mixture was stirred under an atmosphere of ¾ (48 psi) at 30 °C for 96 h. After this time, the reaction mixture was filtered, and the filtrate was concentrated to give a yellow oil. This oil was purified by gel silica chromatography (10: 1 to 1 : 1 petroleum ether / EtOAc) to give the title compound as a colorless oil.

[0658] Intermediate 10

[0659] Methyl fV)-2-(( / tv7-butoxycarbonyl)amino)-2-(4-oxocyclohexyl (acetate

[0660] Dess-Martin periodinane (442 g, 1.04 mol) was added to a solution of methyl ( S)-2-((tert - butoxycarbonyl)amino)-2-(4-hydroxycyclohexyl)acetate (200 g, 696 mmol, Intermediate 9) in DCM (2.0 L) at 0 °C, and the resulting mixture was stirred at 10 °C for 12 h. After this time, a solution of NaiSCb (400 g, 3.2 mol) in water (5 L) was added. The layers were mixed and then separated. The organic layer was washed with a saturated aqueous NaHCCh solution, followed by brine, dried with anhydrous NaiSCri, filtered, and then concentrated to give the title compound as a yellow oil.

[0661] Intermediate 11 Methyl C.Y(-2-(( / t7743utoxycarbonyl (ami no(-2-(4,4-difluorocyclohexyl (acetate

[0662] Bis(2-methoxyethyl)aminosulfur trifluoride (85.6 g, 387 mmol) was added dropwise to a solution of methyl fV(-2-(( / c / 7-butoxycarbonyl (a i no(-2-(4-oxocyclohexyl (acetate (30.0 g, 105 mmol, Intermediate 10) in DCM (300 mL) at 0 °C, and the resulting solution was stirred at 10 °C for 12 h. After this time, a cold saturated aqueous NaHCCh solution was added with stirring until the pH of the aqueous layer was maintained at pH 7. The layers were then separated, and the organic layer was washed with brine, dried with anhydrous NaiSCL, filtered, and concentrated to give a yellow oil. This oil was purified by gel silica chromatography (10: 1 petroleum ether / EtOAc) to give the title compound as a yellow solid.

[0663] Intermediate 12 fV(-2-(( / t77-Butoxycarbonyl (ami no(-2-(4,4-difluorocyclohexyl (acetic acid

[0664] A solution of LiOH'HiO (21.8 g, 520 mmol) in water (250 mL) was added to a solution of methyl fV)-2-(( / t77-butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl (acetate (80.0 g, 260 mmol, Intermediate 11) in THF (500 mL), and the mixture was stirred at 10 °C for 3 h. After this time, DCM (500 mL) was added, and the layers were mixed and then separated. The organic layer was discarded. The pH of the aqueous layer was adjusted to pH 2 with 1 M aqueous HC1, and the resulting mixture was extracted three times with DCM. The organic extracts were combined, dried with anhydrous NaiSCL, filtered, and concentrated to give the title compound as a yellow solid.

[0665] Intermediate 13

[0666] / c / V-Butyl fV)-(3-diazo- l -(4,4-difluorocyclohexyl)-2-oxopropyl (carbarn ate Isobutyl chloroformate (25.6 g, 187 mmol) was added dropwise to a solution of (S)-2-((lerl- butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl)acetic acid (50.0 g, 170.4 mmol, Intermediate 12) and 4-methylmorpholine (18.9 g, 187 mmol) in THF (500 mL) at -20 °C, then the resulting mixture was stirred at -20 °C for 30 min. After this time, the mixture was filtered. A solution of freshly prepared diazomethane in Et20* (1.8 L, approximately 3 equiv.) was then added to the filtrate at 0 °C, the resulting solution was maintained at 0 °C for 12 h. After this time, the solution was partially concentrated to remove excess diazomethane, washed with water, dried with anhydrous INfeSCri, filtered, and concentrated to give a yellow solid. This solid was purified by gel silica chromatography (20:1 petroleum ether / EtOAc) to give the title compound as a light- yellow solid.

[0667] *Prepared according to de Boer, Th. T; Backer, H. J. Org. Synth. 1956, 36, 16.

[0668] Intermediate 14

[0669] / cvV-Butyl fV)-(3-chloro- l -(4, 4-difluorocyclohexyl)-2-oxopropyl (carbarn ate

[0670] A solution of HC1 in EtOAc (7.80 mL, 4.0 M, 31.2 mmol) was added to a solution of / er / -butyl fV)-(3-diazo- l -(4,4-difluorocyclohexyl)-2-oxopropyl (carba ate (9.00 g, 28.3 mmol, Intermediate 13) in EtOAc (100 mL), and the mixture was stirred at 10 °C for 2 h. The mixture was then washed with a saturated aqueous NaHC03solution, dried with anhydrous Na2S04, filtered, and concentrated. The residue was purified by gel silica chromatography (10:1 petroleum ether / EtOAc) to afford a colorless solid. The solid was triturated with petroleum ether (200 mL) and then filtered, and the filter cake was dried under vacuum to give the title compound as a colorless solid.

[0671] Intermediate 15

[0672] / cvV-Butyl fV)-( l -(4,4-difluorocyclohexyl)-3-iodo-2-oxopropyl (carbarn ate The title compound was prepared as described for the synthesis of Intermediate 6, using fe / 7-butyl fV)-(3-chloro- l -(4, 4-difluorocyclohexyl)-2-oxopropyl (carbarn ate (Intermediate 14) in place of / tvV-butyl fV)-(3-chloro- l -cyclohexyl-2-oxopropyl (carbamate.

[0673] Intermediate 16

[0674] A-(5-Chloropyridazin-3 -yl)- 1 , 1 -diphenylmethanimine

[0675] A stirring mixture of CS2CO3 (875 g, 2.68 mol), dppf (59.5 g, 107 mmol), and Pd2(dba)3(49.2 g, 53.7 mmol) in DME (1.4 L) was warmed to 40 °C, and then a solution of 3,5-dichloropyridazine (200 g, 1.34 mol) and benzophenone imine (243 g, 1.34 mol) in DME (600 mL) was added dropwise while maintaining an internal temperature of 40-45 °C. When the addition was complete, the resulting mixture was stirred at 85 °C for 16 h. After this time, the reaction mixture was allowed to cool to rt and then filtered. The filter cake was washed with EtOAc, and the filtrate and wash were combined and concentrated. The residue was diluted with EtOAc (600 mL), and the resulting slurry was stirred at rt for 3 h. The mixture was filtered, and the filter cake was dried by aspiration to afford the title compound as a brown solid.

[0676] Intermediate 17

[0677] 5-Chloropyridazin-3-amine

[0678] A-(5-Chloropyridazin-3-yl)- l , 1 -di phenyl ethani ine (297 g, 84% w / w, 0.85 mol, Intermediate 16) was diluted with EtOAc (1.0 L) and water (700 mL). An aqueous HC1 solution (300 mL, 5.0 N, 1.5 mol) was then added dropwise at 20 °C, and the resulting mixture was stirred at 20 °C for 30 min. After this time, the mixture was filtered, and the filter pad was washed with 1 N aqueous HC1 (100 mL). The layers of the combined filtrate and wash were separated, the aqueous layer was washed three times with EtOAc. The aqueous layers were combined, and the pH was adjusted to pH 8-9 using a 5 N aqueous NaOH solution. After stirring at 10-20 °C for 1 h, the precipitate was collected by filtration and washed with water to give crude title compound as a brown solid (134 g, 71% w / w). This material was combined with another batch obtained in a similar way (36.2 g, 56% w / w). The combined batches were diluted with aqueous HC1 (2.0 L, 1.0 N, 2.0 mol) and stirred at rt for 30 min. The undissolved impurities were removed by filtration, and the filter pad was washed with water (100 mL). SiliaMetS®Thiol (20 g) was added to the combined filtrate and wash, and the resulting mixture was stirred at 40 °C for 2 h and then filtered. Two additional treatments with SiliaMetS®Thiol as described above were carried out. The pH of the final filtrate was adjusted to pH 9-10 using 5 N aqueous NaOH, and the resulting mixture was stirred at 10-20 °C for 1 h. The precipitate was isolated by filtration and then dried under vacuum to give the title compound as an off-white solid.

[0679] Intermediate 18

[0680] Methyl 2-(( / er / -butoxycarbonyl)amino)-2-(4,4-difluorocyclohexylidene)acetate

[0681] A solution of 4,4-difluorocyclohexan-l-one (250 g, 1.86 mol) in DCM (500 mL) was added dropwise to a 0 °C (ice bath) stirring solution of methyl 2-(( / er / -butoxycarbonyl)amino)-2- (dimethoxyphosphoryl) acetate (582 g, 1.96 mol) and DBU (289 g, 1.90 mol) in DCM (2.0 L) at a rate that maintained the internal temperature below 10 °C. Then the reaction was allowed to warm to 20 °C and maintained at this temperature for 16 h. After this time, water (800 mL) was added, and the mixture was stirred for 30 min. The layers were separated, and the organic layer was washed three times with water and then concentrated. The residue was diluted with «-heptane (1 L), and the resulting slurry stirred and then filtered. The filter cake was dried under vacuum at 50 °C to give the title compound as an off-white solid.

[0682] Intermediate 19

[0683] Methyl 2-(( / c77-butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl (acetate

[0684] Methyl-2-(( / er / -butoxycarbonyl)amino)-2-(4,4-difluorocyclohexylidene)acetate (750.0 g, 2.46 mol, Intermediate 18) and Pd / C (75.0 g, 10% w / w, 71 mmol) were added to a reactor containing THF (6.0 L) under an atmosphere of nitrogen gas. The resulting mixture was hydrogenated using a balloon of ¾ at rt for 18 h. After this time, the reaction mixture was filtered, and the filter cake was rinsed with THF (1.5 L). The filtrate and rinse were combined and concentrated. The residue was diluted with «-heptane (3.75 L), and the resulting slurry was stirred and then filtered. The filter cake was dried under vacuum at 50 °C to give the title compound as an off-white solid. Intermediate 20

[0685] / c / V-Butyl (l-(4,4-difluorocyclohexyl)-3-(dimethyl(oxo)-k6-sulfanylidene)-2-oxopropyl) carbamate

[0686] A suspension of trimethyl sulfoxonium chloride (552 g, 4.29 mol) and potassium / c / V-butoxide (386 g, 3.44 mol) in THF (2.64 L) was stirred at 10-20 °C for 2 h. After this time, a solution of methyl 2-(( / c77-butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl (acetate (660 g, 2.15 mol, Intermediate 19) in THF (2.64 L) was added dropwise at a rate that maintained the internal temperature below 20 °C. After the addition was complete, the resulting mixture was stirred at 10-20 °C for 48 h. After this time, a saturated aqueous NH4CI solution (1.32 L) was added dropwise. The resulting mixture was diluted with water (1.32 L) and stirred for 30 min. The mixture was then partially concentrated to remove THF, and the precipitate was isolated by filtration. The filter cake was suspended in water (1 L) and stirred for 2 h. The mixture was filtered, and the filter cake was dried under vacuum at 50 °C to give the title compound as an off-white solid. Intermediate 21

[0687] / c / V-Butyl A-[fV)-(7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)-(4,4-difluorocyclohexyl (methyl] carbamate

[0688] A mixture of 5-chloropyridazin-3-amine (15.0 g, 116 mmol, Intermediate 17), / c / V-butyl (l-(4,4- difluorocyclohexyl)-3 -(dim ethyl (oxo)-A>-sulfaneylidene)-2-oxopropyl (carbamate (46.8 g, 127 mmol, Intermediate 20), K3PO4 (1.23 g, 5.80 mmol), and 4 A molecular sieves (3.0 g) in toluene (500 mL) was stirred at rt for 30 min. Then [Ir(cod)Cl]2(1.56 g, 2.32 mmol) was added under a nitrogen atmosphere, and the resulting mixture was heated to 95 °C and stirred at this temperature for 16 h. After this time, the reaction mixture was allowed to cool to 30 °C and then filtered. The filter pad was washed with EtOAc and then the combined filtrate and wash was concentrated. The residue was purified by silica gel chromatography (5:1 petroleum ether / EtOAc) to give a light- yellow solid. This solid was purified by SFC on a chiral stationary phase (Daicel CHIRALPAK®AS-H, 60:40 2 mM NH3 in MeOH solution / CCb) to give the S enantiomer as the second-eluting isomer. The desired fractions were concentrated, diluted with «-heptane (2.5 volumes), and stirred at rt for 1 h. The product was isolated by filtration and then dried under vacuum to give the title compound as a colorless solid.

[0689] Intermediate 21 alternate synthesis

[0690] / c / V-Butyl (A')-(l -(4,4-difluorocyclohexyl)-3-iodo-2-oxopropyl (carbarn ate (500 mg, 1.98 mmol, Intermediate 15), 5-chloropyridazin-3-amine (171 mg, 1.32 mmol), NaHCCb (302 mg, 3.60 mmol), and / -BuOH (20 mL) were added to a 50 L round-bottomed flask. The resultant mixture was stirred at 135 °C for 20 h. After that time, the reaction was cooled to rt, then triturated with EtOAc (50 mL), filtered, and the filtrate concentrated to dryness under reduced pressure to afford the crude title product, which was purified by silics gel chromatography (10-100% petroleum ether: ethyl acetate) to afford the title compound as a white solid.

[0691] Intermediate 22 / ert-Butyl fV)-((7-chloroimidazo[ 1 ,2-Z>]pyridazin-2-yl)(cyclohexyl)methyl)carbamate

[0692] 5-Chloropyridazin-3-amine (1.5 g, 12 mmol, Intermediate 17) was added to a solution of fe / 7-butyl (S)-( I -cyclohexyl -3 -iodo-2-oxopropyl (carbarn ate (13.2 g, 34.6 mmol, Intermediate 6), and NaHC03(3.89 g, 46.3 mmol) in / -BuOH (30 mL). The mixture was then stirred at 130 °C for 48 h. After this time, the mixture was allowed to cool to rt and then filtered through a pad of Celite®. The pad was rinsed with EtOAc, and the rinse was combined with the filtrate and diluted with water (50 mL). The layers were separated, and the aqueous layer was extracted three times with EtOAc. The organic extracts were combined, washed with brine, dried over anhydrous Na2S04, filtered, and concentrated. The residue was purified by silica gel chromatography (1:0 to 4:1 petroleum ether / EtOAc) to afford the title compound as a brown oil.

[0693] Intermediate 23

[0694] / ert-Butyl fV)-((7-cyanoimidazo[ 1 ,2-Z>]pyridazin-2-yl)(cyclohexyl)methyl)carbamate

[0695] A mixture of / er / -butyl fV)-((7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)(cyclohexyl (methyl) carbamate (800 mg, 2.19 mmol, Intermediate 22), Zn(CN)2 (644 mg, 5.48 mmol), and zinc powder (29 mg, 0.44 mmol) in DMA (8.0 mL) was sparged with argon for 5 min, and then Pd2(dba)3(405 mg, 0.442 mmol) and XPhos (420 mg, 0.881 mmol) were added. The mixture was sparged with argon for another 5 min. The mixture was then stirred at 120 °C under microwave irradiation for 2 h. After this time, the mixture was allowed to cool to rt and then filtered through a pad of Celite®. The pad was rinsed with EtOAc, and the rinse was combined with the filtrate and diluted with water (30 mL). The layers were separated, and the aqueous layer was extracted three times with EtOAc. The organic extracts were combined, dried over anhydrous Na2S04, filtered, and concentrated. The residue was purified by silica gel chromatography (2: 1 petroleum ether / EtOAc) to afford the title compound as a brown oil. Intermediate 24

[0696] ( A(-2-( Ami no(cyclohexyl (methyl (i mi dazo[l ,2- / ]pyridazine-7-carbonitrile hydrochloride

[0697] A solution of HC1 (5.5 mL, 4.0 M in EtOAc, 22 mmol) was added to a 0 °C solution of tert- butyl (ri)-((7-cyanoimidazo[l,2-Z>]pyridazin-2-yl)(cyclohexyl)methyl)carbamate (500 mg, 1.41 mmol, Intermediate 23) and EtOAc (5 mL), and the resulting mixture was stirred for 4 h at 0 °C. The mixture was then concentrated to afford the title compound as a colorless solid.

[0698] Intermediate 25 fV(-Af-((7-Cyanoimidazo[l ,2- / ]pyridazin-2-yl((cyclohexyl (methyl (benzamide

[0699] Neat HATU (156 mg, 0.410 mmol) was added to a 0 °C mixture of (S)-2- (ami no(cyclohexyl (methyl (i mi dazo[l ,2- / >]pyridazine-7-carbonitrile hydrochloride (100 mg, 0.343 mmol, Intermediate 24), benzoic acid (50 mg, 0.41 mmol), and DIPEA (0.20 mL, 1.1 mmol) in DCM (2.0 mL), and the resulting mixture was stirred at 0 °C for 2 h. The mixture was then poured into water (10 mL) and extracted three times with DCM. The organic extracts were combined, washed with brine, dried over anhydrous NaiSCL, filtered, and concentrated. The residue was purified by silica gel chromatography (1 :0 to 3 : 1 DCM / EtOAc) to afford the title compound as a yellow oil.

[0700] Intermediate 26 fV)-Af-((7-( Ami nomethyl )i mi dazo[ l ,2- / ]pyridazin-2-yl((cycl ohexyl (methyl (benzamide

[0701] Raney®-Nickel (193 mg, slurry in water) was added to a mixture of (A)-A-((7-cyanoimidazo[l ,2- / >]pyri dazin-2-yl)(cyclohexyl)m ethyl )benzamide (191 mg, 0.531 mmol, Intermediate 25) and aqueous NH4OH (1.0 mL, 28% w / w ammonia, 15 mmol) in EtOH (10 mL). The reaction mixture was stirred under Eh (15 psi) at rt for 2 h. After this time, the mixture was filtered through a pad of Celite®, and the pad was washed with EtOH. The filtrate and wash were combined and then concentrated to afford the title compound as a brown oil.

[0702] Intermediate 27 / tW-Butyl ( / ra / / .s-2,3)-2-(((2-(fV)- / >enzamido(cyclohexyl)methyl)imidazo[l ,2- / ]pyridazin-7- yl)methyl)carbamoyl)-3-(trifluoromethyl)piperidine-l-carboxylate

[0703] NeatHATU (399 mg, 1.05 mmol)was added to a solution of (A)-A-((7-(aminomethyl)imidazo[l ,2- / >]pyri dazin-2-yl)(cyclohexyl)m ethyl )benzamide (350 mg, 0.963 mmol, Intermediate 26), (trans- 2,3)-l-( / er / -butoxycarbonyl)-3-(trifluoromethyl)piperidine-2-carboxylic acid (273 mg, 0.918 mmol, Intermediate 3) and DIPEA (0.47 mL, 2.7 mmol) in DCM (5 mL) at 0 °C, and the resulting mixture was stirred at 0 °C for 2 h. The mixture was poured into water (30 mL) and then extracted three times with DCM. The organic extracts were combined, washed with brine, dried over anhydrous NaiSCE, filtered, and concentrated. The residue was purified by silica gel chromatography (1:0 to 1:2 petroleum ether / EtOAc) to afford the title compound, a diastereomeric mixture, as a yellow solid.

[0704] Intermediate 28 tert- Butyl ( / ra / / .s-2 / ^*,3 / ^*)-2-(((2-((A,)-benzamido(cyclohexyl)methyl)imidazo[ l ,2- / ]pyridazin-7- yl) methyl)carbamoyl)-3-(trifluoromethyl)piperidine-l-carboxylate

[0705] Intermediate 29 / tvV-Butyl ( / ra / / .s-25f\3 V*)-2-(((2-(fV)-benzamido(cyclohexyl (methyl )i mi dazo[ l ,2- / ]pyridazin-7- yl) methyl)carbamoyl)-3-(trifluoromethyl)piperidine-l-carboxylate

[0706] / er / -Butyl ( / ra / / .s-2,3)-2-(((2-(fV)-benzamido(cyclohexyl)methyl)imidazo[ l ,2- / ]pyridazin-7- yl)methyl)carbamoyl)-3-(trifluoromethyl)piperidine-l-carboxylate (Intermediate 27) was purified by SFC using a chiral stationary phase (Daicel CHIRALPAK®IC, 45:55 EtOH (containing 0.1% (v / v) of 25% aqueous NEbyCCh) to give a pair of diastereomers. The first-eluting isomer was Intermediate 28, and the second-eluting isomer was Intermediate 29.

[0707] Intermediate 30 / t V-Butyl ( / ra / / .s-2,3)-2-(((2-(fV)-cyclohexyl(l -methyl- l / / -pyrazole-5-carboxamido)m ethyl) imidazo[ 1 , 2- / >]pyridazi n-7-yl (methyl (carbarn oyl)-3-(trifluorom ethyl (piperidine-! -carboxyl ate

[0708] The title compound was prepared as described for the synthesis of Intermediate 27, using 1-methyl- l / / -pyrazole-5-carboxylic acid in place of benzoic acid to afford the title compound as a brown solid. Intermediate 31

[0709] / c / V-Butyl ( / mz75-2i?*,3i?*)-2-(((2-((ri)-cyclohexyl(l-methyl-liT-pyrazole-5-carboxamido)methyl) imidazo[ 1 ,2- / >]pyridazin-7-yl (methyl (carbamoyl (-3 -(trifluorom ethyl (pi peri dine-1 -carboxyl ate tert- Butyl ( / ra / / .s-2,3(-2-(((2-(fV(-cyclohexyl(l -methyl - l / / -pyrazole-5-carboxamido(m ethyl) imidazo[ 1 , 2- / >]pyridazi n-7-yl (methyl (carbamoyl (-3 -(trifluorom ethyl (pi peri dine-1 -carboxyl ate (Intermediate 30) was purified by SFC using a chiral stationary phase (Daicel CHIRALPAK®IC, 45:55 z-PrOH (containing 0.1% (v / v) of 25% aqueous NEEyCCh) to give the title compound as the first-eluting isomer.

[0710] Intermediate 32

[0711] (ri)-(7-Chloroimidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methanamine Trifluoroacetic acid (8.0 mL, 100 mmol) was added to / c / T-butyl Af-[fV(-(7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)-(4,4-difluorocyclohexyl (methyl (carbamate (2.00 g, 4.99 mmol, Intermediate 21), and the mixture was stirred at rt for 10 min. After this time, the resulting solution was concentrated and then diluted with a saturated aqueous NaHCCb solution and EtOAc. The layers were mixed and then separated, and the aquesous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered and concentrated to afford the title compound as an off-white solid.

[0712] Intermediate 33 (ri)- / V-((7-Chloroimidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l-(3,3,3- trifluoropropyl )- 1 / / -pyrazol e-4-carb oxami de

[0713] Hiinig’s base (0.52 mL, 3.0 mmol) was added to a mixture of (5)-(7-chloroimidazo[l,2- Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methanamine (750 mg, 2.49 mmol, Intermediate 32), 1- (3,3,3-trifluoropropyl)-li7-pyrazole-4-carboxylic acid (523 mg, 2.54 mmol) and HOBt (337 mg, 2.49 mmol) in MeCN (13 mL), and the suspension was stirred for 10 min. Then EDCI (478 mg, 2.49 mmol) was added, and the mixture was stirred at rt for 3 h. After this time, the suspension was filtered, and the filter cake was washed with MeCN / water (20 mL, 1 : 1 v / v) and then water (20 mL). The filtrate, which became heteogeneous as water was introduced, was combined with the filter cake and refiltered. The new cake was washed with water and then dried by aspiration. This cake was diluted with acetone (~10 mL) and then filtered. The filtrate was then concentrated to afford the title compound as an off-white solid. Intermediate 34

[0714] (ri)- / V-((4,4-Difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-l-(3,3,3- trifluoropropyl )- 1 / / -pyrazol e-4-carb oxami de

[0715] (ri)- / V-((7-Chloroimidazo[l,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l-(3,3,3- tri fl uoropropyl )- 1 / / -pyrazol e-4-carboxam i de (790 mg, 1.37 mmol, 85% w / w, Intermediate 33), potassium trifluoro(vinyl)borate (275 mg, 2.05 mmol), Pd(dtbpf)Ch (180 mg, 0.27 mmol), and K3PO4 (870 mg, 4.1 mmol) were combined in a reactor, and the reactor was evacuated and backfilled with nitrogen three times. The mixture was then diluted with 1,4-dioxane and water (15 mL, 4: 1 v / v), and the resulting mixture was sparged with argon for 15 min. The mixture was then stirred at 100 °C for 2.5 h. After this time, the reaction mixture was allowed to cool to rt and then was diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered and concentrated to afford a brown residue. This residue was purified by silica gel chromatography (50% to 100% EtOAc / hexanes, then 50% to 100% acetone / hexanes) to afford the title compound as a colorless solid. Intermediate 35

[0716] (ri)- / V-((4,4-Difluorocyclohexyl)(7-formylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-l-(3,3,3- trifluoropropyl )- 1 / / -pyrazol e-4-carb oxami de

[0717] A solution of NaI04(1.1 g, 5.2 mmol) in water (25 mL) was added to a solution of fV)-Af-((4,4- difluorocyclohexyl)(7-vinylimidazo[ 1 , 2- / >]pyridazin-2-yl (methyl )-l -(3,3,3-trifluoropropyl)- 1 H- pyrazole-4-carboxamide (500 mg, 1.04 mmol, Intermediate 34) in 1,4-dioxane (25 mL), and then K20S04*2H20 (76 mg, 0.21 mmol) was added, and the resulting mixture was stirred at rt for 1.5 h. After this time, the resulting thick suspension was diluted with water and extracted three times with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered and concentrated to give a brown residue. This residue was purified by silica gel chromatography (30% to 100% acetone / hexanes) to afford the title compound as a colorless solid.

[0718] Intermediate 36 A-(fV)-(7-(( / ' / )-((fV)- / tv7-butylsulfmyl)imino)methyl)imidazo[l ,2- / >]pyridazin-2-yl((4,4- difluorocyclohexyl (methyl)- ! -(3,3,3-trifluoropropyl)- l / / -pyrazole-4-carboxamide

[0719] Copper(II) sulfate (311 mg, 1.95 mmol) and then PPTS (15 mg, 0.061 mmol) were added to a solution of S)- / V-((4,4-difluorocyclohexyl)(7-formylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-l- (3,3,3-trifluoropropyl)-li7-pyrazole-4-carboxamide (310 mg, 0.61 mmol, Intermediate 35) and fV)-(-)-2-methyl-2-propanesulfinamide (77 mg, 0.64 mmol) in THF (2 mL), and the mixture was stirred at rt for 18 h. After this time, an additional portion of CuSCL (311 mg, 1.95 mmol) was added, and the mixture was stirred at 55 °C for 8 h and then at 45 °C for an additional 16 h. After this time, Celite®was added, and the mixture was filtered. The pad was washed with DCM, and the filtrate and wash were combined and then concentrated to give the title compound as a brown solid.

[0720] Intermediate 37 A-((fV)-(7-(((fV)- / t 7-Butyl sulfinyl )amino)(cyclopropyl)m ethyl )i mi dazo[l ,2- / ]pyridazin-2- yl )(4,4-difluorocyclohexyl (methyl)- 1 -(3,3,3-trifluoropropyl)- 1 / / -pyrazole-4-carboxamide

[0721] A solution of cyclopropylmagnesium bromide (2.0 mL, 0.92 M in 2-MeTHF, 1.8 mmol) was added dropwise to a -78 °C stirring solution of Af-((A(-(7-((((A(- / tv7-butylsulfmyl(imino( m ethyl (i mi dazo[l , 2- / >]pyridazin-2-yl((4,4-difluorocyclohexyl(m ethyl (-1 -(3,3,3-trifluoropropyl)- liT-pyrazole-4-carboxamide (360 mg, 0.61 mmol, Intermediate 36) in DCM (6.5 mL), and the resulting solution was allowed to slowly warm to 0 °C over 1 h. After this time, a saturated aqueous NH4CI solution and then water were added. The layers were mixed, and then separated. The aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered, and concentrated to afford a brown foam. This foam was purified by silica gel chromatography (50% to 100% acetone / hexanes) to afford the title compound as a colorless film. 'H NMR analysis showed a 4: 1 mixture of diastereomers.

[0722] Intermediate 38

[0723] A-((fV(-(7-( Ami no(cyclopropyl (methyl }i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4-di fluorocyclohexyl) methyl (-1 -(3,3,3-trifluoropropyl(- 1 / / -pyrazole-4-carboxamide

[0724] A solution of HC1 (0.32 mL, 4.0 M in dioxane, 1.3 mmol) was added to a solution of N-((lS)-(7- (((fY(- / c77-butylsuliinyl)amino((cyclopropyl (methyl )i mi dazo[l ,2- / i]pyridazin-2-yl}(4,4- difluorocyclohexyl ( ethyl)-! -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide (292 mg, 91% w / w, 0.420 mmol, Intermediate 37) in 1,4-dioxane (3.0 mL), and the mixture was stirred for 1.5 h. After this time, the resulting solution was concentrated. The residue was diluted with EtOAc and water. The layers were mixed and then separated, and the aqueous layer was washed with EtOAc. The organic layers were combined, extracted with water, and then discarded. The aqueous layers were combined, made basic with 15% aqueous NaOH, and extracted three times with EtOAc. The organic extracts were combined, dried with anhydrous MgS04, filtered, and concentrated to afford the title compound, a diastereomeric mixture, as an off-white solid.

[0725] Intermediate 39

[0726] / V-((lA)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl (-1 -(3,3,3-trifluoropropyl(-l / / -pyrazole-4-carboxamide

[0727] A mixture of / V-((lri)-(7-(amino(cyclopropyl)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl (methyl)-! -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide (117 mg, 0.210 mmol, 96% w / w, Intermediate 38), 4,4,4-trifluorobutyric acid (34 mg, 0.24 mmol) and HOBt (29 mg, 0.21 mmol) was diluted with MeCN (1.2 mL). Hiinig’s base (0.044 mL, 0.26 mmol) and then EDCI (41 mg, 0.21 mmol) were added, and the resulting solution was maintained at rt for 30 min and then at 45 °C for 2 h. After this time, water and EtOAc were added. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered, and concentrated. The residue was purified by silica gel chromatography (40% to 100% acetone / hexanes) to afford the title compound, a diastereomeric mixture, as a colorless film.

[0728] Intermediate 40

[0729] / V-((lri)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[l,2-Z>]pyridazin- 2-yl )(4,4-difluorocyclohexyl (methyl (-1 -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide

[0730] The title compound was prepared as described for the synthesis of Intermediate 39, using 2 -(3, 3- difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutyric acid to afford the title compound, a diastereomeric mixture, as a colorless solid.

[0731] Intermediate 41 / V-(( LV)-(7-(Cycl opropyl (4,4, 4-trifluoro-3 -(trifluorom ethyl )butan ami do)m ethyl )i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)- 1 -isopropyl- 1 / / -pyrazol e-5-carboxamide

[0732] The title compound was prepared as described for the synthesis of Intermediate 39, using 1- i sopropyl - 1 / / -pyrazol e-5 -carboxyl i c acid in place of 1 -(3,3,3-trifluoropropyl)- 1 / / -pyrazol e-4- carboxylic acid and 4,4,4-trifluoro-3-(trifluoromethyl)butanoic acid in place of 4,4,4- trifluorobutyric acid to afford the title compound, a diastereomeric mixture, as a colorless solid.

[0733] Intermediate 42 / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)benzamide

[0734] The title compound was prepared as described for the synthesis of Intermediate 39, using benzoic acid in place of I -(3,3,3 -tri fl uoropropyl )- 1 / / -pyrazol e-4-carboxyl i c acid to afford the title compound, a diastereomeric mixture, as a colorless solid.

[0735] Intermediate 43

[0736] / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)- l -i sopropyl -1 / / -pyrazol e-5-carboxamide

[0737] The title compound was prepared as described for the synthesis of Intermediate 58, using 1- i sopropyl - 1 / / -pyrazol e-5 -carboxyl i c acid in place of 1 -(3,3,3-trifluoropropyl)- 1 / / -pyrazol e-4- carboxylic acid to afford the title compound, a diastereomeric mixture, as a colorless solid.

[0738] Intermediate 44

[0739] / V-(( LV)-(7-(Cycl opropyl (4,4, 4-trifluoro-3 -(trifluorom ethyl )butan ami do)m ethyl )i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)benzamide The title compound was prepared as described for the synthesis of Intermediate 39, using benzoic acid in place of I -(3,3,3 -tri fl uoropropyl )- 1 / / -pyrazol e-4-carboxyl i c acid and 4,4,4-trifluoro-3- (trifluoromethyl)butanoic acid in place of 4,4,4-trifluorobutyric acid to afford the title compound, a diastereomeric mixture, as a colorless solid. Intermediate 45

[0740] / f / V-Butyl (ri)-((4,4-difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)carbamate tert- Butyl A-[fV)-(7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)-(4,4-difluorocyclohexyl (methyl ] carbamate (9.00 g, 22.5 mmol, Intermediate 21), potassium trifluoro(vinyl)borate (4.51 g, 33.7 mmol), and K3PO4 (14.3 g, 67.4 mmol) were added under a positive pressure of nitrogen gas to a reactor containing 1,4-dioxane and water (250 mL, 5:1 v / v, sparged with argon before use). The mixture was heated to reflux temperature (88 °C), and then a solution of RuPhos Pd G3 (470 mg, 0.56 mmol) in 1,4-dioxane (5 mL) was added, and the mixture was stirred at reflux temperature for 1.5 h. After this time, the mixture was allowed to cool to rt and then concentrated to remove most of the 1,4-dioxane. The residue was diluted with EtOAc and water, the layers were separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered and concentrated to afford the title compound as a brown foam.

[0741] Intermediate 46

[0742] / c / V-Butyl (A)-((4,4-difluorocyclohexyl)(7-formylimidazo[ l ,2- / ]pyridazin-2-yl (methyl (carbarn ate

[0743] A solution of NaKL (24.0 g, 112 mmol) in water (540 mL) was added to a solution of tert- butyl (ri)-((4,4-difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)carbamate (8.81 g, 22.5 mmol, Intermediate 45) in 1,4-dioxane (540 mL), and then K20s04*2H20 (827 mg, 2.25 mmol) was added. The reaction immediately started to warm, so the reactor was placed in an ice bath for 15 min to maintain the temperature close to 30 °C. After this time, the reaction mixture was stirred at rt for 1.75 h. After this time, the resulting thick suspension was filtered through Celite®, and the filter cake was washed with EtOAc. The filtrate and wash were combined, the layers were mixed and then separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with a concentrated aqueous Na2S203solution and then washed with brine, dried with anhydrous MgS04, filtered and then concentrated to give a tan foam. This foam was purified by silica gel chromatography (20% to 50% acetone / hexanes) to afford the title compound as a pale-yellow foam. Intermediate 47

[0744] / c / V-Butyl ((A)-(7-((((A)-fer / -butylsulfmyl)imino)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)carbamate

[0745] A mixture of / er / -butyl C.V(-((4,4-difl uorocyclohexyl ((7-formyl i mi dazo[l ,2- / ]pyridazin-2- yl)methyl)carbamate (7.65 g, 19.4 mmol, Intermediate 46), fV)-(-)-2-methyl-2- propanesulfmamide (2.47 g, 20.4 mmol), CuS04(9.91 g, 62.1 mmol) and PPTS (488 mg, 1.94 mmol) was diluted with THF (64 mL), and the mixture was stirred at 55 °C overnight. After this time, the mixture was diluted with DCM, Celite®was added, and the mixture was filtered. The filter pad was washed with DCM, and the filtrate and wash were combined and concentrated to give the title compound as an orange foam. Intermediate 48

[0746] / tvV-Butyl (fV)-(7-(( / ^)-((fV)- / tv7-butylsulfinyl)amino)(cyclopropyl (methyl )i mi dazo[ 1 ,2-

[0747] / >]pyridazin-2-yl((4,4-difl uorocyclohexyl (methyl (carbamate

[0748] A solution of / c / 7-butyl (fV(-(7-(((fV(- / c / 7-butylsulfinyl(imino( ethyl(imidazo[l ,2- / ]pyridazin-2- yl)(4,4-difluorocyclohexyl)methyl)carbamate (9.65 g, 19.4 mmol, Intermediate 47) in DCM (205 mL) was cooled to -78 °C. A solution of cyclopropylmagnesium bromide in 2-MeTHF (51 mL, 0.88 M, 45 mmol) was then added at a rate that maintained the internal temperature below -60 °C. When the addition was complete, the resulting solution was moved to an ice bath and allowed to slowly warm to 0 °C over 1 h. After this time, a saturated aqueous NEECl solution was added. Enough water was then added to dissolve the precipitate that had formed upon adding the NH4CI solution, and the layers were mixed and then separated. The aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried with anhydrous MgS04, filtered and then concentrated to afford a brown foam. This residue was purified twice by silica gel chromatography (30% to 70% acetone / hexanes) to afford the title compound as a colorless foam.

[0749] Intermediate 49

[0750] / <2 / 7-Butyl (fV)-(7-(( / ^)-ami no(cyclopropyl ( ethyl )i mi dazo[ l ,2- / >]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)carbamate

[0751] A solution of HC1 in 1,4-dioxane (6.7 mL, 4.0 M, 27 mmol) was added to a solution of / er / -butyl (fV)-(7-(( / ^)-((fV)- / t' / 7-butylsulfmyl)amino)(cyclopropyl)m ethyl )i mi dazo[ l ,2- / ]pyridazin-2- yl)(4,4-difluorocyclohexyl)methyl)carbamate (6.64 g, 11.7 mmol, Intermediate 48) in EtOAc (58 mL), and the solution was stirred at rt for 20 h. After this time, additional HC1 in 1,4-dioxane (0.29 mL, 4.0 M, 1.2 mmol) was added to the resulting suspension, and stirring was continued for 24 h. The suspension was then diluted with water (40 mL) and the layers were mixed and then separated. The organic layer was extracted twice with water (2 x 10 mL), and the aqueous layers were all combined and then washed with Et20 (25 mL). The Et20 wash was discarded. The aqueous layer was made basic with a 15% aqueous NaOH solution, and then extracted three times with EtOAc. The organic extracts were combined, dried with anhydrous MgS04, filtered and then concentrated to afford the title compound as a tan foam.

[0752] Intermediate 50

[0753] / <2 / 7-Butyl ((A)-(7-((f?)-cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2- yl)(4,4-difluorocyclohexyl)methyl)carbamate

[0754] A flask was charged with a stir bar, / c / 7-butyl ((S)-(7-((R)- amino(cyclopropyl)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl) carbamate (500 mg, 1.11 mmol, Intermediate 49), 4,4,4-trifluorobutyric acid (171 mg, 1.17 mmol), HOBt (158 mg, 1.17 mmol), acetonitrile (50 mL), and Hunig's base (0.29 mL, 1.67 mmol) and the solution was stirred until homogenous (about 5 min). To the solution was added EDCI (224 mg, 1.17 mmol) and the mixture was stirred for 30 min. The reaction was heated to 45 °C and stirred for 1 h. The reaction was cooled to rt and quenched by the addition of water and ethyl acetate. The layers were separated, and the aqueous phase was further extracted with ethyl acetate (3 x 10 mL). The combined organics were washed with brine, dried over anhydrous MgSCL, filtered and concentrated to yield the title compound as a white solid.

[0755] Intermediate 51

[0756] / V-((i?)-(2-( S)-Amino(4,4-difluorocyclohexyl)methyl)imidazo[l,2-Z>]pyridazin-7-yl) (cyclopropyl)methyl)-4,4,4-trifluorobutanamide

[0757] A vial was charged with a stir bar, / c / V-butyl ((5)-(7-((i?)-cyclopropyl(4,4,4- trifluorobutanamido)methyl)imidazo[ 1 ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl (methyl) carbamate (600 mg, 1.072 mmol, Intermediate 50) and TFA (3 mL, 39.2 mmol) then was stirred for 5 min. The reaction was condensed into a yellow oil and quenched by the careful addition of saturated aqueous NaHCCb. The basic aqueous phase was extracted with ethyl acetate (2x 15 mL). The combined organics were washed with brine, dried over anhydrous MgSCL filtered and condensed to yield the title compound as an off-white foam. Intermediate 52

[0758] (ri)- / V-((7-Chloroimidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2-(3,3,3- trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide A flask was charged with a stir bar, S)-(7-chloroimidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methanamine (0.5 g, 1.48 mmol, Intermediate 32), 2-(3,3,3-trifluoropropyl)- 2i7-l,2,3-triazole-4-carboxylic acid (0.34 g, 1.63 mmol, Intermediate 76), HOBt (0.21 g, 1.56 mmol), acetonitrile (45 mL), and Hiinig’s base (1.02 mL, 0.75 g / mL, 5.93 mmol). The reaction was stirred for 5 min then EDCI (0.298 g, 1.56 mmol) was added to the solution. The reaction was stirred overnight. The reaction was partitioned between water and ethyl acetate. The layers were separated, and the aqueous phase was further extracted with ethyl acetate (3 x 3 mL). The combined organics were washed with brine, dried over anhydrous MgSCri, filtered and condensed to afford the title compound as an off-white foam. Intermediate 53

[0759] (ri)- / V-((4,4-Difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-2-(3,3,3- trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide A microwave vial was charged with a stir bar, CV)-A-((7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / -l ,2,3-triazole-4-carboxamide (460 mg, 0.935 mmol, Intermediate 52), potassium trifluoro(vinyl)borate (188 mg, 1.40 mmol), K3PO4 (596 mg, 2.81 mmol), and 1,4-dioxane and water (10 mL, 5:1 v / v). The reaction mixture was sparged with argon for 5 min and then Pd(dtbpf)Cl2 (122 mg, 0.187 mmol) was added and the mixture was further sparged for 5 min with argon. The vial was sealed and heated to 100 °C with microwave irradiation and stirred for 2 h. After this time, the reaction was cooled to rt and diluted with water and ethyl acetate. The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 5 mL). The combined organics were washed with brine, dried over anhydrous MgSCL, filtered and condensed into a brown oil. The crude material was purified by silica gel chromatography (0-100% ethyl acetate / hexanes) to yield the title compound as a tan solid.

[0760] Intermediate 54

[0761] (ri)- / V-((4,4-Difluorocyclohexyl)(7-formylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-2-(3,3,3- trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide

[0762] A flask was charged with a stir bar, S)- / V-((4,4-difluorocyclohexyl)(7-vinylimidazo[l,2- Z>]pyridazin-2-yl)methyl)-2-(3,3,3-trifluoropropyl)-2i7-l,2,3-triazole-4-carboxamide (350 mg, 0.724 mmol, Intermediate 53), 1,4-dioxane and water (60 mL, 1:1 v / v) and KiOsCL^LLO (53.3 mg, 0.145 mmol). To the solution was added NalCL (0.774 g, 3.62 mmol) and the reaction was stirred at rt for 1 h. After this time the resulting thick suspension was diluted with additional water and extracted with ethyl acetate (3 x 20 mL). The combined organics were washed with brine, dried over anhydrous MgSCL filtered and condensed into a brown residue. The crude material was purified by silica gel chromatography (10-100% ethyl acetate / hexanes) to afford the title compound as an off-white solid.

[0763] Intermediate 55

[0764] A-((k)-(7-(( / ' / )-(((k)- / tv7-Butylsulfinyl)irnino)rn ethyl )i mi dazo[ l ,2- / ]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / - l ,2,3-triazole-4-carboxamide

[0765] A vial was charged with a stir bar, N-((S)-(7-((E)-(((S)-tert- butyl sul fi nyl)imino)m ethyl )i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2- (3,3,3-trifluoropropyl)-2 / / -l ,2,3-triazole-4-carboxamide (280 mg, 0.57 mmol, Intermediate 54) (ri)-2-methylpropane-2-sulfmamide (141 mg, 1.17 mmol), PPTS (39 mg, 0.15 mmol), copper(II) sulfate (956 mg, 5.99 mmol), and THF (2.5 mL). The vial was sealed and stirred overnight at 75 °C. The mixture was cooled to rt and Celite®was added and the mixture was filtered with DCM washing. The filtrate and combined washings were condensed to afford the title compound as a glassy yellow solid.

[0766] Intermediate 56

[0767] A-((bV)-(7-(((fV)- / c / 7-Butyl sulfinyl )amino)(cyclopropyl)m ethyl )i mi dazo[l ,2- / ]pyridazin-2- yl)(4,4-difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / -l ,2,3-triazole-4-carboxamide A flask was charged with A-((k)-(7-(( / ' / )-(((k)- / c / 7-butylsulflnyl)imino)methyl)imidazo[l ,2- 6]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2i7-l,2,3-triazole-4- carboxamide (180 mg, 0.306 mmol, Intermediate 55), and THF (3.25 mL). The flask was cooled to 0 °C and a solution of cyclopropylmagnesium bromide (0.950 mL, 1 M in 2- methyltetrahydrofuran, 0.948 mmol) was added dropwise. The reaction was allowed to warm to rt over 30 min. The reaction was poured over saturated aqueous NTLCl, and further diluted with water and ethyl acetate. The layers were separated, and the aqueous phase was extracted an additional time with ethyl acetate (10 mL). The combined organics were washed with brine, dried over anhydrous MgSCL,filtered and condensed to afford the title compound as an off-white foam. ¾NMR analysis showed a 3:1 mixture of diastereomers.

[0768] Intermediate 57 / V-(( LV)-(7-( Ami no(cyclopropyl (methyl )i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / -l ,2,3-triazole-4-carboxamide

[0769] A flask was charged with a stir bar, N-((lS)-(7-((((S)-tert- butylsulfinyl)amino)(cyclopropyl)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl) methyl)-2-(3,3,3-trifluoropropyl)-2i7-l,2,3-triazole-4-carboxamide (175 mg, 0.27 mmol, Intermediate 56), 1,4-dioxane (2 mL), and HC1 (0.21 mL, 4 M in dioxane). The reaction was stirred for 10 min, then condensed into an off-white residue. The crude was taken up in water and washed with hexanes (2 x 5 mL). The aqueous layer was made basic by the addition 1 N aqueous NaOH, then extracted with ethyl acetate (3 x 5 mL). The combined organics were washed with brine, dried over anhydrous MgSCL,filtered and concentrated to afford the title compound, a diastereomeric mixture, as an off-white foam.

[0770] Intermediate 58

[0771] / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide A vial was charged with a stir bar, 4,4,4-trifluorobutyric acid (40 mg, 0.27 mmol), HATU (105 mg, 0.27 mmol), and DMF (1 mL) then stirred for 5 min. To the stirred homogenous solution was added iV-((15)-(7-(amino(cyclopropyl)methyl)imidazo[l,2-0]pyridazin-2-yl)(4,4- difluorocyclohexyl(methyl)-2-(3,3,3-trifluoropropyl(-2 / / - 1 ,2,3-triazole-4-carboxamide (110 mg, 0.21 mmol, Intermediate 57) and Hiinig’s base (0.072 mL, 0.42 mmol). The reaction was further stirred for 10 min then poured over water and diluted with ethyl acetate. The layers were separated, and the aqueous phase was further extracted with ethyl acetate (2 x 5 mL). The combined organics were washed with 10% aqueous lithium chloride then brine, dried over anhydrous MgSCL, filtered and condensed into and glassy residue. The crude material was purified by silica gel chromatography, (0-100% (10% MeOH in ethyl acetate) / hexane) to yield a mixture of diastereomers as an off-white foam.

[0772] Intermediate 59

[0773] / V-((lri)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[l,2-Z>]pyridazin- 2-yl )(4,4-difluorocyclohexyl (methyl (-1 -(3, 3, 3 -trifluoropropyl(-l / / -pyrazole-3 -carboxamide

[0774] The title compound was prepared as described for the synthesis of Intermediate 58, using 1 -(3,3,3- trifluoropropyl)-li7-pyrazole-3 -carboxylic acid in place of 2-(3,3,3-trifluoropropyl(-2 / / - 1 ,2,3- triazole-4-carboxylic acid and 2-(3,3-difluorocyclobutyl)acetic acid in place of 4,4,4- trifluorobutanoic acid to afford the title compound, a diastereomeric mixture, as a glassy solid.

[0775] Intermediate 60

[0776] / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl (methyl)-! -(3, 3, 3 -trifluoropropyl(-l / / -pyrazole-3 -carboxamide

[0777] The title compound was prepared as described for the synthesis of Intermediate 59, using 4,4,4- trifluorobutanoic acid in place of 2-(3,3-difluorocyclobutyl)acetic acid to afford the title compound, a diastereomeric mixture, as a glassy solid.

[0778] Intermediate 61

[0779] / V-(( LV)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[ 1 ,2- / ]pyridazin- 2-yl)(4,4-difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2iT-l,2,3-triazole-4-carboxamide The title compound was prepared as described for the synthesis of Intermediate 58, using 2 -(3, 3- difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a diastereomeric mixture, as a glassy solid.

[0780] Intermediate 62 / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)- l -methyl- l / / -pyrazole-5-carboxamide

[0781] The title compound was prepared as described for the synthesis of Intermediate 58, using 1 -methyl - l / / -pyrazole-5-carboxylic acid in place of 2-(3,3,3-trifluoropropyl)-2 / / - 1 ,2,3-triazole-4- carboxylic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0782] Intermediate 63

[0783] A-((hV)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[ l ,2- / ]pyridazin- 2-yl)(4,4-difluorocyclohexyl)methyl)-l -methyl- li -pyrazole-5-carboxamide The title compound was prepared as described for the synthesis of Intermediate 62, using 2 -(3, 3- difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0784] Intermediate 64 / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- di fluorocycl ohexyl)methyl)-2-(cyclopropyl methyl )-2 / / -l ,2,3-triazole-4-carboxamide The title compound was prepared as described for the synthesis of Intermediate 58, using 2- ( cycl opropyl m ethyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl i c acid (Intermediate 106) in place of 2-(3,3,3- tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl i c acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0785] Intermediate 65

[0786] / V-(( LV)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[ 1 ,2- / ]pyridazin- 2-yl )(4,4-difluorocyclohexyl (methyl )-2-(cyclopropyl methyl )-2 / / -l ,2,3-triazole-4-carboxamide The title compound was prepared as described for the synthesis of Intermediate 64, using 2-(3,3- difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0787] Intermediate 66 / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(2,2,2-trifluoroethyl)-2 / / -l ,2, 3 -tri azole-4-carboxamide

[0788] The title compound was prepared as described for the synthesis of Intermediate 58, using 2 -(2, 2, 2- trifl uoroethyl )-2H- 1 ,2,3 -tri azol e-4-carboxyl i c acid (Intermediate 104) in place of 2-(3,3,3- tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl i c acid to afford the title compound, a mixture of diastereomers, as a glassy solid. Intermediate 67

[0789] / V-((lri)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[l,2-Z>]pyridazin- 2-yl)(4,4-difluorocyclohexyl)methyl)-2-(2,2,2-trifluoroethyl)-2 / / - 1 ,2,3-triazole-4-carboxamide The title compound was prepared as described for the synthesis of Intermediate 66, using 2 -(3, 3- difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0790] Intermediate 68 / V-((lri)-(7-(Cyclopropyl((f?)-2 -hydroxy-3, 3-dimethylbutanamido)methyl)imidazo[l, 2-

[0791] Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2-(cyclopropylmethyl)-2i7-l,2,3-triazole-4- carboxamide

[0792] The title compound was prepared as described for the synthesis of Intermediate 64, using (R)- 2- hydroxy-3, 3 -dimethylbutanoic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0793] Intermediate 69

[0794] / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluoro-2-hydroxybutanamido)methyl)imidazo[l,2-Z>]pyridazin- 2-yl)(4,4-difluorocyclohexyl)methyl)-2-(2,2,2-trifluoroethyl)-2iT-l,2,3-triazole-4-carboxamide

[0795] The title compound was prepared as described for the synthesis of Intermediate 66 using 4,4,4- trifluoro-2-hydroxybutanoic acid in place of 4,4,4-trifluorobutanoic acid to afford the title compound, a mixture of diastereomers, as a glassy solid.

[0796] Intermediate 70

[0797] (A)-Af-((7-Cyanoimidazo[ l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2-(3,3,3- trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide A microwave vial was charged with a stir bar, (A)-A-((7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / - l ,2,3-triazole-4-carboxamide (1520 mg, 3.09 mmol, Intermediate 52), dicyanozinc (363 mg, 3.09 mmol), XPhos (76 mg, 0.155 mmol), XPhos Pd G1 (122 mg, 0.155 mmol), and NMP (15 mL). The vial was purged with argon for 5 min, sealed, warmed to 110 °C with microwave irradiation, and stirred for 2 h. The reaction was allowed to cool to rt before it was poured over water. The resulting suspension was stirred for 30 min then collected by filtration. The solids were dissolved in ethyl acetate, washed with brine, dried over anhydrous MgSCri, filtered and condensed. The crude residue was purified by silica gel chromatography (0-100% (10% methanol in ethyl acetate) / hexanes) to afford the title compound as an off-white solid.

[0798] Intermediate 71 fV)-Af-((7-( Ami nomethyl )i mi dazo[ l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-2- (3,3,3-trifluoropropyl)-2iT-l,2,3-triazole-4-carboxamide

[0799] A flask was charged with a stir bar, (5)-iV-((7-cyanoimidazo[l,2-0]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-2-(3,3,3-trifluoropropyl)-2 / / - 1 ,2,3-triazole-4-carboxamide (400 mg,

[0800] 0.83 mmol, Intermediate 70), Raney®Nickel (340 mg, 2.9 mmol), NEL (8 mL, 28% in water), and ethanol (24 mL). The flask was evacuated and backfilled with nitrogen three times before the flask was evacuated and placed under a hydrogen atmosphere. The reaction was stirred overnight at rt. The reaction was filtered through a pad of Celite®with MeOH washing. The combined filtrate and organic washes were condensed into a glassy brown solid. The material was purified by acidic HPLC (SunFire®Prep C18 OBD™ 5 pm, 30 x 250 mm column, 0-100% acetonitrile (0.05% TFA) / water (0.05% TFA)) to afford the title compound as an off white solid.

[0801] Intermediate 72 Methyl (4,4,4-trifluorobutanoyl)- / 9-leucinate

[0802] A flask was charged with a stir bar, methyl D-leucinate (500 mg, 2.75 mmol), 4,4,4- trifluorobutyric acid (423 mg, 2.89 mmol), MeCN (50 mL), HOBt (390 mg, 2.89 mmol), and Hiinig’s base (1.2 mL, 6.88 mmol). The reaction was stirred for 10 min then EDCI (555 mg, 2.89 mmol) was added. The reaction was stirred at 45 °C for 2 h. The reaction was allowed to cool to rt, poured over water and extracted with ethyl acetate (3 x 15 mL). The combined organic extracts were washed with brine, dried over anhydrous MgSCL and condensed into a clear oil which was purified by silica gel chromatography (0-100% ethyl acetate / hexanes, ELSD detection, CAM staining for TLC visualization) to afford the title compound as a clear oil. Intermediate 73

[0803] (4,4,4-Trifluorobutanoyl)- / 9-leucine

[0804] A flask was charged with a stir bar, methyl (4,4,4-trifluorobutanoyl)- / 94eucinate (650 mg, 2.40 mmol, Intermediate 72), ethanol (1 mL), water (1 mL), and lithium hydroxide (289 mg, 12.1 mmol). The reaction was stirred overnight at rt. The reaction was condensed to remove the ethanol and was diluted further with water. The reaction was made acidic (pH 5) by the addition of acetic acid. The aqueous phase was extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were washed with brine, dried over anhydrous MgSCL, filtered and condensed to afford the title compound as a white solid.

[0805] Intermediate 74

[0806] Methyl 2-(3,3,3-trifluoropropyl)-2 / / - l ,2,3-triazole-4-carboxylate

[0807] To a mixture of methyl li7-l,2,3-triazole-4-carboxylate (5 g, 38.2 mmol), K2CO3 (5.27 g, 38.2 mmol) and DMF (49 mL) was added 3-bromo-l,l,l-trifluoropropane (4.07 mL, 38.2 mmol) and the resulting mixture was stirred at rt for 17 h. After that time the mixture was filtered through a pad of Celite®, rinsing with EtOAc and the filtrate concentrated under vacuum. The residue was partitioned between EtOAc (50 mL) and water (50 mL). The layers were separated and the aqueous further extracted with EtOAc (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 75% EtOAc / hexanes; second eluting isomer) to provide the title compound as a white solid.

[0808] Intermediate 75 Methyl 1 -(3, 3, 3 -tri fl uoropropyl )-l / / - l , 2, 3 -tri azole-5 -carboxyl ate

[0809] The title compound was prepared as described for the synthesis of Intermediate 74 and was the first eluting isomer isolated as a clear colorless oil.

[0810] Intermediate 76

[0811] 2-(3, 3, 3 -Tri fl uoropropyl )-2 / / -l ,2,3-triazole-4-carboxylic acid

[0812] To a mixture of methyl 2-(3 ,3 , 3 -tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl ate (4.28 g, 19.2 mmol, Intermediate 74) in THF (58 mL) was added 2 M aqueous NaOH (58 mL, 115 mmol) and the mixture was stirred at rt for 15 h. After that time, the mixture was concentrated to remove the THF and then washed with EtOAc (2 x 50 mL). The aqueous layer was then acidified to pH 3 by the addition of 1 N aqueous HC1 and extracted with 2-MeTHF (3 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous NaiSCL, filtered and concentrated to dryness to provide the title compound as a white solid.

[0813] Intermediate 77 l-(3,3,3-Trifluoropropyl)-liT-l,2,3-triazole-5-carboxylic acid The title compound was prepared as described for the synthesis of Intermediate 76, using methyl 1 -(3, 3, 3-trifl uoropropyl)-! H-\ ,2,3-triazole-5-carboxylate (Intermediate 75) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate, to provide the title compound as a white solid. Intermediate 78

[0814] Methyl 1 -(3,3-difluoropropyl)- 1 H-\ ,2,4-tri azole-5-carboxylate

[0815] To a microwave vial was added methyl- IH- 1, 2, 4-triazole-3-carboxylate (1.25 g, 9.64 mmol), 3,3- difluoropropan-l-ol (1.39 g, 14.5 mmol), PPI13 (2.76 g, 10.5 mmol) and THF (16 mL). Then, DIAD (2 mL, 10.5 mmol) was added and the resulting mixture stirred at rt for 1 h. The reaction mixture was concentrated to dryness and the residue purified by silica gel chromatography (0 to 100% EtOAc / hexanes) to provide the title compound as a light yellow oil. Intermediate 79

[0816] Methyl 1 -(3 -fl uoropropyl )-l / / -l ,2,4-tri azol e-5-carboxyl ate

[0817] The title compound was prepared as described for the synthesis of Intermediate 78, using 3- fluoropropan-l-ol in place of 3,3-difluoropropan-l-ol, and cooling the mixture to 0 °C prior to addition of DIAD, to provide the title compound as a clear colorless oil.

[0818] Intermediate 80

[0819] 1 -(3 -Fl uoropropyl )-l H-\ ,2,4-triazole-5-carboxylic acid A solution of methyl 1 -(3 -fl uoropropyl )- 1 H- 1 ,2,4-tri azol e-5-carboxyl ate (300 mg, 1.6 mmol, Intermediate 79) in THF (1.6 mL) was cooled to 0 °C and then 1 M aqueous LiOH (1.76 mL, 1.76 mmol) was added slowly. The resulting mixture was stirred at 0 °C for 1 h. After that time, the mixture was concentrated to remove THF and then washed with EtOAc (2 x 15 mL). The aqueous layer was acidified to pH 1.5 by the addition of 1 N aqueous HC1 and a precipitate formed. The precipitate was collected by filtration, rinsed with water and dried under vacuum to provide the title compound as a white solid.

[0820] Intermediate 81 Methyl 1 -(cyclopropylmethyl)- 1 / / - 1 ,2,3-triazole-5-carboxylate

[0821] The title compound was prepared as described for the synthesis of Intermediate 74, using (bromomethyl)cyclopropane in place of 3-bromo-l,l,l-trifluoropropane to provide the title compound as a yellow oil.

[0822] Intermediate 82

[0823] 1 -(Cyclopropylmethyl )-l H-\ ,2,3-triazole-5-carboxylic acid

[0824] The title compound was prepared as described for the synthesis of Intermediate 76, using methyl 1 -(cyclopropyl methyl)-! H- 1 ,2,3-triazole-5-carboxylate (Intermediate 81) in place of methyl 2-

[0825] (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate to provide the title compound as a white solid.

[0826] Intermediate 83 Ethyl 1 -(3,3-difluoropropyl)-l H-\ ,2,3-triazole-5-carboxylate

[0827] The title compound was prepared as described for the synthesis of Intermediate 78, using ethyl 1 H- 1 ,2,3-triazole-4-carboxylate in place of methyl- \H- 1, 2, 4-triazole-3-carboxylate, cooling the mixture to 0 °C prior to addition of DIAD, and stirring at rt for 2.5 h instead of 1 h to provide the title compound as a yellow oil.

[0828] Intermediate 84

[0829] 1 -(3, 3-Difl uoropropyl )-l H- \ ,2,3-triazole-5-carboxylic acid

[0830] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 1- (3,3-difl uoropropyl )-\H- 1 , 2,3 -tri azol e-5 -carboxyl ate (Intermediate 83) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate, and stirring at rt for 5 days instead of 15 h, to provide the title compound as a white solid.

[0831] Intermediate 85 fV)-Af-((7-Chloroimidazo[l ,2- / ]pyridazin-2-yl)(4,4-difluorocyclohexyl (methyl )-5-m ethyl - - (3, 3, 3 -tri fl uoropropyl )-l / / -pyrazole-4-carboxamide

[0832] A mixture of fV)-(7-chloroimidazo[l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl)methanamine (75 mg, 0.25 mmol, Intermediate 32), 5-methyl-l-(3,3,3-trifluoropropyl)-li7-pyrazole-4- carboxylic acid (67 mg, 0.29 mmol), HOBt (35 mg, 0.26 mmol), DIPEA (52 pL, 0.3 mmol) and ACN (2.8 mL) was stirred until homogeneous. Then, EDCI (50 mg, 0.26 mmol) was added and the resulting mixture stirred at rt for 3.5 h. After this time, water was added to the mixture and the solution was extracted with EtOAc (2 x 15 mL). The organic layers were combined, washed with brine (20 mL), dried over anhydrous NaiSCE, filtered and concentrated to dryness to provide the title compound as a light brown solid. Intermediate 86

[0833] (ri)- / V-((4,4-Difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-5-methyl-l- (3,3,3-trifluoropropyl)-l / / -pyrazole-4-carboxamide To a microwave vial was added fV)-A-((7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)(4,4- difluorocyclohexyl)methyl)-5-methyl-l-(3,3,3-trifluoropropyl)-li7-pyrazole-4-carboxamide (985 mg, 1.95 mmol, Intermediate 85), potassium trifluoro(vinyl)borate (392 mg, 2.93 mmol), K3PO4 (1.24 g, 5.85 mmol) and 1,4-dioxane / water (5 / 1, 17 mL total) and the mixture sparged with nitrogen for 10 min. Then, Pd(dtbpf)Cl2 (257 mg, 0.39 mmol) was added and the mixture sparged with nitrogen for 5 min. The vial was capped and stirred at 100 °C for 2 h. After that time, the mixture was cooled to rt, diluted with water and extracted with EtOAc (3 x 25 mL). The organic layers were combined, washed with brine (30 mL), dried over anhydrous NaiSCL, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 100% EtOAc / hexanes) to provide the title compound as an amber oil.

[0834] Intermediate 87

[0835] (ri)- / V-((4,4-Difluorocyclohexyl)(7-formylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-5-methyl-l- (3,3,3-trifluoropropyl)-l / / -pyrazole-4-carboxamide To a mixture of (ri)- / V-((4,4-difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-5- m ethyl - 1 -(3 , 3 ,3 -tri fl uoropropyl )- 1 / / -pyrazol e-4-carboxam i de (580 mg, 1.17 mmol, Intermediate 86) and KiOsO^EhO (86 mg, 0.23 mmol) in 1,4-dioxane / water (1:1, 30 mL) was added Na L (1.25 g, 5.84 mmol) and the resulting mixture was stirred at rt for 1.5 h. After that time, another portion of K^OsO^EhO (86 mg, 0.23 mmol) was added and the mixture stirred at 37 °C for 30 min. After that time, the mixture was cooled to rt, diluted with water (25 mL) and extracted with EtOAc (3 x 20 mL). The organic layers were combined, washed with brine (25 mL), dried over anhydrous INfeSCL, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 100% EtOAc / hexanes) to provide the title compound as a yellow foam.

[0836] Intermediate 88

[0837] A (C.V)-(7-(( / ',’)-((CV)- / t77-Butyl sulfinyl)imino)m ethyl )i mi dazo[l ,2- / >]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl )-5-methyl-l -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide

[0838] To a sealed tube was added (ri)- / V-((4,4-difluorocyclohexyl)(7-formylimidazo[l,2-Z>]pyridazin-2- yl (methyl (-5-methyl-l -(3,3,3-trifluoropropyl(- 1 / / -pyrazole-4-carboxamide (418 mg, 0.84 mmol, Intermediate 87), pyridine 4-methylbenzenesulfonate (56 mg, 0.22 mmol), copper (II) sulfate (1.39 g, 8.72 mmol), (ri)-(-)-2-methyl-2-propanesulfmamide (206 mg, 1.7 mmol) and THF (10.5 mL). The tube was capped and stirred at 80 °C for 16 h. After that time, the mixture was cooled to rt and filtered through a pad of Celite®, rinsing with DCM. The filtrate was concentrated to dryness and the resulting residue purified by silica gel chromatography (0 to 100% EtOAc / hexanes) to provide the title compound as a yellow oil.

[0839] Intermediate 89

[0840] A-((fV)-(7-(((fV)- / tv7-Butyl sulfinyl )amino)(cyclopropyl)m ethyl )i mi dazo[l ,2- / ]pyridazin-2- yl((4,4-difluorocyclohexyl (methyl (-5-methyl-l -(3,3,3-trifluoropropyl)-l / / -pyrazole-4- carboxamide

[0841] A solution of cyclopropylmagnesium bromide (1.9 mL, 1 M in 2-MeTHF, 1.9 mmol) was added dropwise to a -78 °C stirring solution of AA(A(-(7-((A(-(((A(- / c77-butylsuliinyl(imino( methyl)imidazo[l,2- / ]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-5-methyl-l-(3,3,3- tri fl uoropropyl )- 1 / / -pyrazol e-4-carboxa i de (368 mg, 0.61 mmol, Intermediate 88) in DCM (6.5 mL), and the resulting solution was allowed to slowly warm to 0 °C over 1 h. Then, the solution was allowed to warm to rt over 1.5 h. After this time, a saturated aqueous aqueous NLLCl (25 mL) and then water (10 mL) were added. The layers were mixed, and then separated. The aqueous layer was extracted with EtOAc (2 x 20 mL). The organic layers were combined, washed with brine (20 mL), dried over anhydrous Na2S04, filtered, and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 100% (10% 2 M NtL / MeOH in DCM) / DCM) to provide the title compound as a light yellow oil.

[0842] Intermediate 90 A-((fV(-(7-( Ami no(cyclopropyl (methyl (i mi dazo[l ,2- / ]pyridazin-2-yl((4,4-difluorocyclohexyl( methyl )-5 -methyl -1 -(3, 3, 3 -tri fl uoropropyl (-1 / / -pyrazol e-4-carboxamide

[0843] A solution of HC1 (0.21 mL, 4.0 M in dioxane, 0.84 mmol) was added to a solution of / V-((lri)-(7- ((((A)- / er / -butylsulfinyl)amino)(cyclopropyl)methyl)imidazo[l,2- / >]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl )-5-methyl-l -(3, 3, 3 -tri fl uoropropyl (-1 / / -pyrazol e-4-carboxamide (270 mg, 0.42 mmol, Intermediate 89) in EtOAc (4.5 mL), and the mixture was stirred for 30 min. Another aliquot of HC1 solution (0.1 mL, 4.0 M in dioxane, 0.4 mmol) was added and the solution stirred at rt for 3 h. After this time, the resulting solution was concentrated, water (20 mL) was added and the mixture washed with hexane (2 x 20 mL). The aqueous layer was made basic by the addition of 1 N aqueous NaOH and then extracted with EtOAc (2 x 25 mL). The organic layers were combined, washed with brine (25 mL), dried over anhydrous Na2S04, filtered and concentrated to dryness to provide the title compound, a diastereomeric mixture, as a yellow oil.

[0844] Intermediate 91

[0845] / V-((lri)-(7-(Cyclopropyl(2-(3,3-difluorocyclobutyl)acetamido)methyl)imidazo[l,2-Z>]pyridazin- 2-yl)(4,4-difluorocyclohexyl (methyl )-5 -methyl - 1 -(3,3,3-trifluoropropyl(- 1 / / -pyrazole-4- carboxamide

[0846] A mixture of / V-((lri)-(7-(amino(cyclopropyl)methyl)imidazo[l,2- / >]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl )-5-methyl-l -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide (102 mg, 0.19 mmol, Intermediate 90), 2-(3,3-difluorocyclobutyl)acetic acid (34 mg, 0.22 mmol), HOBt (27 mg, 0.2 mmol), DIPEA (39 pL, 0.23 mmol) and ACN (2.1 mL) was stirred until homogeneous. Then, EDCI (38 mg, 0.2 mmol) was added and the resulting mixture stirred at rt for 2 h. After this time, water was added and the mixture was extracted with EtOAc (2 x 20 mL). The organic layers were combined, washed with brine (25 mL), dried over anhydrous NaiSCE, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 100% (10% 2 M NEE in MeOH / DCM) / DCM) to provide the title compound, a diastereomeric mixture, as a cream-colored solid.

[0847] Intermediate 92

[0848] / V-((lri)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl (-5-methyl-l -(3,3,3-trifluoropropyl(- l / / -pyrazole-4-carboxamide

[0849] The title compound was prepared as described for the synthesis of Intermediate 91, using 4,4,4- trifluorobutyric acid in place of 2-(3,3-difluorocyclobutyl)acetic acid, and heating the mixture to 40 °C for 1.5 h after stirring at rt, to afford the title compound, a diastereomeric mixture, as a cream-colored solid.

[0850] Intermediate 93

[0851] Methyl 1 -(cyclopropylmethyl)-! / / -! ,2,4-triazole-5-carboxylate The title compound was prepared as described for the synthesis of Intermediate 74, using methyl - 1 H- 1 , 2, 4-tri azole-3 -carboxyl ate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and (bromomethyl)cyclopropane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a light yellow oil. Intermediate 94

[0852] 1 -(Cyclopropylmethyl)- 1 H- 1 ,2,4-triazole-5-carboxylic acid

[0853] To a mixture of methyl 1 -(cycl opropyl methyl )- l / / - l ,2, 4-tri azol e-5-carboxyl ate (500 mg, 2.76 mmol, Intermediate 93) in THF (2.76 mL) was added 2 M aqueous NaOH (2.76 mL, 5.52 mmol) and the mixture was stirred at rt for 2 h. After that time, the mixture was concentrated to remove the THF and then washed with EtOAc (2 x 15 mL). The aqueous layer was then acidified to pH 1- 2 by the addition of 1 N aqueous HC1 and a precipitate formed. The mixture was filtered and the filter cake rinsed with water and dried under vacuum to provide the title compound as a white solid.

[0854] Intermediate 95 Methyl 1 -(3,3,3-trifluoropropyl)- 1 / / - 1 , 2, 4-tri azole-5 -carboxyl ate

[0855] The title compound was prepared as described for the synthesis of Intermediate 78, using 3,3,3- trifluoropropan-l-ol in place of 3,3-difluoropropan-l-ol, and stirring at 120 °C in the microwave for 2 h instead of rt, to provide the title compound as a clear colorless oil.

[0856] Intermediate 96 l-(3,3,3-Trifluoropropyl)-lif-l,2,4-triazole-5-carboxylic acid

[0857] The title compound was prepared as described for the synthesis of Intermediate 94, using methyl 1 -(3,3,3-trifluoropropyl)- 1 H-\ ,2,4-triazole-5-carboxylate (Intermediate 95) in place of methyl 1-

[0858] ( cycl opropyl ethyl )- 1 H- 1 , 2, 4-tri azol e-5 -carboxyl ate, to provide the title compound as a white solid.

[0859] Intermediate 97 Ethyl 1 -(2-(trifluoromethoxy)ethyl)-l / / -pyrazole-4-carboxylate

[0860] To a mixture of ethyl lif-pyrazole-4-carboxylate (650 mg, 4.64 mmol), K2CO3 (641 mg, 4.64 mmol) and DMF (11 mL) was added l-bromo-2-(trifluoromethoxy)ethane (0.56 mL, 4.64 mmol) and the resulting mixture was stirred at rt for 20 h. After that time the mixture was partitioned between EtOAc (30 mL) and water (30 mL). The layers were separated and the aqueous layer further extracted with EtOAc (2 x 30 mL). The organic layers were combined, washed with water (30 mL) followed by brine (30 mL), dried over anhydrous Na2S04, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 75% EtOAc / hexanes) to provide the title compound as a white solid.

[0861] Intermediate 98

[0862] 1 -(2-(Trifluoromethoxy)ethyl)- l / / -pyrazole-4-carboxylic acid

[0863] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 1- (2-(trifluoromethoxy)ethyl)- l / / -pyrazole-4-carboxylate (Intermediate 97) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / - l ,2, 3 -tri azol e-4-carboxyl ate and stirring at 90 °C for 2 h after stirring at rt for 19 h, to provide the title compound as a white solid.

[0864] Intermediate 99

[0865] Ethyl 1 -(2-(difluoromethoxy)ethyl)- 1 / / -pyrazole-4-carboxylate

[0866] The title compound was prepared as described in the synthesis of Intermediate 97, using 1-bromo- 2-(difluoromethoxy)ethane in place of l-bromo-2-(trifluoromethoxy)ethane to provide the title compound as a white solid.

[0867] Intermediate 100

[0868] 1 -(2-(Difluoromethoxy)ethyl)- 1 / / -pyrazol e-4-carb oxyl i c acid

[0869] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 1- (2-(difluoromethoxy)ethyl)- l / / -pyrazole-4-carboxylate (Intermediate 99) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate and stirring at 90 °C for 3 h after stirring at rt for 19 h, to provide the title compound as a white solid.

[0870] Intermediate 101

[0871] Ethyl 2-(3, 3 -difl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate The title compound was prepared as described for the synthesis of Intermediate 78, using ethyl 1 H- 1 ,2,3-triazole-4-carboxylate in place of methyl- 1 / / - 1 ,2,4-triazole-3-carboxylate, cooling the mixture to 0 °C prior to addition of DIAD, and stirring at rt for 2.5 h instead of 1 h to provide the title compound as a clear colorless oil. Intermediate 102

[0872] 2-(3, 3 -Dili uoropropyl )-2 / / -l ,2,3-triazole-4-carboxylic acid

[0873] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 2- (3 ,3 -di fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl ate (Intermediate 101) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / - l ,2, 3 -tri azol e-4-carboxyl ate, and stirring at rt for 2 h instead of 15 h, to provide the title compound as a white solid.

[0874] Intermediate 103

[0875] Ethyl 2-(2,2,2-trifluoroethyl)-2 / / -l ,2,3-triazole-4-carboxylate

[0876] To a mixture of ethyl li7-l,2,3-triazole-4-carboxylate (1 g, 6.73 mmol), CS2CO3 (2.19 g, 6.73 mmol) and DMF (8.6 mL) was added 2-iodo-l,l,l-trifluoroethane (0.67 mL, 6.73 mmol) and the resulting mixture was stirred at 40 °C for 2.5 h. After that time, another aliquot of 2-iodo-l,l,l- trifluoroethane (0.67 mL, 6.73 mmol) was added and the mixture stirred at 60 °C for 3 d. After that time, the mixture was stirred at 80 °C for 3 d. After that time, the mixture was cooled to rt and filtered through a pad of Celite®, rinsing with EtOAc and the filtrate concentrated under vacuum. The residue was partitioned between EtOAc (30 mL) and water (30 mL). The layers were separated and the aqueous layer was further washed with EtOAc (2 x 30 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (0 to 75% EtOAc / hexanes) to provide the title compound as a clear colorless oil.

[0877] Intermediate 104 2-(2,2,2-Trifluoroethyl)-2 / / -l ,2,3-triazole-4-carboxylic acid

[0878] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 2- (2,2,2-trifluoroethyl)-2 / / -l ,2,3-triazole-4-carboxylate (Intermediate 103) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / - 1 ,2,3 -tri azol e-4-carboxyl ate, to provide the title compound as a white solid.

[0879] Intermediate 105

[0880] Methyl 2-(cyclopropyl methyl )-2 / / - l ,2,3-triazole-4-carboxylate The title compound was prepared as described for the synthesis of Intermediate 74, using (bromomethyl)cyclopropane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a clear colorless oil. Intermediate 106

[0881] 2-(Cycl opropyl methyl )-2 / / - l ,2,3-triazole-4-carboxylic acid

[0882] The title compound was prepared as described for the synthesis of Intermediate 76, using methyl 2-(cycl opropyl methyl )-2 / / - 1 ,2,3-triazole-4-carboxylate (Intermediate 105) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate to provide the title compound as a white solid.

[0883] Intermediate 107

[0884] Ethyl 2-(2-m ethoxy ethyl)-27T- 1,2, 3 -triazole-4-carboxylate

[0885] The title compound was prepared as described for the synthesis of Intermediate 74, using ethyl 1H- 1 ,2,3-triazole-4-carboxylate in place of methyl \H-\ ,2,3-triazole-4-carboxylate and 2- bromoethyl methyl ether in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a yellow oil.

[0886] Intermediate 108

[0887] 2-(2-Methoxyethyl)-2 / / - l ,2,3-triazole-4-carboxylic acid The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 2- (2-methoxyethyl)-2 / / - 1 ,2,3-triazole-4-carboxylate (Intermediate 107) in place of methyl 2-(3,3,3- tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl ate to provide the title compound as a yellow solid. Intermediate 109

[0888] Ethyl 2-(2-(difluoromethoxy)ethyl)-2 / / - l ,2,3-triazole-4-carboxylate

[0889] The title compound was prepared as described for the synthesis of Intermediate 74, using ethyl 1 H- 1 ,2,3-triazole-4-carboxylate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and 1-bromo- 2-(difluoromethoxy)ethane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a yellow oil.

[0890] Intermediate 110

[0891] Ethyl 1 -(2-(difluoromethoxy)ethyl)- 1 H- 1 ,2,3-triazole-5-carboxylate

[0892] The title compound was prepared as described for the synthesis of Intermediate 74, using ethyl 1 H- 1 ,2,3-triazole-4-carboxylate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and 1-bromo- 2-(difluoromethoxy)ethane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a yellow oil.

[0893] Intermediate 111

[0894] 2-(2-(Difluoromethoxy)ethyl)-2 / / - l ,2,3-triazole-4-carboxylic acid

[0895] The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 2- (2-(difluoromethoxy)ethyl)-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate (Intermediate 109) in place of methyl 2-(3 ,3 , 3 -tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carb oxyl ate to provide the title compound as a white solid.

[0896] Intermediate 112

[0897] 1 -(2-(Difluoromethoxy)ethyl)- 1 H- 1 ,2,3-triazole-5-carboxylic acid The title compound was prepared as described for the synthesis of Intermediate 76, using ethyl 1- (2-(difluoro ethoxy)ethyl )- ] / / - ] ,2, 3 -tri azole- 5 -carboxyl ate (Intermediate 110) in place of methyl 2-(3 ,3 , 3 -tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carb oxyl ate to provide the title compound as a white solid. Intermediate 113

[0898] Methyl 1 -(2,2-difluoroethyl)- 1 H- 1 ,2,4-triazole-5-carboxylate

[0899] The title compound was prepared as described for the synthesis of Intermediate 74, using methyl - 1 H- 1 , 2, 4-tri azole-3 -carboxyl ate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and 2-bromo- 1,1-difluoroethane in place of 3-bromo-l,l,l-trifluoropropane. An additional aliquot of 2-bromo- 1,1-difluoroethane (1.03 mL, 11.6 mmol) was added to the mixture after stirring at rt for 17 h and stirring was continued for an additional 24 h to provide the title compound as a clear colorless oil.

[0900] Intermediate 114 Methyl 1 -(2-fluoroethyl)- 1 H- 1 ,2,4-triazole-5 -carboxylate

[0901] The title compound was prepared as described for the synthesis of Intermediate 78, using 2- fluoroethanol in place of 3,3-difluoropropan-l-ol, and cooling the mixture to 0 °C prior to addition of DIAD, to provide the title compound as a clear colorless oil.

[0902] Intermediate 115

[0903] 1 -fl ,3-Difluoropropan-2-yl)- l / / -pyrazole-5-carboxylic acid The title compound was prepared as described for the synthesis of Intermediate 76, using methyl 1 -(1 ,3-difluoropropan-2-yl)-l / / -pyrazole-5-carboxylate (Intermediate 122) in place of methyl 2- (3,3,3 -tri fl uoropropyl )-2 / / -l ,2, 3 -tri azol e-4-carboxyl ate to provide the title compound as a white solid. Intermediate 116

[0904] Methyl 1 -(2,2,2-trifluoroethyl)- 1 H- 1 ,2,4-triazole-5-carboxylate

[0905] The title compound was prepared as described for the synthesis of Intermediate 78, using 2,2,2- trifluoroethanol in place of 3,3-difluoropropan-l-ol, and stirring at 120 °C in the microwave for 2 h instead of rt, to provide the title compound as a white solid.

[0906] Intermediate 117

[0907] Methyl 1 -(3, 3, 3 -tri fl uoropropyl )-l / / -l , 2, 4-tri azole-3 -carboxyl ate

[0908] The title compound was prepared as described for the synthesis of Intermediate 78, using 3,3,3- trifluoropropan-l-ol in place of 3,3-difluoropropan-l-ol, and stirring at 120 °C in the microwave for 2 h instead of rt, to provide the title compound.

[0909] Intermediate 118

[0910] Methyl 2-((3, 3 -difluorocyclobutyl (methyl )-2 / / -l ,2,3-triazole-4-carboxylate

[0911] The title compound was prepared as described for the synthesis of Intermediate 74, using 3- (brom om ethyl)- 1,1-difluorocyclobutane in place of 3-bromo-l,l,l-trifluoropropane to provide the title compound as a clear colorless oil.

[0912] Intermediate 119

[0913] 2-((3, 3 -Difluorocyclobutyl (methyl )-2 / / -l ,2,3-tri azole-4-carboxylic acid

[0914] The title compound was prepared as described for the synthesis of Intermediate 76, using methyl 2-((3, 3 -difluorocyclobutyl (methyl (-2 / / -1 ,2,3-tri azole- 5 -carboxyl ate (Intermediate 118) in place of methyl 2-(3 ,3 , 3 -tri fl uoropropyl )-2H- 1 , 2,3 -tri azol e-4-carboxyl ate to provide the title compound as a white solid.

[0915] Intermediate 120

[0916] Methyl 1 -(2-(difluoromethoxy)ethyl)- 1 H- 1 ,2,4-triazole-5-carboxylate

[0917] The title compound was prepared as described for the synthesis of Intermediate 74, using methyl - 1 H- 1 ,2, 4-tri azole-3 -carboxyl ate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and 1-bromo- 2-(difluoromethoxy)ethane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a clear colorless oil.

[0918] Intermediate 121

[0919] Methyl 1 -(2-(trifluoromethoxy)ethyl)- 1 H- 1 ,2,4-triazole-5-carboxylate The title compound was prepared as described for the synthesis of Intermediate 74, using methyl - 1 H- 1 , 2, 4-tri azole-3 -carboxyl ate in place of methyl 1 H- 1 , 2,3 -tri azol e-4-carboxyl ate and 1-bromo- 2-(trifluoromethoxy)ethane in place of 3-bromo-l,l,l-trifluoropropane, to provide the title compound as a clear colorless oil. Intermediate 122

[0920] Methyl 1 -(1 , 3-difl uoropropan-2-yl )- 1 / / -pyrazol e-5-carboxyl ate

[0921] The title compound was prepared as described for the synthesis of Intermediate 78, using 1,3- difluoro-2-propanol in place of 3,3-difluoropropan-l-ol to provide the title compound as a clear light-yellow oil. Intermediate 123

[0922] (A)-A-((7-Chloroimidazo[l,2- / ]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l-(3,3,3- trifluoropropyl)- ! H- 1 ,2,3-triazole-5-carboxamide A mixture containing fY)-(7-chloroimidazo[ l ,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl) methanamine (618 mg, 2.06 mmol, Intermediate 32), 1 -(3,3,3-trifluoropropyl)- 1 H- \ ,2,3-triazole- 5-carboxylic acid (571 mg, 2.73 mmol, Intermediate 77), HOBt (366 mg, 2.71 mmol), and EDCI (530 mg, 2.77 mol) in DIEPA (1.4 mL) and DMF (10 mL) was stirred at rt. After 3 h, the mixture was warmed to 40 °C. After 1.5 h, the reaction was allowed to cool to rt and then portioned between water and ethyl acetate. The layers were separated. The organic layer was washed with water and then half- saturated sodium bicarbonate solution. The washed solution was dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (hexanes / ethyl acetate) to afford the title compound as a white foam.

[0923] Intermediate 124

[0924] 0V)-Af-((4,4-Difluorocyclohexyl)(7-vinylimidazo[ l ,2- / ]pyridazin-2-yl)methyl)- l -(3,3,3- trifluoropropyl)- ! H- 1 ,2,3-triazole-5-carboxamide The title compound was prepared as described for the synthesis of Intermediate 34, using ( S)-N - ((7-chloroimidazo[l, 2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l -(3,3,3- tri fl uoropropyl )- 1 H- 1 , 2,3 -tri azol e-5 -carboxam i de (Intermediate 123) in place of (S)-N-((7- chloroimidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l-(3,3,3-trifluoropropyl)- liT-pyrazole-4-carboxamide.

[0925] Intermediate 125 (A)- / V-((4,4-Difluorocyclohexyl)(7-formylimidazo[l,2- / ]pyridazin-2-yl)methyl)-l-(3,3,3- trifluoropropyl)-! H- 1 ,2,3-triazole-5-carboxamide

[0926] The title compound was prepared as described for the synthesis of Intermediate 35, using ( S)-N - ((4,4-difluorocyclohexyl)(7-vinylimidazo[l,2-Z>]pyridazin-2-yl)methyl)-l-(3,3,3-trifluoropropyl)- li7-l,2,3-triazole-5-carboxamide (Intermediate 124) in place of (S)-N-((4,4- difluorocyclohexyl)(7-vinylimidazo[ 1 ,2- / >]pyridazin-2-yl)methyl)- 1 -(3, 3, 3 -trifluoropropyl)-! H- pyrazole-4-carboxamide.

[0927] Intermediate 126 A-(fV)-(7-(( / '’)-((fV)- / t' / 7-Butylsulfinyl)imino) ethyl)imidazo[l ,2- / >]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl )-l -(3,3,3-trifluoropropyl)- 1 / / - 1 ,2,3-triazole-5-carboxamide

[0928] The title compound was prepared as described for the synthesis of Intermediate 36, using ( S)-N - ((4,4-difluorocyclohexyl)(7-formylimidazo[l,2- / >]pyridazin-2-yl)methyl)-l-(3,3,3- trifluoropropyl)- liT-1, 2, 3-triazole-5-carboxamide (Intermediate 125) in place of (L')-l-((4,4- difluorocyclohexyl)(7-formylimidazo[l ,2- / ]pyridazin-2-yl)methyl)-l -(3, 3, 3 -trifluoropropyl)-! H- pyrazole-4-carboxamide. Intermediate 127

[0929] A-((hV)-(7-((((V)- / t' / 7-Butyl sulfinyl )amino)(cyclopropyl)m ethyl )i mi dazo[l ,2- / ]pyridazin-2- yl ((4,4-difluorocyclohexyl (methyl)- 1 -(3,3,3-trifluoropropyl(- 1 H-\ , 2, 3 -tri azole-5 -carboxamide

[0930] The title compound was prepared as described for the synthesis of Intermediate 37, using N-((S)- (7-((((ri)- / er / -butylsulfmyl)imino)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4- di fluorocyclohexyl (methyl (-1 -(3,3,3-trifluoropropyl(- 1 / / - 1 ,2,3-triazole-5-carboxamide (Intermediate 126) in place of / V-((ri)-(7-((((ri)- / er / -butylsulfmyl)imino)methyl)imidazo[l,2- / >]pyridazin-2-yl)(4,4-difluorocyclohexyl(methyl(- 1 -(3,3,3-trifluoropropyl(-l / / -pyrazole-4- carboxamide.

[0931] Intermediate 128

[0932] A-((fV(-(7-( Ami no(cyclopropyl (methyl }i mi dazo[l ,2- / ]pyridazin-2-yl}(4,4- difluorocyclohexyl(methyl}-l -(3,3,3-trifluoropropyl)-l / / -l ,2, 3 -tri azole-5 -carboxamide

[0933] The title compound was prepared as described for the synthesis of Intermediate 38, using N-((\S)- (7-((((A(- / c77-butyl sulfmyl )amino((cyclopropyl (methyl )i mi dazo[l ,2- / ]pyridazin-2-yl}(4,4- difluorocyclohexyl)methyl)-l-(3,3,3-trifluoropropyl)-liT-l,2,3-triazole-5-carboxamide (Intermediate 127) in place of A-((fV(-(7-((((A(- / c77-butylsulfmyl (amino) (cyclopropyl (methyl (i mi dazo[l ,2- / ]pyridazin-2-yl ((4, 4-difIuorocycl ohexyl (methyl (-1 -(3,3,3- trifluoropropyl )- 1 / / -pyrazol e-4-carb oxami de . Intermediate 129

[0934] A-((hV)-(7-(Cyclopropyl(4,4,4-trifluorobutanamido)methyl)imidazo[ l ,2- / >]pyridazin-2-yl((4,4- di fluorocyclohexyl (methyl (-1 -(3,3,3-trifluoropropyl(- 1 / / - 1 ,2,3-triazole-5-carboxamide

[0935] The title compound was prepared as described for the synthesis of Intermediate 39, using Af-(( fV)- (7-(amino(cyclopropyl)methyl)imidazo[l,2-Z>]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l- (3,3,3-trifluoropropyl)-li7-l,2,3-triazole-5-carboxamide (Intermediate 128) in place (7-(amino(cyclopropyl (methyl (i mi dazo[l , 2- / >]pyridazin-2-yl ((4, 4-di fluorocyclohexyl (methyl (-1 - (3,3,3-trifluoropropyl)-li7-pyrazole-4-carboxamide.

[0936] Intermediate 130

[0937] A-((fV(-(7-(Cyclopropyl(2-(3,3-difIuorocyclobutyl(acetamido( ethyl(imidazo[l ,2- / ]pyridazin- 2-yl ((4, 4-difIuorocyclohexyl (methyl (-1 -(3,3,3-trifIuoropropyl(-l / / -l ,2,3-triazole-5-carboxamide

[0938] The title compound was prepared as described for the synthesis of Intermediate 39, using A-(( fV(- (7-(amino(cyclopropyl (methyl (i mi dazo[l ,2- / ]pyridazin-2-yl ((4, 4-difluorocyclohexyl ( ethyl (-1 - (3,3,3-trifluoropropyl)-liT-l,2,3-triazole-5-carboxamide (Intermediate 128) in place (7-(amino(cyclopropyl)methyl)imidazo[l,2-0]pyridazin-2-yl)(4,4-difluorocyclohexyl)methyl)-l- (3,3,3-trifluoropropyl)-liT-pyrazole-4-carboxamide and 2-(3,3-difluorocyclobutyl)acetic acid in place of 4,4,4-trifluorobutyric acid. Intermediate 131

[0939] Methyl 2-(2,2,2-trifluoro- 1 -hydroxy ethyl)isonicotinate

[0940] Trimethyl(trifluoromethyl)silane (14.5 g, 102 mmol) was added to a stirring, ice-water cooled solution of methyl 2-formylisonicotinate (16 g, 97 mmol) and CsF (22.1 g, 145 mmol). The mixture was allowed to warm to rt. After 2 h, the reaction mixture was poured into an aqueous, 2 M solution of HC1 (20 mL) at 10 °C. After 3 h, the mixture was extracted numerous times with ethyl acetate. The organic fractions were combined, dried over anhydrous NaiSCri, filtered and concentrated under vacuum to afford a residue. The residue was purified by silica gel chromatography (0 to 30 % ethyl acetate / petroleum ether) to provide the title compound as a yellow solid.

[0941] Intermediate 132

[0942] 2-(2,2,2-Trifluoro-l-((methylsulfonyl)oxy)ethyl)isonicotinate

[0943] MsCl (8.4 g, 73 mmol) was added to a stirring solution of methyl 2-(2,2,2-trifluoro-l- hydroxyethyl)isonicotinate (10 g, 43 mmol Intermediate 131) and DIPEA (16.5 g, 128 mmol) in dichloromethane (100 mL). After 2 h, saturated aqueous sodium bicarbonate solution was added and the biphasic mixture was separated and the organics were washed with brine solution, dried over anhydrous NaiSCE, filtered and concentrated under vacuum to afford a residue. The residue was purified by silica gel chromatography (0 to 25 % ethyl acetate / petroleum ether) to provide the title compound as a yellow oil.

[0944] Intermediate 133

[0945] Methyl 2-(2,2,2-trifluoroethyl)isonicotinate Palladium on carbon (2 g, 10% wt) was added to a stirring mixture of 2-(2,2,2-trifluoro-l- ((methylsulfonyl)oxy)ethyl)isonicotinate (11.5 g, 36.7 mmol, Intermediate 132) in methanol (100 mL). The reaction mixture was placed under an atmosphere of hydrogen (15 psi). After 12 h, the mixture was filtered, and the filtrate was concentrated under reduce pressure to provide a residue. The residue was purified by silica gel chromatography (0 to 25 %, ethyl acetate / petroleum ether) to provide the title compound as a colorless oil.

[0946] Intermediate 134

[0947] 2-(2,2,2-Trifluoroethyl)isonicotinic acid

[0948] A mixture of methyl 2-(2,2,2-trifluoroethyl)isonicotinate (3.6 g, 16.4 mmol, Intermediate 133) and aqueous 12 M HC1 solution (36 mL) was heated to 100 °C. After 12 h, the mixture was concentrated under reduced pressure to provide the title compound as a white solid.

[0949] Intermediate 135

[0950] Ethyl 3 -(3 , 3 ,3 -trifluoropropyl)i soxazole-4-carboxyl ate

[0951] NCS (392 mg, 2.93 mmol) was added to a solution of 4,4,4-trifluorobutanal oxime (394 mg, 2.79 mmol, Intermediate 154) and chloroform (2 mL). The reaction mixture was stirred at rt for 3 h. Ethyl-3-(diethylamino)acrylate (400 mg, 2.79 mmol) was added and the reaction mixture was stirred at rt for 16 h. The mixture was concentrated under reduced pressure, the residue was dispersed into a mixture of EtOAc (10 ...

Claims

We Claim1. A compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5 to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups;Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -O i- 3>alkyl or -OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o- i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH3 -CHF2, -CF3, OH and =0;R4is -C(3-6)Cycloalkyl, phenyl, or a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and - i-4al kyl wherein the -0C(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, - C(i-4)alkyl and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3- 4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5 to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl) or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;R4CI, R4c2, R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N,O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and R5is hydrogen or halogen; wherein when R4is 1,2,4-triazolyl, then R4iswhen R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

2. A compound of Formula G:or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, or a 5- to 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one to three Rlcgroups;R2is H, -C(3-5)Cycloalkyl, -C(i-4)alkyl, or a 6-membered heterocycle having 1 to 2 oxygen atoms; wherein the -C(i-4)alkyl is unsubstituted or substituted with one to six R2agroups; and wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;Rla, Rlband R2aare each independently fluorine, -C(3-5)Cycloalkyl, -CN, -OH, -O i- 3>alkyl or -OC(3-4)Cycloalkyl, wherein the -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; each Rlcis independently -OCH3, -OCF3, -OCHF2, or -C(i-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms;R3is -C(o-i)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl or -C(i-2)alkyl-0-C(i-3)alkyl, wherein the - o-1)alkylC(3-6)Cycloalkyl, -C(3-6>alkyl and -C(i-2)alkyl-0-C(i-3)alkyl are unsubstituted or substituted with one to five R3agroups each independently selected from fluorine, -CH -CHF2, -CF3, OH and =0;R4is -C(3-6)Cycloalkyl, phenyl, or a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen, -OC(i-3)alkyl, and - i- 4>alkyl wherein the -OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one to three R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, - C(i-4)alkyl and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3- 4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -OH, -N(R4cl)(R4c2), -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o-2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -O3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i-4)alkyl)or a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms;R4CI, R4c2, R4dland R4d2are each independently H or -Cn-ualkyl, wherein the -C(i.3>alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3- to 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; andR5is hydrogen or halogen; wherein when R4is 1,2,4-triazolyl, then R4iswhen R4is a substituted 6-membered heteroaryl, the substituted heteroaryl is unsubstituted at the para-position.

3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the piperidinyl is unsubstituted or substituted with one to three Rlcgroups;Rlaand Rlbare each independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine; each Rlcis independently -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms;R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl;R3is -C(5-6)Cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms;R4is -C(3-4)Cycloalkyl, phenyl, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen and Cn-ualkyl that is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl; wherein the phenyl is unsubstituted or substituted with one or two R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i-4)alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3- 4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i- 4>alkyl), wherein the -C(i-3)alkyl, -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms;R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N,O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; and R5is hydrogen or fluorine; wherein: when R4is 1,2,4-triazolyl, then R4is4. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-C(i-3)perfluoroalkyl, pyrrolidinyl, or piperidinyl; wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to six Rlbgroups; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with one to three Rlcgroups;Rlaand Rlbare each independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine; each Rlcis independently -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms;R2is H, -C(3-5)Cycloalkyl, or -C(i-4)alkyl; wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;R3is -C(5-6)Cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms;R4is -C(3-4)Cycloalkyl, phenyl, or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-6)Cycloalkyl is unsubstituted or substituted with one to three R4agroups each independently selected from halogen and Cn-ualkyl that is unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl;wherein the phenyl is unsubstituted or substituted with one or two R4bgroups each independently selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i-4)alkyl, and a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3- 4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the 5-membered heteroaryl is unsubstituted or substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i- 4>alkyl), wherein the -C(i-3)alkyl, -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms;R4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; andR5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -CH2C(3-6)Cycloalkyl, or piperidinyl wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -CH2C(3-6)Cycloalkyl is unsubstituted or substituted with one to four fluorine atoms; and wherein the piperidinyl is unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine;R2is H, -C(3-5)Cycloalkyl, or -C(i-3)alkyl;R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms;R4is -C(3-4)Cycloalkyl, spiropentanyl, spirohexanyl, spiroheptanyl, spirooctanyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl; wherein the - 3- 4)Cycloalkyl is unsubstituted or substituted with one to three groups selected from halogen, and C(i.2>alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one or two groups selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i.4>alkyl, and a 3 to 6- membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl are substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o-2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is6. The compound of claim 2 or claim 4, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(i-6)alkyl, -C(i-2)alkylC(3-6)Cycloalkyl, -C(o-2)alkyl-cyclopropyl-CF3, pyrrolidinyl, or piperidinyl wherein the -C(i-6)alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(i-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to four fluorine atoms; and wherein the pyrrolidinyl and piperidinyl are unsubstituted or substituted with - i- 2>al kyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH, -OCH3, -OCF3, -OCHF2, or fluorine;R2is H, -C(3-5)Cycloalkyl, or -C(i-3)alkyl; wherein the -C(3-5)Cycloalkyl is unsubstituted or substituted with -CN;R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms;R4is -C(3-4)Cycloalkyl, spiropentanyl, spirohexanyl, spiroheptanyl, spirooctanyl, phenyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl; wherein the -3- 4)Cycloalkyl is unsubstituted or substituted with one to three groups selected from halogen, and C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one or two groups selected from halogen, -CN, -C(o-2)alkyl-C(3-4)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -OC(i-3)alkyl, C(i.4>alkyl, and a 3 to 6- membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -OC(i-3)alkyl, -C(o-2)alkyl-C(3-4)Cycloalkyl and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms, and wherein the heterocyclyl is unsubstituted or substituted with 1 oxo; wherein the pyrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl and thiadiazolyl are substituted with one or two R4Cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein:wherein the -C(3-5>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein theis unsubstituted or substituted with one to four fluorine atoms;wherein theis unsubstituted or substituted with one to four fluorine atoms; and wherein theis unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH or fluorine;R2is H, methyl, isopropyl or cyclopropyl;R3is cyclohexylR4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl; wherein the cyclopropyl is unsubstituted or substituted with one to three groups selected from fluorine and C aralkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one to two groups selected from chlorine and C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is unsubstituted or substituted with Cn-ualkyl, wherein the Cn-ualkyl is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl, or 1,2,5-thiadiazolyl are unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-4)alkyl, wherein the - o- i)alkylC(3-4)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; andR5is hydrogen or fluorine; whereinwhen R4is 1,2,4-triazolyl, then R4is8. The compound of any one of claims 2, 4, or 6, or a pharmaceutically acceptable salt thereof, wherein:wherein the -C(3-5>alkyl is unsubstituted or substituted with one to six Rlagroups; A wherein the ^ is unsubstituted or substituted with one to four fluorine atoms; wherein theis unsubstituted or substituted with one to four fluorine atoms; wherein theis unsubstituted or substituted with one to four fluorine atoms; and wherein theis unsubstituted or substituted with -C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; each Rlais independently -OH or fluorine;R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN;R3is cyclohexylR4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl or 1,2,5-thiadiazolyl;wherein the cyclopropyl is unsubstituted or substituted with one to three groups selected from fluorine and C aralkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the phenyl is unsubstituted or substituted with one to two groups selected from chlorine and C(i-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; wherein the 1,2,3-thiadiazolyl is unsubstituted or substituted with C(i-3)alkyl, wherein the Cn-ualkyl is unsubstituted or substituted with one to three fluorine atoms; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, thiazolyl, isothiazolyl, or 1,2,5-thiadiazolyl are unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-4)alkyl, wherein the - o- i)alkylC(3-4)Cycloalkyl and -C(i-4)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen or fluorine; wherein when R4is 1,2,4-triazolyl, then R4is9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein:wherein the -C(3-5>alkyl is substituted with one to six Rlagroups; wherein theis unsubstituted or substituted with one to two fluorine atoms;wherein thesubstituted with two fluorine atoms; and wherein theis substituted with -CF3; each Rlais independently -OH or fluorine;R2is H, methyl, isopropyl or cyclopropyl;R3is cyclohexylR4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, 1,2,3-thiadiazolyl or 1,2,5- thiadiazolyl; wherein the cyclopropyl is substituted with one to two groups selected from fluorine and palkyl that is unsubstituted or substituted with three fluorine atoms; wherein the phenyl is unsubstituted or substituted with -chlorine, or -C(i-2)alkyl; wherein the 1,2,3-thiadiazolyl and 1,2,5-thiadiazolyl are substituted with 2- 3>alkyl; wherein the pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl and imidazolyl are substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the - o- i)alkylC(3-4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen; wherein when R4is 1,2,4-triazolyl, then R4is10. The compound of any one of claims 2, 4, 6, or 8, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(3-5)alkyl,wherein the -C(3-5)alkyl is substituted with one to six Rlagroups; wherein thei is unsubstituted or substituted with one to two fluorine atoms; wherein theis unsubstituted or substituted with one to four fluorine atoms; wherein thesubstituted with two fluorine atoms; and wherein theis substituted with -CF3; each Rlais independently -OH or fluorine;R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN;R3is cyclohexylR4is cyclopropyl, spiropentanyl, spirohexanyl, phenyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl, imidazolyl, 1,2,3-thiadiazolyl or 1,2,5- thiadiazolyl; wherein the cyclopropyl is substituted with one to two groups selected from fluorine and palkyl that is unsubstituted or substituted with three fluorine atoms; wherein the phenyl is unsubstituted or substituted with -chlorine, or -C(i-2)alkyl; wherein the 1,2,3-thiadiazolyl and 1,2,5-thiadiazolyl are substituted with 2- 3>alkyl; wherein the pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, triazolyl, tetrazolyl and imidazolyl are substituted with one or two R4cgroups;each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, or -C(i-3)alkyl, wherein the - o- i)alkylC(3-4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; each R4dis independently -OCH3, -OCF3, -OCHF2, or fluorine; and R5is hydrogen; wherein when R4is 1,2,4-triazolyl, then R4is11. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R1isR1is -C(3-6>alkyl, -C(o-2)alkylC(3-6)Cycloalkyl, or a 6-membered heterocyclyl having 1 to 2 nitrogen atoms; wherein the -C(i.6>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(o-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one to three Rlbgroups; and wherein the 6-membered heterocyclyl is substituted with one Rlcgroup; each Rlais independently fluorine or -OH; each Rlbis independently fluorine;Rlcis -C(i-4)alkyl that is substituted with one to three fluorine atoms.

12. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:R1is -C(3-6>alkyl, -C(i-2)alkylC(3-6)Cycloalkyl, or -C(i-2)alkyl-cyclopropyl-CF3; wherein the -C(i.6>alkyl is unsubstituted or substituted with one to six Rlagroups; wherein the -C(i-2)alkylC(3-6)Cycloalkyl is unsubstituted or substituted with one or two Rlbgroups; each Rlais independently fluorine; each Rlbis independently fluorine.

13. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R1is:

14. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R1is:

15. The compound of claim 2, 12, or 14, or a pharmaceutically acceptable salt thereof, wherein R1is:

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1is:

17. The compound of any one claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R1is18. The compound of any one of claims 1 to 6 or 11 to 17, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, isopropyl or cyclopropyl.

19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R2is unsubstituted cyclopropyl.

20. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, which is a compound of formula la:

21. The compound of any one of claims 2, 4, 6, 12, 14, or 15, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, isopropyl, cyclopropyl, or cyclobutyl; wherein the cyclopropyl and cyclobutyl are unsubstituted or substituted with -CN.

22. The compound of any one of claims 2, 4, 6, 8, 10, 12, 14, 15, or 21, or a pharmaceutically acceptable salt thereof, wherein R2is cyclopropyl substituted with -CN.

23. The compound of any one of claims 2, 4, 6, 8, 10, 12, 14, 15, 21, or 22, or a pharmaceutically acceptable salt thereof, wherein R2is24. The compound of any one of claims 2, 4, 6, 8, 10, 12, 14, 15, or 21, or a pharmaceutically acceptable salt thereof, wherein R2is cyclobutyl substituted with -CN.

25. The compound of any one of claims 2, 4, 6, 8, 10, 12, 14, 15, 21, or 24, or a pharmaceutically acceptable salt thereof, wherein R2is:

26. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R2is H, methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, tetrahy dropyranyl ,27. The compound of any one of claims 1, 2, or 11 to 26, or a pharmaceutically acceptable salt thereof, wherein R3is -C(o-i)alkylC(3-6)cycloalkyl that is unsubstituted or substituted with one to two fluorine atoms.

28. The compound of any one of claims 1 to 4, or 11 to 27, or a pharmaceutically acceptable salt thereof, wherein R3is cyclohexyl that is unsubstituted or substituted with one to two fluorine atoms.

29. The compound of any one of claims 1 to 28, or a pharmaceutically_!_ / \<Facceptable salt thereof, wherein R3is ' — ' F .

30. The compound of any one of claims 1 to 6, 11 to 19, 27, or 28, or a pharmaceutically acceptable salt thereof, which is a compound of formula lb:

31. The compound of any one of claims 1 to 6, 11 to 19, 27, 28, or 30, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-2a:

32. The compound of any one of claims 1 to 19 or 27-31, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ib-3a:

33. The compound of any one of claims 1, 2, or 11-26, or a pharmaceutically acceptable salt thereof, wherein R3is34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, whereinR4is -C(3-6)Cycloalkyl that is unsubstituted or substituted with one to three R4agroups; andeach R4ais independently selected from halogen, -OC(i-3)alkyl, and -C(i-4)alkyl, wherein the -OC(i-3)alkyl, and -C(i-4)alkyl are unsubstituted or substituted with one to three fluorine atoms; alternatively, two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a C(3-6)Cycloalkyl.

35. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein each R4agroup is fluorine, methyl, or -CF3, or two R4agroups attached to the same ring atom can be combined with the atom to which they are attached to form a cyclopropyl, cyclobutyl or cyclopentyl.

36. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein R4is cyclopropyl that is unsubstituted or substituted with one to three groups selected from fluorine, CH3, and CF3.

37. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein R4is38. The compound of any one of claims 1, 2, or 11-33, or a pharmaceutically acceptable salt thereof, wherein R4is:

39. The compound of any one of claims 1 to 35 or 38, or a pharmaceutically acceptable salt thereof, wherein R4is:

40. The compound of any one of claims 1 to 35, 38, or 39, or a pharmaceutically acceptable salt thereof, wherein R4is:

41. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, whereinR4is phenyl that is unsubstituted or substituted with one to two R4bgroups; and each R4bis independently selected from chlorine, fluorine, -CN, cyclopropyl, -OCH2- cyclopropyl, -OC(i-2)alkyl, -C(i-2)alkyl and pyrrolidin-2-one, wherein the cyclopropyl, -OC(i-2)alkyl, and Cn-2)alkyl are unsubstituted or substituted with one to three fluorine atoms.

42. The compound of any one of claims 1 to 33 or 41, or a pharmaceutically acceptable salt thereof, wherein each R4bgroup is independently H, fluorine, chlorine, -CN, methyl, ethyl, -CHF2, -CH2CF3, -OCHF2, -OCH2CHF2, -OCH2CF3, cyclopropyl,43. The compound of any one of claims 1 to 33, 41 or 42, or a pharmaceutically acceptable salt thereof, wherein R4is phenyl that is unsubstituted or substituted with chlorine, -CH3, or -CH2CH3.

44. The compound of any one of claims 1 to 33 or 41 to 43, or a pharmaceutically acceptable salt thereof, wherein R4is:

45. The compound of any one of claims 1 to 33 or 41 to 44, or a pharmaceutically acceptable salt thereof, wherein R4is:

46. The compound of any one of claims 1, 2 or 11 to 33, or a pharmaceutically acceptable salt thereof, whereinR4is a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S, that is substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -C(o-2)alkylC(3-6)Cycloalkyl, -OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), or -C(o-2)alkyl-N(C(i-4)alkyl)C(0)(C(i- 4>alkyl), wherein the -C(i-3)alkyl, -OC(i-3)alkyl and -OC(3-4)Cycloalkyl groups are unsubstituted or substituted with one to three fluorine atoms; andR4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N,O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; wherein when R4is 1,2,4-triazolyl, then R4is l / / -l,2,4-triazolyl, and when R4is a 6-membered heteroaryl, the heteroaryl is unsubstituted at the para-position.

47. The compound of any one of claims 1, 2 or 11 to 33, or a pharmaceutically acceptable salt thereof, wherein:R4is a 5 to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S, that is substituted with one or two R4cgroups; each R4Cis independently halogen, -CN, -NTh, -N(CH3)2, -C(o-2)alkylC(3-6)Cycloalkyl, - OC(o-2)alkyl-C(3-4)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl, or a 3 to 6-memberedheterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the - o- 2)alkylC(3-6)Cycloalkyl, -C(i-4)alkyl, -OC(i-3)alkyl and heterocyclyl groups are unsubstituted or substituted with one to six R4dgroups; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; each R4dis independently fluorine, -CN, -OH, oxo, -C(i-3)alkyl, -OC(i-3)alkyl, -O 3- 4)Cycloalkyl, -C(o-2)alkyl-N(R4dl)(R4d2), -C(o-2)alkyl-N(C(i.4)alkyl)C(0)(C(i.4>alkyl), or a 3- to 6-membered heterocyclyl having 1 to 2 heteroatoms selected from N and O, wherein the -C(i-3)alkyl, -OC(i-3)alkyl, -OC(3-4)Cycloalkyl, and heterocyclyl groups are unsubstituted or substituted with one to three fluorine atoms; andR4dland R4d2are each independently H or -C(i-3)alkyl, wherein the -C(i-3)alkyl is unsubstituted or substituted with one to six groups selected from fluorine and chlorine; alternatively R4dland R4d2can be combined with the atom to which they are attached to form a 3 to 6 membered heterocyclyl having 1 to 3 heteroatoms selected from N, O and S, wherein the heterocyclyl is unsubstituted or substituted with 1 to 4 fluorine atoms; wherein when R4is 1,2,4-triazolyl, then R4is l / / -l,2,4-triazolyl, and when R4is a 6-membered heteroaryl, the heteroaryl is unsubstituted at the para-position.

48. The compound of any one of claims 1 to 6, 11 to 33, 46, or 47, or a pharmaceutically acceptable salt thereof, wherein each R4Cis independently fluorine, -CN, methyl, ethyl, isopropyl, -CD2CD3, -OCH3, - OCH2CH3, -OCH(CH )2, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, - CF2CH3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -CH(CH )CF3, - CH(CH2F)2, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCHF2, -CH2CH2OCF3, - OCHF2, -OCH2CHF2, -OCH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, -CH2- cyclopropyl, -O-cyclopropyl, -O-cyclobutyl,alternatively two R4cgroups attached to adjacent ring atoms can be combined to form the group:

49. The compound of any one of claims 1, 2, 11 to 33, or 47, or a pharmaceutically acceptable salt thereof, wherein each R4cis independently fluorine, -CN, -NH2, N(CH3)2, methyl, ethyl, isopropyl, -CD3, -CD2CD3, -OCH3, -OCH2CH3, -OCH(CH3)2, - OC(CH3)3, CH(CH3)OH, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CF2CH3, - CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -CH(CH3)CHF2, -CH(CH3)CF3, -CH(CH2F)2, -CH2CF2CH3, -CH2CH2CF2CH3, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCHF2, -CH2CH2OCF3, -CH2OCHF2, -OCHF2, -OCH2CHF2, -OCH2CH2F, -OCH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, -CH2-cyclopropyl, -O-cyclopropyl, -O-cyclobutyl,alternatively two R4cgroups attached to adjacent ring atoms can be combined to form the group:

50. The compound of any one of claims 1-4, 11-33, or 46 to 49, or a pharmaceutically acceptable salt thereof, whereinR4is a 5 membered heteroaryl ring having from 1 to 4 heteroatoms selected from N, O and S, that is substituted with one or two R4cgroups, wherein when R4is 1,2,4-triazolyl, then R4is51. The compound of any one of claims 1 to 6, 11 to 33 or 46 to 50, or a pharmaceutically acceptable salt thereof, whereinR4is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl or thiadiazolyl, that is substituted with one or two R4cgroups, wherein when R4is 1,2,4-triazolyl, then R4is52. The compound of any one of claims 1 to 6, 11 to 33 or 46 to 51, or a pharmaceutically acceptable salt thereof, wherein R4is pyrrolyl, pyrazolyl, imidazolyl, 1 / / - 1 ,2,3 - triazolyl, 2H- 1 ,2,3-triazolyl, \H- 1,2,4-triazolyl, tetrazolyl, furanyl, oxazolyl, isoxazolyl, 1,2,3- oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl or 1,3,4-thiadiazolyl, that is substituted with one or two R4cgroups.

53. The compound of any one of claims 1 to 6, 11 to 33 or 46 to 52, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl, imidazolyl, \H- 1,2, 3 -triazolyl,2H-\ ,2,3-triazolyl, 1 H- 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, thienyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, or 1,2,5-thiadiazolyl, that is substituted with one or two R4Cgroups.

54. The compound of any one of claims 1 to 33 or 46 to 51, or a pharmaceutically acceptable salt thereof, whereinR4is oxazolyl, isoxazolyl or oxadiazolyl that is substituted with one or two R4cgroups, wherein each R4cis independently C(3-5)Cycloalkyl, -C(i-3)alkyl orwherein the C(3-5)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with - OCH3, or one to three fluorine atoms.

55. The compound of any one of claims 1 to 33, 46 to 51 or 54, or a pharmaceutically acceptable salt thereof, wherein R4is isoxazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, -CF3, -CH2CH2F, -CH2CH2CF3, -CH2-OCH3, cyclopropyl, cyclopentyl, oroxazolyl substituted with one isopropyl, or oxadiazolyl substituted with one methyl or ethyl.

56. The compound of any one of claims 1, 2, 11 to 33, 47, or 49 to 51, or a pharmaceutically acceptable salt thereof, wherein R4is oxazolyl, isoxazolyl or oxadiazolyl that is substituted with one or two R4cgroups, wherein each R4cis independently -NFh, -N(ϋ¼)2, -C(o-i)alkylC(3-5)Cycloalkyl, - OC(3-4)Cycloalkyl, -C(i-3)alkyl, -OC(i-3)alkyl,wherein the -C(o-i)alkylC(3-5)Cycloalkyl, -C(i-3)alkyl, and -OC(i-3)alkyl groups are unsubstituted or substituted with one to three groups selected from -OH, - OCH3, -OCHF2, -CH3, and fluorine.

57. The compound of any one of claims 1, 2, 11 to 33, 47, 49 to 51, or 56, or a pharmaceutically acceptable salt thereof, wherein R4is isoxazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, -CF3, -CH2CH2F, -CH2CH2CF3, -CH2OCH3, cyclopropyl, cyclopentyl, oroxazolyl substituted with one isopropyl, or oxadiazolyl substituted with one methyl, ethyl, -OCH2CHF2, or cyclopropyl.

58. The compound of any one of claims 1 to 33, 46 to 51, or 54 to 57, or a pharmaceutically acceptable salt thereof, wherein R4is oxadiazolyl substituted with one - C(i-3)alkyl.

59. The compound of any one of claims 1 to 33 or 46 to 54, 56, or 57, or a pharmaceutically acceptable salt thereof, whrein R4is 1,2,5-oxadiazolyl substituted with cyclopropyl.

60. The compound of any one of claims 1 to 33 or 46 to 56, or a pharmaceutically acceptable salt thereof, wherein R4is:

61. The compound of any one of claims 1, 2, 11 to 33, 47, 49, or 56, or a pharmaceutically acceptable salt thereof, wherein R4is:

62. The compound of any one of claims 1 to 6, 11 to 33 or 47, 49, 56, or 61, or a pharmaceutically acceptable salt thereof, wherein R4is:

63. The compound of any one of claims 1 to 33, 46 to 57, or 60 to 62, or a pharmaceutically acceptable salt thereof, wherein R4is:

64. The compound of any one of claims 1 to 33, 46 to 54, 56, 57, 61 or 62, or a pharmaceutically acceptable salt thereof, wherein R4is:

65. The compound of any one of claims 1 to 19, 21 to 29, 33, or 46 to 59, or a pharmaceutically acceptable salt thereof, which is a compound of formula Tf:

66. The compound of any one of claims 2, 4, 6, 8, 12, 14, 15, 21, 24, 25, 27 to 29, 33, or 46 to 59, or a pharmaceutically acceptable salt thereof, which is a compound of formula Tg:

67. The compound of any one of claims 2, 4, 6, 8, 10, 12, 14, 15, 21 to 23, 27 to 29, 33, or 46 to 59, or a pharmaceutically acceptable salt thereof, which is a compound of formula Th:

68. The compound of any one of claims 1 to 33 or 46 to 53, or a pharmaceutically acceptable salt thereof, whereinR4is pyrazolyl or imidazolyl that is unsubstituted or substituted with one or two R4cgroups, wherein each R4cis independently fluorine or -C(i-3)alkyl that is unsubstituted or substituted with one to three groups selected from -CHF2, -CF3, -OCHF2, -OCF3and fluorine.

69. The compound of any one of claims 1 to 33, 46 to 53 or 68, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one or two R4cgroups each independently methyl, ethyl, isopropyl, -CD2CD3, fluorine, -CHF2, -CF3, -CH2CHF2, -CH2CF3, -CH(CH )CF3, -CH(CH2F)2, -CH2CH2OCHF2, or -CH2CH2OCF3, or imidazolyl substituted with one isopropyl.

70. The compound of any one of claims 1 to 33 or 46 to 53, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one or two R4cgroups each independently cyclopropyl, methyl, ethyl, isopropyl, -CD3, -CD2CD3, fluorine, -CHF2, -CF3, - CH2CHF2, -CH2CF3, -CH(CH )CF3, -CH(CH2F)2, -CH2CH2OCHF2, or - CH2CH2OCF3, or imidazolyl substituted with one methyl or isopropyl.

71. The compound of any one of claims 1 to 33, 46 to 53, or 68 to 70, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with one - i- 3)alkyl.

72. The compound of any one of claims 1 to 33, 46 to 53, or 68 to 71, or a pharmaceutically acceptable salt thereof, wherein R4is pyrazolyl substituted with isopropyl, - CD , or -CD2CD3.

73. The compound of any one of claims 1 to 33, 46 to 53, 68, or 69, or a pharmaceutically acceptable salt thereof, wherein R4is:

74. The compound of any one of claims 1 to 33, 46 to 53, 68, or 70, or a pharmaceutically acceptable salt thereof, wherein R4is75. The compound of any one of claims 1 to 33, 46 to 53, 68, 70, or 74, or a pharmaceutically acceptable salt thereof, wherein R4is76. The compound of any one of claims 1 to 33 or 46 to 51, or a pharmaceutically acceptable salt thereof, whereinR4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently -C(o-i)alkylC(3-4)Cycloalkyl, -C(i-3)alkyl,wherein the -C(o-i)alkylC(3-4)Cycloalkyl and -C(i-3)alkyl groups are unsubstituted or substituted with one to four R4dgroups; and each R4dis independently -OCH3, -OCF3, -OCHF2, fluorine,wherein when R4is 1,2,4-triazolyl, then R4is77. The compound of any one of claims 1 to 33, 46 to 51, or 76, or a pharmaceutically acceptable salt thereof, whereinR4is triazolyl that is unsubstituted or substituted with one or two R4cgroups; and each R4Cis independently methyl, ethyl, isopropyl, -CH2CH20CH3,-CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -CH2CH2OCHF2, -CH2CH2OCF3, cyclopropyl, -CFh-cyclopropyl,wherein when R4is 1,2,4-triazolyl, then R4is78. The compound of any one of claims 1 to 33, 46 to 51, 76, or 77, or a pharmaceutically acceptable salt thereof, wherein R4is:

79. The compound of any one of claims 1 to 33 or 46 to 51, or a pharmaceutically acceptable salt thereof, wherein R4is80. The compound of any one of claims 1 to 33 or 46 to 53, or a pharmaceutically acceptable salt thereof, wherein R4is tetrazolyl substituted with -C(i-4)alkyl.

81. The compound of any one of claims 1 to 33, 46 to 53 or 80, or a pharmaceutically acceptable salt thereof, wherein R4is tetrazolyl substituted with methyl or isopropyl.

82. The compound of any one of claims 1 to 33, 46 to 53, 80 or 81, or a pharmaceutically acceptable salt thereof, wherein R4is:

83. The compound of any one of claims 1 to 33 or 46 to 51, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl, thiazolyl, isothiazolyl or thiadiazolyl, each substituted with -C(i-3)alkyl, or -C(3-6)Cycloalkyl.

84. The compound of any one of claims 1 to 33, 46 to 51 or 83, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl, thiazolyl, isothiazolyl or thiadiazolyl, each substituted with methyl, isopropyl or cyclopropyl.

85. The compound of any one of claims 1 to 33, 46 to 51, 83 or 84, or a pharmaceutically acceptable salt thereof, wherein R4is thienyl substituted with isopropyl, isothiazolyl substituted with methyl, thiazolyl substituted with isopropyl, orthiadiazolyl substituted with methyl, isopropyl or cyclopropyl.

86. The compound of any one of claims 1 to 33, 46 to 51, or 83 to 85, or a pharmaceutically acceptable salt thereof, wherein R4is:

87. The compound of any one of claims 1, 2, 11 to 33, or 46 to 49, or a pharmaceutically acceptable salt thereof, whereinR4is a 6-membered heteroaryl having 1 to 2 heteroatoms selected from N, that is substituted with one or two R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3- 4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and C(i.3>alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms, alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the heteroaryl is unsubstituted at the para-position.

88. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, or 87, or a pharmaceutically acceptable salt thereof, whereinR4is a pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl, that is substituted with one or two R4Cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3- 4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and C(i.3>alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the heteroaryl is unsubstituted at the para-position.

89. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87 or 88, or a pharmaceutically acceptable salt thereof, whereinR4is pyridyl that is unsubstituted or substituted with 1 to 2 R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, C(3-4)Cycloalkyl, -OC(3-4)Cycloalkyl, -OC(i-3)alkyl, or C(i.3>alkyl wherein the -OC(i-3)alkyl, and i- 3>alkyl are unsubstituted or substituted with -OCH3, or one to three fluorine atoms; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a C(4-6)Cycloalkyl; wherein the pyridyl is unsubstituted at the para-position.

90. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, or 87 to 89, or a pharmaceutically acceptable salt thereof, wherein R4is pyridyl unsubstituted or substituted with C(i-2)alkyl unsubstituted or substituted with one to three fluorine atoms, wherein the pyridyl is unsubstituted at the para-position.

91. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, or 87 to 89, or a pharmaceutically acceptable salt thereof, whereinR4is pyridyl that is unsubstituted or substituted with 1 to 2 R4cgroups; and each R4Cgroup is independently fluorine, -CN, pyrrolidin-2-one, cyclopropyl, cyclobutyl, -O-cyclopropyl, -O-cyclobutyl, -OMe, -OEt, -O-isopropyl, -OCHF2, -OCH2CHF2, -OCH2CF3, methyl, ethyl, isopropyl, -CH2-OCH3, -CHF2, -CF3, -C(CH )F2, - CH2CHF2, -CH2CF3, or -CH2CH2CHF2; alternatively, two R4cgroups attached to adjacent ring atoms can be combined to form a cyclopentyl, wherein the pyridyl is unsubstituted at the para-position.

92. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87 to 89, or 91, or a pharmaceutically acceptable salt thereof, wherein R4is:

93. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87 or 88, or a pharmaceutically acceptable salt thereof, whereinR4is pyridazinyl, pyrimidinyl, or pyrazinyl, wherein each is unsubstituted or substituted with one or two R4cgroups; each R4Cis independently selected from -C(3-4)Cycloalkyl, -OC(i-3)alkyl and -C(i-4)alkyl, wherein the -C(i-4)alkyl groups are unsubstituted or substituted with one to three fluorine atoms, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position.

94. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87, 88 or 93, or a pharmaceutically acceptable salt thereof, whereinR4is pyridazinyl, pyrimidinyl, or pyrazinyl, wherein each is unsubstituted or substituted with one or two R4cgroups; and each R4Cis independently selected from methyl, isopropyl, -OMe, cyclopropyl, -CHF2, and -CF3, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position.

95. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87, 88, 93 or 94, or a pharmaceutically acceptable salt thereof, wherein R4is pyridazinyl unsubstituted or substituted with -OCH3or -CH3,pyrimidinyl unsubstituted or substituted with methyl, isopropyl, -OCH3, or cyclopropyl, wherein the methyl is unsubstituted or substituted with one to three fluorine atoms, or pyrazinyl unsubstituted or substituted with -OCH3, -CH3, or -CF3, wherein the pyridazinyl, pyrimidinyl and pyrazinyl are unsubstituted at the para-position.

96. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87, 88 or 93 to 95, or a pharmaceutically acceptable salt thereof, wherein R4is:

97. The compound of any one of claims 1, 2, 11 to 33, 46 to 49, 87, 88 or 93 to 96, or a pharmaceutically acceptable salt thereof, wherein R4is:

98. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 1A, Table IB, Table 1C, Table ID, Table IE, Table IF, Table 1G, Table 1H, Table II and Table 1J.

99. The compound of claim 98, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

100. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is101. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is102. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is103. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is104. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is105. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is106. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is107. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is108. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is109. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is110. The compound of claim 98, or a pharmaceutically acceptable salt thereof, which is111. The compound of claim 2, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 2A, Table 2B, Table 2C, Table 2D, Table 2E, Table 2F, Table 2G, Table 2H, Table 21, Table 2J, Table 2K, and Table 2M.

112. The compound of claim 111, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

113. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is114. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is115. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is116.The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is117.The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is118.The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is119. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is120. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is121. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is122. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is123. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is124. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is125. The compound of claim 111, or a pharmaceutically acceptable salt thereof, which is126. A pharmaceutical composition, comprising a compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

127. A pharmaceutical composition made by mixing a compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

128. The pharmaceutical composition of claim 126 or 127, which is administered orally.

129. The pharmaceutical composition of claim 128, which is administered as a tablet or a capsule.

130. A process for making a pharmaceutical composition comprising mixing a compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

131. A method for treating and / or ameliorating an IL- 17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof.

132. The method of claim 131, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

133. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriasis.

134. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis.

135. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is rheumatoid arthritis.

136. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is ankylosing spondylitis.

137. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is hidradenitis suppurativa.

138. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is bullous pemphigoid.

139. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is atopic dermatitis.

140. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is vitiligo.

141. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple sclerosis.

142. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

143. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is asthma.

144. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is uveitits.

145. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is chronic obstructive pulmonary disorder.

146. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple myeloma.

147. The method of claim 132, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

148. The method of any of claims 132 to 147, wherein the compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof, is administered orally.

149. The method of any of claims 132 to 148, wherein the compound of any one of claims 1 to 125, or a pharmaceutically acceptable salt thereof, is administered as a tablet or a capsule.

150. A compound as described herein.

151. A method as described herein.